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Small cell lung cancer (SCLC) accounts for 25% of all new bronchial tumours and is
characterised by an extremely aggressive clinical course resulting in a five-year
survival rate of only 5%. The early dissemination ofmetastases and the development
of resistance to chemotherapy are the two fundamental processes responsible for the
highly malignant phenotype of this tumour. This thesis examines the mechanisms
that regulate SCLC anchorage-dependence, drug resistance and apoptosis.
Phosphoinositide 3-kinase (PI 3-kinase), a regulator of multiple cellular processes
including mitogenesis and invasion, is shown to be constitutively active in SCLC cell
lines resulting in elevated levels of phosphatidyhnositol 3,4,5 trisphosphate and
protein kinase B (PKB). Inhibition of PI 3-kinase abrogated SCLC cell proliferation
and colony formation and stimulated apoptosis. These data represent the first
description of constitutively activated PI 3-kinase/PKB in any human cancer.
Constitutive activation of PI 3-kinase may mimic integrin-dependent signal
transduction thereby promoting cellular proliferation, anchorage-independence and
tumourigenicity in SCLC.
Tumour recurrence following chemotherapy remains a major obstacle to the cure of
SCLC. We hypothesised that a factor(s) within the local environment of SCLC cells
might provide a 'survival' signal or block a 'death' signal, thereby accounting for the
protection of SCLC cells from chemotherapy-induced apoptosis. Integrin-dependent
adhesion of SCLC cells to ECM proteins, which occur in profusion in SCLC tumours
in vivo, conferred resistance to chemotherapy-induced apoptosis. ECM protein-
induced tyrosine phosphorylation was found to block chemotherapy-induced
activation of the 'death' protease caspase-3 and hence, apoptosis. Survival of tumour
cells attached to ECM proteins may explain the local recurrence of SCLC often seen
clinically after chemotherapy.
In vivo, cancer cells exist in a state of dynamic interplay between anchorage-
dependence and independence. Alterations in cell adhesion and migration are
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dependent upon rapid, controlled alterations of the affinity of integrins for their
extracellular ligands. CD98 has recently been identified as a unique and highly
specific regulator of integrin affinity but its mechanism of action is not known.
CD98 is highly expressed on SCLC cells both in vivo and in vitro. PI 3-kinase and
PKB could both be activated with an anti-CD98 antibody (4F2) but not with
monovalent 4F2-Fab showing that cross-linking of CD98 is required for their
activation. Cross-linking CD98 stimulated SCLC anchorage-independent growth in
semi-solid agarose medium. This effect could be blocked by a PI 3-kinase inhibitor.
These data supports the hypothesis that CD98 promotes integrin-like intracellular
signalling and is able to regulate anchorage-dependence and independence.
In conclusion, one can hypothesise that SCLC cells, in vivo, exist in a state of
dynamic flux between anchorage-dependence and independence. The regulation of
integrin adhesion is governed by complex signalling pathways and feedback loops
involving PI 3-kinase and CD98. At any one time a proportion of cells are
anchorage-independent and therefore can potentially migrate and metastasise, while
others, are adhered to ECM proteins and are protected from chemotherapy-induced
apoptosis. This would appear to be a good model to explain the aggressive nature of
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1.1.1 Epidemiology ofLung Cancer
Each year nearly six million people are diagnosed with cancer worldwide. Of these,
approximately two thirds will die as a consequence of their disease. This represents
about 10% of all deaths (WHO, 2000). In most countries lung cancer is the
commonest cause of cancer death. It has been calculated recently that lung cancer is
the cause of 12.8% of cancer cases and 17.8% of cancer deaths worldwide (Parkin et
al., 1999). In the UK in 1995 there were 36,600 deaths from lung cancer (WHO,
2000).
The incidence of lung cancer varies widely between different countries being highest
in the more developed countries ofNorth America and northern Europe. For men,
Scotland has the highest national incidence in the world at 135/100,000 compared
with 70/100,000 for the United States. The incidence is lower in Scandinavia at
44/100,000 and only 7/100,000 in India (WHO, 2000). For women, the overall
pattern is similar but the incidence is generally about a third of that in men. In recent
years there has been evidence from western countries of a fall in the incidence of
lung cancer in men (Peto et al., 2000). However, rather worryingly, there continues
to be a rise in the incidence in women (Osann, 1998). Furthermore, in developing
nations where smoking rates are high, mortality from lung cancer has been rising
steadily and this rise is expected to continue (Liu et al., 1998).
1.1.2 Classification ofLung Cancer
Bronchogenic carcinomas arise from the mucosa of the tracheobronchial tree. The
most extensively used classification currently is the World Health Organisation's
histological classification published in 1999 (WHO, 1999). This classification
subdivides the main types of lung cancer into four categories:
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a. Squamous cell carcinoma
b. Adenocarcinoma
c. Large cell carcinoma
d. Small cell carcinoma
Squamous cell carcinoma, adenocarcinoma and large cell carcinoma are collectively
known as non-small cell lung cancer (NSCLC).
1.1.2a Squamous cell carcinoma
Squamous cell carcinoma arises from metaplastic squamous epithelial cells. These
tumours are endobronchial and arise centrally within the lung. They tend to grow
relatively slowly and produce symptoms and signs such as lobar collapse and
obstructive pneumonia due to local 'mass' effects. Squamous cell carcinoma tends
to metastasise relatively late and therefore is the subtype most amenable to surgical
resection. In recent years in North America the proportion of squamous cell
carcinoma has decreased from about 40% of all lung cancers to 20-25%. However,
this trend is not so apparent in European countries and squamous cell carcinoma
remains the commonest cell-type (Hoffman et al., 2000).
1.1.2b Adenocarcinoma
Adenocarcinomas appear to arise from either surface epithelial cells (ciliated and
mucus producing cells) which give rise to mucin-containing and mucin-secreting
tumours or the progenitor cells of the peripheral airways (Clara cells and type II
pneumocytes) which give rise to peripheral airway cell tumours (Gazdar and
McDowell, 1988).
Until recently adenocarcinoma accounted for about 20-25% of lung cancers in
Europe and North America. Recently this figure has risen to 40% in North America
and is also increasing in Europe. The reasons for this are not fully understood but
may, in part, reflect the increasing numbers ofwomen who are smoking, as this
subtype is more common in women. It has also been suggested that these changes
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are the result of alteration in cigarette design (Thun et al., 1997). The smoke in filter
tip cigarettes tends to be inhaled more deeply than that of the older unfiltered types
and as a result tobacco-specific carcinogens are transported more distally into the
lung toward the bronchoalveolar junction where adenocarcinomas often arise.
Although cigarette smoking causes the majority of adenocarcinomas, this is the
subtype that occurs most commonly in non-smokers. Not infrequently patients
present with symptoms due to metastatic disease because of the propensity of this
tumour to metastasise early. The primary tumour may be a relatively symptomless
peripheral nodule. The principal subgroup of adenocarcinoma is bronchoalveolar
carcinoma. These may be unifocal or multifocal. This subgroup of adenocarcinomas
metastasise less commonly than the other cell types.
1.1.2c Large cell carcinoma
These represent a group of primary lung carcinomas arising from bronchial
epithelium that have not differentiated sufficiently to allow them to be placed in
either the squamous or adenocarcinoma groups. Clinically these tumours are often
large peripheral masses, sometimes with cavitation and they account for 10% of all
lung cancers.
1.1.2d Small cell lung cancer
Small cell lung cancer (SCLC) accounts for 20-25% of all new bronchial carcinomas.
The precise origin of small cell lung cancer is open to debate. These tumours were
originally thought to arise from cells of the diffuse neuroendocrine system which
occurs throughout the bronchial tree (Gazdar et al., 1985a). However, it is now
thought that they may arise from a common stem cell (see below). SCLC is now
considered to be a systemic disease and almost invariably has metastasised by the
time of presentation. Unlike other bronchial tumours, SCLC is extremely sensitive
to chemotherapy and radiotherapy.
1.1.3 Aetiology of lung cancer
The main risk factor for lung cancer is cigarette smoking. This risk was first
appreciated in 1950 in a series of case control studies (Wynder and Graham, 1950;
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Levin et al., 1950; Mills and Porter, 1950; Schrek et al., 1950). Sir Richard Doll
established a cohort of 40,637 British doctors in 1951 and this group has been
followed for 40 years (Doll and Peto, 1976; Doll et al., 1994). The mortality rate
ratio for lung cancers in smokers versus non-smokers was 14.9 and this dropped to
4.1 in ex-smokers. The loss of expectation of life for all cigarette smokers in this
study was 8.0 years. A similar study by the American Cancer Society found that the
lung cancer mortality rate ratio for smokers versus non-smokers was 23.9 for men
and 14 for women (Thun et al., 1995). Overall, it is estimated that 85-90% of lung
cancers can be linked to active smoking.
Besides smoking, other environmental and occupational exposures, such as to
aromatic hydrocarbons, radon, asbestos, nickel, arsenic and chromium are important
determinants of lung cancer risk. These account for 5% of female and 15% ofmale
lung cancer deaths (WHO, 1982). Of these, the most important aetiology in terms of
number of cancers caused is probably asbestos exposure. Asbestos exposure
(particularly to the crocidolite type) significantly increases the risk of developing
lung cancer quite apart from the risk of developing malignant mesothelioma.
Hammond et al, (1979) reported on a cohort of 17,800 asbestos insulators in the
United States and Canada. Compared with non-smoking controls with no history of
asbestos exposure, asbestos workers with a history of smoking had a 53-fold
increased mortality rate from lung cancer. This was greater than the sum of the
increases for lung cancer from asbestos exposure alone (5-fold) or cigarette smoking
alone (11-fold).
Although lung cancer is largely preventable by elimination of these exposures, this
disease will be a major public health problem for the foreseeable future because ex-
smokers continue to have a significantly increased risk of developing lung cancer.
1.1.4 A modelfor lung cancer development
Each of the four main types of lung cancer reflect phenotypic features of the cell
types that make up the normal bronchial epithelium. One hypothesis that is
becoming increasingly accepted is that the four types of lung cancer are related
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through a common differentiation pathway in the bronchial epithelium (reviewed in
Mabry et al., (1991)). This proposal is supported by clinical evidence that
demonstrates potential for transitions between the different tumours (i.e. that tumours
can be admixtures of the different phenotypes). For instance, neuroendocrine
features can be found in 25% of bronchial adenocarcinomas and this confers an
initial sensitivity to chemotherapy and radiotherapy. Furthermore, individual cells
have been observed to manifest features ofSCLC and NSCLC simultaneously. It is
proposed that these transitions mimic normal cellular transitions in bronchial mucosa
and are mediated by the consistent genetic abnormalities now being described for
lung cancer.
Mabry et al., (1991) described an in vitro model system which examined these
transitions. They utilised a non-tumourigenic cell line derived from bronchial
epithelium (BEAS-2B) which had been transfected with the simian virus (SV40),
allowing continuous growth (Gruenert et al., 1988; Bonfil et al., 1989). Using this
model it was shown that overexpression and point mutations of different oncogenes
produced different histological types of tumours. Overexpression of c-myc and c-
raf-1 resulted in the development of a large cell carcinoma (Pfeifer et al., 1989).
Transfection with H-ras and HER-2/neu led to the development of adenocarcinomas,
whereas transfection ofmutant p53 led to the development of squamous cell
carcinomas. Furthermore, insertion of a mutated H-ras gene into SCLC cells that
overexpressed either an endogenously amplified c-myc or N-myc gene, or a
transfected human c-myc gene caused transition to a large-cell undifferentiated
phenotype (Mabry et al., 1988).
1.1.5 Molecular events in lung cancer development
The current hypothesis of lung carcinogenesis is that it is a multi-stage process
involving mutations in several genes involved in DNA repair, cell growth, signal
transduction and cell cycle control. These mutations can cause activation of
oncogenes (e.g. members of the myc and ras families, c-raf-l and bcl-2) or deletion
of tumour suppressor genes (e.g. rb gene, p53, 3p, 9q and 5q). In combination with
environmental exposures and inherited polymorphisms in a variety of genes,
5
particularly the carcinogen metabolism genes, these mutations can affect the
susceptibility of an individual to develop lung cancer. Such genetic changes result in
pathological changes, which initially at least, may be reversible. However, as
progressive chromosomal changes become more complex, irreversible damage
occurs and lung cancer develops (Figure 1.1). The multi-step model proposes that
two or more genetic mutations are required to transform a cell. Inheritance of one or
more of these mutations allows tumours to develop earlier than if several
spontaneous mutations have to accumulate in a cell. Many studies have been
undertaken to assess the role of genetics in the development of lung cancer after
exposure to long-term carcinogens such as cigarette smoke (Heighway et al., 1986).
The evidence that susceptibility to lung cancer has a genetic component is suggested
by studies, which show that only 10% of individuals who smoke develop lung cancer
and that some individuals who do not smoke develop lung cancer. Furthermore,
there is a significantly increased risk of lung cancer, as well as of other tumours,
among blood relatives of lung cancer patients compared with controls (Ooi et ah,
1986; Lynch et ah, 1986). There are reports linking inherited mutations in the
retinoblastoma gene on chromosome 13 (Sanders et ah, 1989), the p53 gene on
chromosome 17 (Malkin et ah, 1992) and an H-ras allele on chromosome 11
(Heighway et ah, 1986) with an increased risk for lung cancer. The molecular
changes which lead to an accumulation of genetic changes resulting in activation of
oncogenes and inactivation of tumour suppresser genes are not fully understood, but
a mutator phenotype leading to genomic instability may be an early step in the
development of some cancers. Work on a mutator or replication error phenotype has
demonstrated a high frequency ofmicrosatellite instability in SCLC compared to
NSCLC (Merlo et ah, 1994; Mao et ah, 1994; Fong et ah, 1995; Fong et ah, 1995).
In both SCLC and NSCLC with associated microsatellite instability, tumours are
characterised by widespread allelic loss (loss of heterozygosity) as a result of loss of
chromosomes or portions of chromosomes. Sequential accumulation of loss of
heterozygosity is a frequent event in lung cancer and occurs during progression from
primary tumours to metastatic sites (Shiseki et ah, 1994). Dominant oncogenes
require only one mutation for their tumourigenic potential to be activated, whereas






































Molecular pathogenesis of lung cancer. Lung cancer is believed to be a multi¬
stage process involving mutations in up to 20 genes involved in DNA repair, cell
growth and signal transduction. Such mutations can cause activation of oncogenes or
deletion of tumour suppressor genes. The resulting genetic changes result in
pathological changes, which initially, may be reversible. However, as the
chromosomal changes become more complex irreversible damage occurs and lung
cancer develops.
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deletion or mutation, in both alleles. SCLC has been shown to exhibit frequent
losses of 3p, 5q, 13q and 17p (Whang-Peng et ah, 1982a; Yokota et ah, 1987;
Whang-Peng et ah, 1982b). NSCLC show consistent loss of heterozygosity at 3p,
9p, 1 lp, 13q and 17p (Shiseki et ah, 1994).
1.2 SMALL CELL LUNG CANCER
1.2.1 The clinicalpicture
SCLC tumours usually arise centrally and are smoking-related. Histologically SCLC
cells may be relatively small and round with little cytoplasm (lymphocyte-like) or
somewhat larger and fusiform (classical 'oat' cell type) or of relatively nondescript
or 'polygonal' cell type. As well as these true small cell tumours, a variant known as
the 'intermediate' type can occur which consists of larger cells although they
maintain the histological characteristics of the smaller cell variants. The cytoplasm
is characterised by small dense-core granules which are a manifestation of the
peptide and hormone secretion that is the hall mark of the 'neuroendocrine'
properties observed in SCLC, but relatively infrequently in other types of lung
cancer.
SCLC accounts for 20-25% of all new bronchial tumours and is characterised by an
extremely aggressive clinical course. Untreated the median survival from diagnosis
is only 5 to 12 weeks depending upon the stage at diagnosis. Clinically there are no
specific features to distinguish SCLC from other primary lung tumours. The primary
site is usually within the central bronchial tree and cough, dyspnoea, haemoptysis,
wheeze and post obstructive pneumonia are all common symptoms. Chest pain can
occur with parietal pleural involvement and mediastinal invasion. Superior sulcus
tumours may produce shoulder pain, arm pain, brachial plexopathy or a Horner's
syndrome. Mediastinal invasion can lead to recurrent laryngeal nerve palsy, superior
vena cava obstruction and phrenic nerve palsy. Oesophageal symptoms and
pericardial invasion are recognised but are rarer.
SCLC is associated with a variety of paraneoplastic syndromes. These syndromes
are due to the synthesis and release of a variety of hormones and peptides by the
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tumour. Adrenocorticotropic hormone and anti-diuretic hormone secretion cause
Cushing's syndrome and the syndrome of inappropriate anti-diuretic hormone
respectively (Bliss et al., 1990). Immune reactions to tumour antigens can result in
the Eaton-Lambert myasthenic syndrome, in which the presence of circulating
antibodies react with voltage-gated calcium channels (De Aizpurua et al., 1988).
Two thirds ofpatients will have evidence of distant metastases, most often to liver,
bone, bone marrow, the central nervous system and the adrenals, at the time of initial
diagnosis. This excludes the possibility of surgical resection for the majority of
cases. SCLC is extremely sensitive to chemotherapy and radiotherapy and this
remains the mainstay of treatment. However, although most patients will benefit
from treatment with an improvement in symptoms and increase in survival, the
tumour invariably recurs and proves fatal. Survival to 5 years is rare.
1.2.2 The management ofsmall cell lung cancer
The management of SCLC is, in part, dependent upon the stage of the disease at
presentation. The traditional TNM staging system is not appropriate for SCLC, as
the tumour is almost always systemic at the time of diagnosis. A two-stage
classification for SCLC staging has been proposed which divides patients into those
with either limited or extensive disease. Limited disease describes tumour confined
to one hemithorax (including pleural effusion), ipsilateral mediastinal and
supraclavicular lymph nodes. Extensive disease is defined as the presence of tumour
beyond these sites. About 70% of patients fall into the latter category (Elias, 1997).
1,2.2a Chemotherapy for small cell lung cancer
The first study on the use of chemotherapy for the treatment of SCLC was published
in 1969 by the Veterans' Administration lung cancer study group (Green et al.,
1969). The use of single-agent cyclophosphamide produced a doubling ofmedian
survival compared with a placebo-controlled group. Subsequent studies comparing
radiotherapy alone with radiotherapy and chemotherapy showed significant
improvements in survival for the patients who had received chemotherapy. Phase II
studies have now shown that a number of cytotoxic drugs are active against SCLC.
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However, historical data suggests that the use of combination chemotherapy gives
better results than monotherapy. The use of combination chemotherapy has
improved survival by four to five fold compared with untreated patients (Evans et al.,
1985; Hong et ah, 1989; Jett et ah, 1990). With aggressive combined modality
therapy or combination chemotherapy, response rates of 80 to 100 percent (50 to 70
percent complete response) in limited disease and 60 to 80 percent (15 to 40 percent
complete response) in extensive disease have been achieved (Seifter and Ihde, 1988).
However, responses tend to be short-lived with a median duration of approximately
six to eight months. From the time of diagnosis, the median ranges of survival for
limited and extensive disease are 14 to 20 months and 8 to 13 months, respectively
(Osterlind et ah, 1986). Once recurrent, median survival is about four months.
Approximately 20 to 40 percent of limited stage and less than 5 percent of extensive
stage patients survive two years. Survival beyond five years occurs in only 3 to 8
percent ofpatients.
At least 15 to 20 different chemotherapeutic agents have major activity against
SCLC in both untreated and relapsed patients. The major agents are etoposide,
cisplatin, carboplatin, ifosfamide, cyclophosphamide, vincristine and doxorubicin.
Despite a large number of regimens almost all produce similar outcomes. However,
one conclusion from these studies is that etoposide containing regimens are well
tolerated and highly active (Hong et ah, 1989; Jett et ah, 1990). The etoposide and
cisplatin combination is most frequently used and appears to be superior to
cyclophosphamide, adriamycin and vincristine (Evans et ah, 1985).
The inability to destroy residual cells despite initial chemosensitivity suggests the
existence of a small number of tumour stem cells resistant to cytotoxic therapy. In
order to try and overcome the problem of drug resistance alternating or sequential
combination protocols were designed to expose the tumour to a large number of
active cytotoxic agents. However, a number of randomised trials have failed to show
clinically significant improvements in disease-free or overall survival with these
alternating regimens (Evans et ah, 1987; Roth et ah, 1992; Fukuoka et ah, 1991).
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Maintenance chemotherapy beyond four to six cycles produces minor prolongation
of response without survival benefit. Furthermore, cumulative toxicity is
encountered.
1.2.2b Consolidation radiotherapy
For patients with limited-stage disease who have achieved a complete clinical
response to chemotherapy, it is usual to give a course of radiotherapy to the
mediastinum and the site of primary disease. A large randomised study showed that
the combined-modality group had a median survival of 15 months, and 2 year
survival of 28% compared with 11.6 months and 12% for the chemotherapy-only
group (Bunn, Jr. et al., 1987). A meta-analysis of 2103 patients in 13 trials
confirmed a 14% reduction in mortality and 5% increase in 3-year survival (Pignon
etah, 1992).
There has been a considerable amount ofwork performed looking at the benefits of
giving radiotherapy in combination with initial chemotherapy for patients with
limited disease. Although there are theoretical advantages, such as reducing the
development of drug resistant clones, there is an increased risk of serious toxicity
and this approach is still restricted to trials (Arriagada et ah, 1995).
1,2.2c Prophylactic cranial irradiation
For patients who achieve a complete remission after chemotherapy there is a 20%
risk of subsequently developing brain metastases. For some, this may be the first and
only site ofmetastasis. Therefore, patients with limited-stage disease who achieve a
complete remission should be offered prophylactic cranial irradiation. This reduces
the risk of brain metastases to about 8% but does not affect overall survival (Abner,
1993; Bunn, Jr. and Kelly, 1995).
1.2.2d Surgery for Small cell lung cancer
When it was appreciated in the early 1970s that SCLC is a systemic disease the use
of surgery to resect the primary tumour was largely abandoned. However, for a
small group of patients surgery may still play a role. Patients who present with
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small, apparently localised, pulmonary nodules may benefit from resection with
adjuvant chemotherapy. One study by Meyer (1987) combined surgery with
adjuvant chemotherapy for stage I and II carcinomas and reported an 80% survival
rate at 30 months. However, the overall number of patients who will fall into this
category are very small (about 1%).
1.2.2e Management of relapsed SCLC
Most patients with SCLC who have been treated with chemotherapy will relapse
within two years of initial treatment. When this occurs the results of treating them
again with chemotherapy are generally poor with response rates of only 20-25% and
a median survival of only three to four months. In general, response to second line
chemotherapy is better if there has been a disease-free interval. It may be possible to
induce a period of remission with the same drugs used for the initial treatment or
with a different regimen in the hope that there is not cross-resistance.
1.2.2f New agents
At the time ofwriting a number of new agents are being evaluated for activity
against SCLC. These include altretamine, paclitaxel, docetaxel, vinorelbine,
gemcitabine and topoisomerase I inhibitors such as topotecan and irinotecan. In a
recent phase III study topotecan was compared with the standard cyclophosphamide,
adriamycin and vincristine regimen. Response rates, median time to progression and
survival were similar in the two groups of patients, but topotecan resulted in an
improved control of several symptoms (von Pawel et al., 1999). In another study,
taxol and topotecan are being evaluated as a first line treatment in previously
untreated patients with extensive disease. Early reports have been encouraging with
complete remission in 19 percent and partial remission in 29 percent (Jacobs et al.,
1999).
1.2.3 An 'in vitro' modelfor small cell lung cancer
In 1985 Carney et al., described the growth and characterisation of 50 SCLC cell
lines established from patients between 1977 and 1984. Much of the subsequent
work on SCLC has utilised either these cell lines, or others, established in a similar
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fashion. Biochemical characterisation of these lines for the expression of L-dopa
decarboxylase, bombesin-like immunoreactivity, neurone-specific enolase and the
brain isoenzyme of creatine kinase showed that SCLC cell lines could be subdivided
into two types, classical and variant. Classical SCLC lines express elevated levels of
all four biomarkers while variant lines have undetectable levels of L-dopa
decarboxylase and bombesin-like immunoreactivity but continue to express neurone-
specific enolase and the brain isoenzyme of creatine kinase.
Based on their appearance, SCLC cell lines can be grouped into 4 major categories
called types 1, 2, 3 and 4 (Carney et al., 1985). Type 1 lines grow as tightly packed
spherical aggregates of floating cells, which frequently demonstrate areas of central
necrosis in larger spheroids. Type 2 lines grow as relatively densely packed floating
aggregates, amorphous and irregular in outline and Type 3 cells grow as very loosely
adherent floating aggregates in small clumps and intertwined cords. Central necrosis
does not occur in either of these lines. Type 4 cells grow attached to substrate and
consist of large overlapping polygonal cells lacking the epithelioid appearance of
adherent NSCLC cell cultures. In addition, SCLC cells are able to form colonies in
soft agarose and are tumourigenic in athymic nude mice (Carney et ah, 1980).
Doubling times in culture range from 32-72 hours. In vitro studies have shown that
variant cell lines have a more rapid growth rate and a higher cloning efficiency in
soft agarose and nude mice than classical cell lines (Gazdar et ah, 1985b). It has
been proposed that variant cell lines represent the in vitro counterpart of SCLC
tumours that have relapsed and become chemoresistant. However, when biomarker
expression of cell lines established from untreated patients were compared with those
who had relapsed from intensive combination chemotherapy considerable overlap
occurred and no significant differences could be observed (Carney et ah, 1985).
1.2.4 Growth factors for SCLC
1.2.4a Neuropeptides
One of the most striking characteristics of SCLC cells is their ability to produce a
large number of hormones and peptides in vivo and in vitro including bombesin,
neurotensin, cholecystokinin and vasopressin (Gazdar et ah, 1985b). Early work
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concentrated on the hypothesis that these peptides might regulate the growth and
perhaps degree of differentiation of SCLC in an autocrine or paracrine fashion. The
hypothesis of autocrine growth inhibition by gastrin releasing peptide (GRP) in
SCLC was first tested by Cuttitta et al., (1985) using a monoclonal antibody (2A11)
to [Lys3] bombesin. Under serum-free conditions this antibody inhibited the clonal
growth of two SCLC cell lines and retarded the growth of SCLC xenografts in nude
mice. Furthermore the specific bombesin/GRP receptor antagonist, [Leu13-
(p(CH2NH)-Leu14] bombesin was shown to inhibit basal colony growth ofH345 cells
in semi-solid medium. The use of exogenously added bombesin to stimulate human
SCLC growth in vivo was extended by Alexander and colleagues (1988) who found
that intra-peritoneal administration of bombesin to nude mice bearing human SCLC
implants significantly stimulated tumour growth compared with controls.
A number of studies examining the molecular pathways by which neuropeptide
mitogens elicit cellular growth have exploited a murine fibroblast model system.
Several neuropeptides including bombesin (Rozengurt and Sinnett-Smith, 1983),
vasopressin (Rozengurt et al., 1979), bradykinin (Woll and Rozengurt, 1988) and
vasoactive intestinal peptide (Zurier et al., 1988) are able to act as growth factors for
cultured Swiss 3T3 cells. Cloning and sequencing of the cDNA for several
mitogenic peptide receptors including bombesin (Battey et al., 1991), neuromedin-B
(Corjay et al., 1991), bradykinin (McEachern et al., 1991) and vasoactive intestinal
peptide (Sreedharan et al., 1991) revealed that these receptors are seven
transmembrane domain spanning G-protein-coupled receptors. Binding of
neuropeptides and vasoactive peptides causes phospholipase C (PLC) induced
hydrolysis of phosphatidylinositol 4,5 bisphosphate (PtdIns(4,5)P2) generating the
second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG),
which mobilise Ca2+ from intracellular stores and activate protein kinase C (PKC)
respectively (Rozengurt, 1992). Studies using SCLC cell lines have demonstrated a
similar set of signalling events to those in murine 3T3 fibroblasts. Woll and
Rozengurt (1989) demonstrated that bradykinin, cholecystokinin, galanin,
neurotensin, and vasopressin induce a rapid and transient increase in intracellular
calcium in several SCLC cell lines (Woll and Rozengurt, 1989). There is, however,
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considerable heterogeneity of response to individual peptides among SCLC cell
lines. Such variation is attributed to differences in receptor expression. The Ca2+ -
mobilising effects of each neuropeptide are mediated by distinct receptors as shown
by the use of specific peptide antagonists and by the induction of homologous
desensitisation.
Sethi and Rozengurt (1991) subsequently showed that a variety of neuropeptides
could, over the same concentration range as required for Ca2+ mobilisation, stimulate
the clonal growth of SCLC cell lines in semi-solid agarose. These findings showed
that the previously identified autocrine growth loop involving bombesin-like peptide
is only one of an extensive network of paracrine and autocrine circuits that sustain
the proliferation of SCLC.
1.2.4b Polypeptide hormones
Insulin-like growth factor (IGF-I) is a mitogen for many cell types both in vitro and
in vivo (Schoenle et al., 1982; Froesch et al., 1985). Several groups have shown that
IGF-I or IGF-I-like peptides are produced and released by cultured human tumour
cell lines including lung cancer (Minuto et al., 1986; Macaulay et al., 1990).
Subsequent studies confirmed the presence of an autocrine proliferation loop.
Exogenous addition of IGF-I, IGF-II or insulin resulted in marked proliferation of
human SCLC cells as measured by in vitro growth assays (Nakanishi et al., 1988).
More recently the type I insulin-like growth factor receptor (IGF-R) has been
identified as the receptor for these ligands (Sell et al., 1994; Resnicoff et al., 1994).
The growth and tumourigenicity of transformed cells can be inhibited by disruption
of IGF-R function using a monoclonal antibody (a-IR3) which inhibits the
interaction of the IGF-R with its ligands (Zia et al., 1996). Historically IGF-I was
believed to be the biologically relevant ligand for the IGF-1/IGF-R autocrine loop
but recent work has identified IGF-II as the predominant IGF involved. Despite
expression of IGF-I, IGF-II and IGF-R mRNA in the majority of lung and breast
cancer cell lines examined, only IGF-II peptide was identified (Quinn et al., 1996).
A similar role for IGF-II has recently been reported in prostate cancer (Angelloz-
Nicoud and Binoux, 1995) and cervical cancer cell lines (Steller et al., 1995).
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A number of other polypeptide hormones have been proposed as being regulators of
growth in lung cancer. Epidermal growth factor (EGF) is a polypeptide hormone
that has both growth stimulatory and growth inhibitory effects on normal and tumour
cells in vitro (Kamata et al., 1986). Both NSCLC and SCLC have receptors for EGF
and various studies have shown that EGF can have both stimulatory (Haeder et al.,
1988; Veale et al., 1989) and inhibitory effects (Rabiasz et al., 1992) on tumour cell
growth. Similarly, the data available for nerve growth factor (NGF) in lung cancer is
conflicting. One group has reported that NGF can stimulate clonal growth of human
SCLC cell lines (Oelmann et al., 1995) while another group has reported that NGF
abrogates the tumourigenicity of SCLC cell lines (Missale et al., 1998). These
differences may be attributable to the use of different cell lines expressing different
receptor populations but more work is required to elucidate the role ofNGF in lung
cancer cell proliferation.
1.2.4c Stem cell factor and c-kit
Over 70% of SCLC cell lines and tumour specimens co-express the c-kit proto-
oncogene and its ligand stem cell factor (SCF) (Hibi et al., 1991; Plummer, III et al.,
1993; Rygaard et al., 1993). The c-kit gene encodes a tyrosine kinase growth factor
receptor in the same group as those for platelet-derived growth factor (PDGF) and
colony stimulating factor-1 (CSF-1) (Yarden et al., 1987). SCF, also known as mast
cell growth factor, kit ligand or steel factor is a haemopoietic growth factor that can
support the proliferation and differentiation of multiple haemopoietic cell lineages
from early precursors (Martin et al., 1990; Anderson et al., 1990; Huang et al., 1990).
Growth stimulation by exogenous SCF has been demonstrated in selected SCLC cell
lines (Sekido et al., 1993). However, most SCLC cell lines that co-express receptor
and ligand fail to respond to soluble SCF (Turner et al., 1992). In order to examine
this further Krystal et al., (1996) transfected a SCLC cell line that expresses only
SCF, with a c-kit expression vector. The transfected cells grew more vigorously in
serum-free medium compared with control-transfected cells. This growth advantage
could be blocked by a selective tyrosine kinase inhibitor. Furthermore, a cell line
which naturally co-expresses SCF and c-kit was transfected with a kinase-defective
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c-kit gene. These cells showed a marked decrease in their ability to grow under
growth factor-free conditions compared with cells transfected with the empty
expression vector. Taken together these experiments showed that SCF and c-kit do
contribute to SCLC growth.
1.3 THE TUMOUR CELL MICROENVIRONMENT
Under normal physiological conditions, tissue architecture is a complex and highly
ordered arrangement. Far from existing as independent units, cells are critically
dependent upon interactions with their immediate environment. The mammalian
organism is divided into a series of tissue compartments separated by the
extracellular matrix unit consisting of the basement membrane and its underlying
interstitial stroma. Both the interstitial matrix and the basement membranes contain
collagens, glycoproteins and proteoglycans. The interstitial matrix, which is
produced by mesenchymal cells, contains fibrillar collagens, fibronectin, hyaluronic
acid and fibril-associated proteoglycans. The basement membrane is produced by
parenchymal cells. Cells are polarised to it such that their basal surfaces abut it.
Basement membranes are composed of collagen type IV, laminin and proteoglycans.
Although tumour stroma is composed of the same components as normal connective
tissues it is recognised that the amounts of extracellular matrix (ECM) can vary
markedly between tumours. At one end of the spectrum lie tumours such as
scirrhous carcinomas where almost all of the tumour mass is formed by dense, hard
collagenous connective tissue and at the other end are, for example, medullary
carcinomas with only minimal connective tissue between clusters of tumour cells.
1.3.1 Extracellular matrixproteins
1.3.1a Fibronectin
The fibronectin family consists of a large family of heterodimeric and polymeric
glycoproteins. In humans, fibronectin is encoded for by a single gene and is notable
for its multiple forms of alternative splicing (Kornblihtt and Gutman, 1988).
Splicing of the IIICS region can be combined with splices of the ED-A and ED-B
regions to form the 20 variants constituting the fibronectin family. The final product
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is a dimer of approximately 250 kDa. While the IIICS region has adhesive functions
the roles of the ED-A and ED-B regions have been unknown until recently. Recent
studies show that they are expressed during tissue remodelling including
embryogenesis, injury and wound healing and in malignancy (Vartio et ah, 1987;
Peters et ah, 1988).
Fibronectin is the prototype cell attachment protein found in the matrix surrounding
normal cells. Fibronectin mediates cell adhesion and anchorage through a number of
fibronectin-binding integrins including a5pi, a3(31 and a4pi. Secreted fibronectin
does not form matrix spontaneously. Cells use a5pi integrin to capture secreted
fibronectin and convert it into fibrils, which are then deposited in the matrix.
1.3.1b Laminin
Laminin is the major glycoprotein found in the basement membrane. It is able to
bind to other matrix components such as type IV collagen, heparan sulphate
proteoglycan and entactin and to itself. Laminin is composed of three chains
designated A, B1 and B2 which are held together in a cruciform-like structure by
disulphide bonds. The complete structure has now been determined through cDNA
cloning and sequencing (reviewed in Sasaki and Yamada, 1987).
Laminin has a variety of biological activities including promotion of cell adhesion,
polarity, growth, migration, differentiation, neurite outgrowth and formation of
tumour metastases.
Using proteolytic cleavage and specific antibodies recent progress has been made in
identifying, at the amino acid level, some of the biologically active sites on laminin.
A unique sequence of five amino acids, YIGSR, from one of the EGF-like repeats in
the pi chain, has been identified as important in promoting cell adhesion and
migration. An RGD sequence in the A chain can also promote cell attachment. It is




Collagen is the most abundant protein in mammals constituting about one quarter of
the total. It is the major fibrous element of skin, bone, tendon, cartilage, blood
vessels and teeth. It is present to some extent in nearly all organs and serves to hold
cells together in discrete units. Five forms have now been described and the basic
structural motif is modified to meet the specialised needs of particular tissues.
Collagen IV and collagen V are the only types to be found in basement membrane,
and in the lung are localised to the basement membrane of the alveolar walls of
capillaries and bronchioles. Within the basement membrane collagen IV co-localises
with laminin and provides a scaffold on which other components of the basement
membrane are formed.
1.3.Id Tenascin
The tenascin family comprises four members, C-, R-, X- and Y-tenascin (Chiquet-
Ehrismann et al., 1994). Tenascin-C was identified initially and is the best
characterised form. It is a high molecular weight glycoprotein consisting of 6 similar
subunits linked to their amino terminal by disulphide bonds. Tenascin is widely
expressed in the developing brain, cartilage and mesenchyme and is re-expressed in
tumours, wound healing and sites of inflammation. This apparently regulated and
specific expression implies a crucial role in embryonic development and
restructuring. Although various roles for tenascin have been proposed as a result of
in vitro work, recent experiments using a tenascin-C gene knockout revealed that
tenascin deficient mice develop normally and show no apparent defects (Saga et ah,
1992). Therefore, at present the role for tenascin remains elusive.
1.3.2 Proteoglycans
In addition to proteins and glycoproteins, tumour stroma contains significant
amounts of proteoglycans, including versican, decorin and various chondroitin
sulphate-based proteoglycans. These molecules have recently been implicated in the
regulation of cytokine concentration and function in tumours (Iozzo and Cohen,
1994). Several tumours are reported to contain elevated levels of decorin and
chondroitin sulphate. It is speculated that some cytokines such as PDGF, EGF,
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fibroblast growth factor and transforming growth factor a and P may be presented by
binding to proteoglycans (Yeo et al., 1991).
1.3.3 Inflammatory cells and cytokines
The presence of leucocytes in tumour tissues has been recognised for many years.
Their role is still unclear. However, it has been demonstrated that macrophages,
when appropriately stimulated, are capable of killing transformed cells in vitro
whereas untransformed cells are normally fairly resistant to killing by activated
macrophages (Adams and Snyderman, 1979). Although in vivo studies are difficult
to perform, one group has recently reported that the number ofmacrophages in
human tumours inoculated in nude mice was negatively correlated with tumour size
(Zhang et al., 1997). Whether this finding is a true representation of the in vivo
situation is uncertain. Novel immunohistochemical techniques suggest that the
number of inflammatory cells present in a tumour is possibly much higher than
previously appreciated. Such results raise the question of whether tumours are able
to regulate the recruitment of inflammatory cells. Human tumours are reported to
release a range of factors chemotactic for monocytes and macrophages including
monocyte chemotactic protein-1 (MCP-1) (Graves et al., 1989; Yoshimura et al.,
1989), MCP-2 and MCP-3 (Van Damme et al., 1992), tumour necrosis factor (TNF),
vascular endothelial growth factor (VEGF) and macrophage colony stimulating
growth factor (Clauss et al., 1990; Graves and Valente, 1991). Furthermore, an
inhibitory polypeptide known as macrophage deactivating factor has been reported
(Ding et al., 1990). This suggests that a balance between chemotactic and inhibitory
cytokines may regulate extravasation ofmonocytes in neoplasms. A further degree
of complexity resulted from the identification that macrophages could enhance the
proliferation of tumour cells. The macrophage products interleukin-6 (IL-6), IL-1
and TNF have been reported to promote ovarian carcinoma proliferation (Naylor et
al., 1993). Such data suggest the existence of a paracrine loop.
1.3.4 Proteases
Tumours, like all actively growing tissues, are constantly turning over. New blood
vessels, ECM and basement membrane are constantly being laid down and
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subsequently remodelled. ECM is degraded by proteases ofwhich several types
have been identified in tumours including plasmin, cathespins and matrix
metalloproteinases (MMP). MMPs are believed to promote tumour progression by
initiating carcinogenesis, enhancing tumour angiogenesis, disrupting local tissue
architecture and by breaking down basement membrane barriers for metastatic
spread. Although some MMPs are expressed by tumour cells themselves (MMP-2, 7
and 13), most are produced by surrounding host stromal and inflammatory cells in
response to factors released by tumours (Guo et al., 1997). As well as proteases,
inhibitors of proteases exist in tumour tissues. Overexpression of a tissue inhibitor of
metalloproteinases (TIMP) led to suppression of tumour growth in an in vivo model
of breast carcinoma (Anand-Apte et ah, 1996). However, a number of studies
correlating the levels ofmatrix metalloproteinases and TIMPS with outcome from
cancer have shown a mixed picture. Sier et ah (1996) measured MMP-2 and MMP-9
in gastric carcinomas and found that high levels were of prognostic significance for a
poor overall survival. Similar studies in breast carcinoma failed to show any
correlation between MMP levels and outcome (Remacle et ah, 2000). In lung
cancer, recent surveys ofMMPs and TIMPs have shown that they are widely
expressed in both NSCLC and SCLC but again a correlation between expression
levels and prognosis is unclear (Michael et ah, 1999; Thomas et ah, 2000).
1.4 INTEGRINS
The term integrin is used to describe cell surface receptors that mediate cellular
adhesion to ECM proteins and to other cells (Tamkun et ah, 1986; Ruoslahti and
Pierschbacher, 1987). Integrins are composed of non-covalently associated a and (3
chains which form heterodimeric receptor complexes. Each subunit contains a large
extracellular domain, a short transmembrane domain and a cytoplasmic carboxy
terminal domain of variable length. The extracellular domains of the a and P chains
are responsible for ligand binding. To date, the integrin family is composed of 17 a
and 8 p subunits that form heterodimers to produce some 22 different a.p cell surface
receptors. Whilst some subunits (P4) only bind with one other subunit (a.6), others
such as pi, P2 and av are far more promiscuous. The extracellular ligand-binding
specificity of an integrin is generated jointly by both subunits. As well as binding to
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various ECM components such as fibronectin, collagen and laminin, certain integrins
can bind soluble ligands such as fibrinogen or counter receptors on adjacent cells
such as intracellular adhesion molecules. Integrins display various degrees of
specificity. While some integrins are widely expressed, others are only expressed in
one cell type. Examples of such cell type specific integrins are allbp3 in platelets
and a6p4 in epithelial cells. Although some integrins selectively recognise a single
ECM protein ligand, others can bind two or more ligands (Hynes, 1992). Several
integrins recognise the tripeptide Arg-Gly-Asp (RGD), whereas others recognise
alternative short peptide sequences. Nevertheless, they are capable of distinguishing
different RGD sequences such that some bind primarily to fibronectin and others to
vitronectin (Ruoslahti and Pierschbacher, 1986).
1.4.1 Integrins in cancer
It has been known for a long time that tumour cells, unlike normal cells, have the
ability to grow in suspension and are not dependent upon adhesion to an ECM for
survival, so called anchorage-independent growth. Anchorage-independence
correlates with tumourigenesis in vivo. Not surprisingly, the role of integrins in
tumour growth has received considerable attention.
Fibronectin mediates cell adhesion and anchorage through a number of integrins, in
particular a5pi. The fibronectin matrix appears to play an important role in the
behaviour of cells. When Chinese hamster ovary cells were transfected with the a5
and pi integrin subunit genes, a 30-fold increase in expression of a5pi was achieved
and the cells showed a loss of tumourigenicity and a decrease in proliferation rate
(Giancotti and Ruoslahti, 1990). Conversely, loss of a5pi expression led to
enhanced tumourigenicity (Schreiner et al., 1991). While some of the a5pi integrin
effect may be related to the signalling role of the integrin (Varner et al., 1995), the
increase in fibronectin matrix assembly that accompanies increased a5pi expression
or activity appears to be responsible for most of the effect (Giancotti and Ruoslahti,
1990; Wu et al., 1996). Loss of expression of a2pi in breast epithelial cells has been
correlated with the transformed phenotype and ectopic expression of a2pi in the
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same cell type has been shown to suppress growth and induce differentiation (Zutter
et ah, 1995).
By contrast, expression of some integrins positively regulates tumour cell
proliferation. The integrin avp3 is seen in malignant melanomas but not in benign
forms (Albelda et ah, 1990). When melanoma cells were selected for loss of the av
integrin subunit, the cells exhibited significantly reduced proliferation and
tumourigenicity and this could be restored by re-expression of the integrin (Felding-
Habermann et al., 1992; Sanders et al., 1992). Expression of a3 and a6 integrin
subunits is also associated with transformation and tumour progression. Integrin
a3(31 is expressed in a high percentage of metastatic tumours (Bartolazzi et al., 1994)
and a6 is expressed in head and neck, bladder and lung cancers (Costantini et al.,
1990; Van Waes and Carey, 1992; Liebert et al., 1993).
1.4.2 Anchorage independence and anoikis
The fundamental difference between a transformed cell and an untransformed cell is
that the former has the potential to metastasise and invade. In order to achieve this
the cancer cell must become independent of anchorage. This phenomenon has been
recognised for many years but it is only relatively recently that it has been recognised
to be an integrin-mediated event, and even more recently that the molecular
mechanisms underlying it have begun to be elucidated (Frisch and Francis, 1994). If
an untransformed endothelial or epithelial cell becomes detached from its matrix it
undergoes apoptosis. This has been termed anoikis (Frisch and Francis, 1994). The
likely biological purpose of this response is that it causes detached cells to die before
they can reattach in a new location and disturb normal tissue architecture. However,
transformed cells are able to overcome these regulatory control mechanisms, migrate
in the bloodstream or lymph and invade new tissues thus spreading the cancer.
Anchorage-independent transformed cells are able to circumvent the necessity of
integrin-mediated signalling. The mechanisms by which this can occur seem to be
varied but probably focus around focal adhesions. Focal adhesions are specialised
areas of cell-matrix contact in which integrin clusters link actin filaments to ECM.
As a result of the integrin and cytoskeletal clustering, various signalling molecules
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including a number of protein tyrosine kinases become concentrated in focal
adhesions at the cytoplasmic surface of the cell membrane. One such kinase is focal
adhesion kinase (FAK) which can bind directly to integrin cytoplasmic domains.
Activated FAK is able to activate the Ras/Raf/mitogen activated protein kinase
(MAPK) pathway through the adapter protein Grb-2 as well as the phosphoinositide
3-kinase (PI 3-kinase) pathway (Chen and Guan, 1994a; Schlaepfer et al., 1994).
Recent work by Khwaja et al., (1997) suggests that the PI 3-kinase/protein kinase B
pathway plays a more important role in preventing anoikis than does the MAPK
pathway. The importance ofFAK in regulating anoikis is further supported by the
observation that microinjection of a peptide-mimicking the FAK binding site of the
pi integrin cytoplasmic domain inactivates endogenous FAK and induces anoikis
(Hungerford et al., 1996). The role ofFAK in integrin signalling is discussed in
more detail in the section on integrin signalling below.
1.4.3 Invasion andmotility
Cell migration is a result of a dynamic interplay between the migrating cell, the ECM
and the cellular cytoskeleton. The a5pi, avp3 and other av integrins appear to play
an important role in cell migration. The avP3 integrin has a central role in
melanoma survival and metastasis. Negative selection of avP3 expressing
melanoma cells results in cells that cannot form tumours or invade. Restoration of
avp3 expression by transfection leads to tumour formation and the ability to invade
the dermis (Albelda et al., 1990; Natali et al., 1997). In wound healing keratinocytes
express the av integrin subunit at the leading edge of the epidermis migrating into
the wound (Gailit et al., 1994; Zambruno et al., 1995; Sheppard, 1996). The a5pi
integrin is also expressed in migrating but not resting keratinocytes (Zambruno et al.,
1995). Cell migration is dependent upon rapid controlled alterations of the affinity
of integrins for their extracellular ligands. Thus, the repeated activation and
inactivation of integrins regulates cell migration through co-ordinated adhesion at the
leading edge of the cell and de-adhesion events at the trailing edge. The NPXY
motif, which regulates the activation of integrin p subunits, may play a critical role
during tumour cell migration. Transfection of melanoma cells with a mutated NPXY
sequence inhibits tumour cell migration in vitro and metastasis formation in vivo
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(Filardo et al., 1995). Recent work suggests that cell migration and invasion is likely
to be regulated by complex interactions between 'outside-in' signalling and 'inside-
out' signalling. It seems likely that members of the small GTP-binding protein
family such as R-ras and H-ras play an important role here. R-ras activates integrins
(Zhang et al., 1996), whereas H-ras blocks integrin activation (Hughes et al., 1997).
The modulation of integrin affinity will be considered in more detail in Chapter 5.
In addition to the mechanisms discussed above, cell migration and invasion is also
dependent upon proteases to facilitate the breakdown of tissues and allow tumour
cells to spread. This is covered in the section on proteases (see above).
1.4.4 Angiogenesis
Tumours up to 1 mm are able to obtain nutrients and oxygen by diffusion.
However, further growth requires the development of a blood supply. Certain
integrins have been shown to play a crucial role in the process of angiogenesis. The
integrin avP3 is minimally expressed on resting or normal blood vessels but is
significantly upregulated on vascular cells within tumours (Brooks et al., 1994a;
Brooks et al., 1994b; Brooks et al., 1994b) and in response to growth factors (Sepp et
al., 1994). The induction of tumour angiogenesis is mediated by the release of a
variety of angiogenic molecules including basic fibroblast growth factor (bFGF),
transforming growth factor a (TGFa), VEGF and TNFa from tumour cells and host
cells (Fidler and Ellis, 1994). These growth factors promote increased expression of
the Hox D3 homeobox gene, which, in turn, controls expression of avP3 (Boudreau
et al., 1997). Evidence to support a role for av|33 integrin in angiogenesis comes
from experiments using a monoclonal antibody to avp3 which was able to inhibit
angiogenesis both in vitro and in vivo (Friedlander et al., 1995). Recently the
existence of a second angiogenic pathway has been demonstrated. Whereas bFGF
mediates avP3 mediated angiogenesis, VEGF appears to mediate an avP5-dependent
mechanism (Friedlander et al., 1995).
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1.5 INTEGRIN SIGNALLING
Despite the vast amount of work that has been done on integrin signalling no specific
integrin mediators have been identified. Instead, the majority of signalling molecules
implicated in ECM-integrin interactions are the rather ubiquitous mediators of signal
transduction. At least twenty different proteins including Rho GTPases, Raf, Ras,
FAK and MAPKs, PI 4-kinase and PI 3-kinase can be recruited to the ECM
ligand/integrin-binding site.
1.5.1 FAK
The binding of ligands to integrin receptors leads to integrin cross-linking and
clustering (Komberg et al., 1991). This promotes the formation of focal adhesions at
the cell membrane. A large number of structural and signalling proteins including
integrins, cytoskeletal proteins and protein kinases have been shown to be
concentrated at these sites. Actin binding proteins that co-localise with integrins at
focal adhesion plaques include a-actinin, talin, tensin, paxillin and vinculin
(Richardson and Parsons, 1995). Early work demonstrated that tyrosine kinase
inhibitors could block the formation of focal adhesions (Burridge et al., 1992).
Integrins, however, lack intrinsic tyrosine kinase activity. This led to the
identification ofFAK, a 120 kDa non-receptor tyrosine kinase. FAK undergoes
rapid tyrosine kinase phosphorylation following integrin ligation and clustering
(Schaller et al., 1992; Hanks et al., 1992). The mechanism by which integrins
activate FAK is incompletely understood. Although FAK is unable to phosphorylate
other substrates directly, integrin-dependent autophosphorylation allows it to interact
with docking or adapter proteins including paxillin, tensin and Grb-2 (Vuori et al.,
1996; Schlaepfer and Hunter, 1997; Schlaepfer et al., 1997). These, in turn, are able
to activate downstream signalling mediators including the Ras/Raf/MAPK pathway
and the PI 3-kinase/protein kinase B pathway (Chen et al., 1996). Evidence for a
role for FAK in integrin-mediated signalling comes from experiments in which
tyrosine residues critical for FAK autophosphorylation are mutated (Schlaepfer et al.,
1994). In this case integrin-mediated proliferation is blocked. Furthermore,
oncogenic transformation of cells, which removes the requirement for anchorage-
dependent growth, activates FAK (Guan and Shalloway, 1992). Consistent with
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these findings is the observation that constitutively active FAK leads to cell
transformation, anchorage-independent growth and the suppression of apoptosis
(Frisch et al., 1996).
In addition to activation by integrins, FAK can be activated by certain soluble growth
factors. Recent work has shown that focal adhesions also contain receptors for
bFGF, EGF and PDGF (Plopper et al., 1995; Miyamoto et al., 1995; Miyamoto et al.,
1996). Recruitment of growth-factor receptors to focal adhesions has been shown to
result in enhanced phosphorylation and activation of the growth-factor receptor,
accumulation of downstream substrates and an enhanced growth response to
exogenous mitogens.
1.5.2 Phosphoinositide 3-kinase
The role ofPI 3-kinase in integrin signalling is discussed in the section on PI 3-
kinase (see below).
1.5.3 MAPK
Activation of the MAPK pathway leads to transcriptional regulation of genes that are
crucial for cell growth and differentiation. Early studies showed that the MAPK
pathway could be activated by soluble mitogens. Adhesion of cells to ECM proteins
including fibronectin, vitronectin, collagen, tenascin and laminin can also activate the
MAPK pathway probably through FAK as described above. In vivo, it is likely that
integrins and growth factor receptors may synergise to enhance Ras-MAPK
activation. However, activation ofMAPK independent ofFAK and Ras can occur
implying the use of alternative or parallel pathways. In certain cases FAK related
proteins such as CAKp and PYK2 may compensate for FAK thereby linking
integrins to MAPK by alternative effectors (Lev et al., 1995)
1.6 PHOSPHOINOSITIDE 3-KINASE SIGNALLING
1.6.1 The canonicalphosphoinositide pathway
For many years our knowledge of phosphoinositide metabolism was confined to the
canonical phosphoinositide turnover pathway. In this pathway phosphatidylinositol
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is sequentially phosphorylated by PI 4-kinase and PI(4)P 5-kinase to generate
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). PtdIns(4,5)P2 is the major
substrate of phospholipase C (PLC). Activation of PLC in response to ligand-
receptor interaction results in the hydrolysis of PtdIns(4,5)P2 by PLC and the
generation of two second messengers, inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol (DAG). IP3 promotes release of Ca2+ from intracellular stores and
DAG activates PKC (Figure 1.2). Both the rises in intracellular Ca2+and PKC
activity are thought to be important steps in signalling from the cell surface to the
nucleus.
1.6.2 Phosphoinositide 3-kinase
PI 3-kinase was identified following characterisation of the different PI kinase
activities present in fibroblasts. Two biochemically distinct PI kinases termed type I
and type II had previously been recognised. Type I PI kinase activity could be
distinguished from type II by its preference for substrate presented as vesicles rather
than micelles, by its Km for ATP and by its resistance to inhibition by adenosine
(Whitman et al., 1987). Using immunoprecipitates of pp60v-src and middle
T/pp60c-src complexes derived from transformed cells, Whitman et al., (1988)
showed that type I PI kinase specifically phosphorylated the D3 position of the
inositol ring to generate a novel phospholipid, PtdIns(3)P. In contrast, the main PI
kinase in fibroblasts (Type II) specifically phosphorylated the D4 position to produce
PtdIns(4)P. At about the time that PI 3-kinase was first described, PtdIns(3,4,5)P3, a
lipid not previously known to exist, was detected in activated neutrophils (Traynor-
Kaplan et al., 1988). Subsequently, PI 3-kinase was shown to phosphorylate





















Three classes of PI 3-kinase have now been described on the basis of their primary
structure, regulation and in vitro lipid substrate specificity.
Class I PI 3-kinases phosphorylate Ptdlns, PtdIns(4)P and PtdIns(4,5)P2 to
PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3 respectively. However, PtdIns(4,5)P2
is believed to be their preferred substrate. Class I PI 3-kinases are heterodimeric
complexes comprised of a catalytic subunit (pi 10) and a regulatory subunit (p50,
p55, p85 or p 101). Class I PI 3-kinase catalytic subunits can be divided into two
subclasses according to the type of regulatory subunit with which they associate.
Class la PI 3-kinases comprise either an a, P or 5 pi 10 catalytic subunit plus one of a
family of regulatory subunits (p85a, p85[3, p55y and their splice variants). The
regulatory units bind phosphorylated tyrosine residues, thereby linking class la PI 3-
kinase subunits to tyrosine kinase signalling pathways. Each regulatory subunit
protein contains two SH2 domains linked by an inter-SH2 region to which the
catalytic subunit binds. The SH2 domains bind phosphorylated tyrosine residues
specifically within a P-Tyr-x-x-Met motif. The 85 kDa adapters also contain an SH3
domain and a breakpoint cluster region homology domain whose precise role is
unclear.
Class lb PI 3-kinases are stimulated by G-protein Py subunits and do not interact with
the SH2 domain containing adapters that bind to class la PI 3-kinases. The
mammalian form of the catalytic subunit in this class is pi lOy and this has been
shown to bind to a plOl regulatory subunit (Stephens et al., 1994). To date, pi lOy
has only been identified in haemopoietic cell types and osteosarcoma cell lines
(Stephens et al., 1994; Morris et al., 1995).
Class II PI 3-kinases phosphorylate Ptdlns and PtdIns(4)P, in vitro, but not
PtdIns(4,5)P2. Presently it is not known whether class II PI 3-kinase activity is
regulated by extracellular stimuli. Class III PI 3-kinases have a substrate specificity
restricted to Ptdlns. These PI 3-kinases are homologous to Vps34p, the only PI 3-
kinase present in yeast.
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1.6.3 Mechanism ofactivation ofPI 3-kinase
Class I PI 3-kinases can be activated by the majority of receptors with intrinsic or
associated tyrosine kinase activity and by receptors linked to heterotrimeric G
proteins. Phosphorylated tyrosine residues, generated on receptors (e.g. PDGF-R) or
associated substrate molecules (e.g. IRS-1), form the docking sites for the SH2
domains of the PI 3-kinase adapter subunits. This adapter-mediated translocation of
PI 3-kinases to receptor tyrosine kinases and their substrates is likely to help position
the catalytic subunits close to membranes that contain their lipid substrates. At
present the mechanism of activation of PI 3-kinase via G-protein coupled receptors is
not fully understood.
All class I PI 3-kinases can be activated by the small GTP binding protein Ras
(Rodriguez-Viciana et al., 1994; Kodaki et al., 1994; Rodriguez-Viciana et al., 1996).
Evidence from experiments using PDGF-R mutants also suggests that accumulation
of GTP-bound Ras is required for full activation of class la PI 3-kinases by PDGF.
However, at present it is not known to what extent PI 3-kinase activation by receptor
tyrosine kinases also occurs independently of Ras.
1.6.4 Integrin Activation
Although not fully understood, integrin activation of PI 3-kinase is believed to occur
through a number ofmechanisms. The best characterised mode of recruitment of PI
3-kinase is via the association of the SH2 domain of the p85 subunit with the tyrosine
phosphorylated sequence P-Tyr-x-x-Met in the cytoplasmic domain of a cell surface
receptor. A number of integrin regulators possess this motif, in particular CD28,
CD7 and CD19 (Weng et ah, 1994; Ward et ah, 1995; Rudd, 1996). Other molecules
that function as integrin regulators, such as CD2, CD3 and surface immunoglobulins
are also coupled to PI 3-kinase signalling pathways although the mode of association
of PI 3-kinase does not appear to involve a P-Tyr-x-x-Met motif (Shimizu et ah,
1995; Cambier, 1995). Another mechanism of integrin activation of PI 3-kinase is
through FAK. Phosphorylation ofFAK occurs upon clustering of (31 integrins and
PI 3-kinase has been shown to associate with phosphorylated tyrosine residues of
FAK (Kornberg et ah, 1992; Chen and Guan, 1994b; Chen et ah, 1996).
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Alternatively, as PI 3-kinase is a major target of Ras, the activation of PI 3-kinase by
integrins could be mediated by the ability of the SH2-SH3 adapter protein She to
activate Ras. She is known to lie in close proximity to focal adhesion complexes
which are formed on the integrin binding of specific heterodimers such as
alpl, avp3 and a5pi (Wary et al., 1996; Giancotti, 1997).
1.6.5 Toolsfor studying the role ofPI 3-kinase
The majority ofwork examining the roles and downstream effectors ofPI 3-kinase
has made use of either pharmacological inhibitors or constitutively active or
dominant negative mutants of PI 3-kinase. The two principal pharmacological
inhibitors of PI 3-kinase that have been widely used are wortmannin and 2-(4-
morpholinyl)-8-phenyl-4H-1 -benzopyran-4-one (LY294002). Wortmannin,
originally isolated from soil bacteria, is a non-competitive inhibitor of PI 3-kinase
with respect to ATP. It binds irreversibly to the pi 10 catalytic subunit and alkylates
lysine 802 in the ATP-binding site (Powis et al., 1994; Wymann et al., 1996).
LY294002 is a morpholino derivative of the broad-spectrum kinase inhibitor
quercetin. It acts as a competitive inhibitor at the ATP binding site of PI 3-kinase
(Vlahos et al., 1994a). The IC50 values for wortmannin and LY294002 are 3 nM and
1.4 pM respectively. Neither compound shows any significant selectivity within the
PI 3-kinase family. Most isoforms are inhibited at comparable concentrations to
those required to inhibit p85a/pl 10a. Recently some doubt has been cast on the
specificity ofwortmannin and LY294002 as both compounds lose specificity for PI
3-kinase at higher concentrations. Protein kinases related to PI 3-kinase such as
ataxia telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK)
are also inhibited by LY294002 and wortmannin at concentrations 50-100 fold
higher than those that inhibit p85a/pl 10a (Stein and Waterfield, 2000). LY294002
has also been found to inhibit casein kinase 2 at similar concentrations to those
which inhibit PI 3-kinases (Davies et al., 2000). This finding may have implications
for the interpretation of data obtained using LY294002, as casein kinase 2 is a
ubiquitous, constitutively active kinase that is involved in transcription, signalling
and proliferation. However, awareness of the shortcomings of each compound
32
coupled with their use at appropriate concentrations should allow them to continue to
be used in the investigation ofPI 3-kinase and its effectors.
Using these tools, PI 3-kinase has been implicated in a wide range of cellular
functions including secretion and trafficking, morphological change, proliferation,
resistance to apoptosis, transformation, anchorage independence and migration.
1.7 EFFECTORS OF PI 3-KINASE
1.7.1 Protein Kinase B
Protein kinase B (PKB), also known as Akt and RAC, is a 57 kDa serine/threonine
kinase which was first identified in 1991 by three independent groups. Two groups
identified the kinase as a result of its homology to both protein kinase A and protein
kinase C. A third group identified the kinase as the product of the oncogene v-akt of
the acutely transforming retrovirus AKT8 found in a rodent T-cell lymphoma
(Bellacosa et al., 1991; Coffer and Woodgett, 1991; Jones et al., 1991a).
Mammals have three closely related PKB genes that encode the isoforms PKBa,
PKBP and PKBy. PKB(3 and PKBy share 81% and 83% homology with PKBa
respectively. PKB has both a serine/threonine kinase domain and a pleckstrin
homology (PH) domain at its amino-terminal end (amino acids 1-106), which makes
up the major part of the amino-terminal regulatory domain (residues 1-147). The
kinase domain stretches from amino acid 148-411, with the carboxy-terminal tail
region (amino acids 412-480) accounting for the remainder of the protein.
All PKB isoforms show a broad tissue distribution. Highest levels have been shown
to exist in the brain, thymus and lung (Coffer and Woodgett, 1991; Jones et al.,
1991b). Expression ofPKBy appears to be more selective with the highest levels
found in the brain and testes. Currently, little is known about the regulation of
expression ofPKB; however, it appears to be upregulated as cells become terminally
differentiated (Altomare et al., 1995; Kohn et al., 1996).
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PKB can be activated by a wide variety of growth stimuli including insulin,
thrombin, NGF, PDGF and EGF. It is now well established that PKB is a
downstream effector of PI 3-kinase. Evidence to support this concept has come from
several avenues. Growth factor-induced activation ofPKB is inhibited by the PI 3-
kinase inhibitor wortmannin and also by the expression of a dominant negative form
ofPI 3-kinase, Ap85, derived from its regulatory subunit (Franke et al., 1995). In
addition, the ability ofmutants of the PDGF receptor to activate PKB correlates with
their ability to activate PI 3-kinase. PDGF receptors in which Tyr740 and Tyr751 have
been mutated to phenylalanine fail to bind to the SH2 domains of p85 and fail to
stimulate both PI 3-kinase and PKB activity (Franke et al., 1995). Furthermore, the
expression of constitutively active forms of PI 3-kinase result in stimulation ofPKB
(Klippel et al., 1996; Marte and Downward, 1997; Franke et al., 1997).
1.7.1a Mechanism of activation ofPKB
Full activation ofPKBa by insulin and growth factors requires phosphorylation of
both Thr308 in the kinase domain and Ser473 in the C-terminal regulatory domain
(Alessi et al., 1996). The PKBP and PKBy isoforms are also activated by
phosphorylation of residues equivalent to Thr308 and Ser473 (Walker et al., 1998).
Thr308 is phosphorylated by 3'-phosphoinositide-dependent kinase-1 (PDK1) (Alessi
et al., 1997). PDK1 is a 63 kDa serine/threonine kinase which is ubiquitously
expressed in human tissues. It consists of an N-terminal kinase domain and a C-
terminal PH domain. In vitro, its PH domain binds PtdIns(3,4,5)P3 and PtdIns(3,4)P2
with higher affinity than other Pis such as PtdIns(4,5)P2. Initially it was thought that
phosphorylation of Ser473 would be catalysed by a distinct protein kinase and this
was provisionally named PDK2 (Alessi et al., 1997). The true identity of this kinase
is still unknown. It has recently been claimed that integrin-linked kinase is capable
of phosphorylating Ser473 ofPKBa in vitro (Delcommenne et al., 1998). A more
recent study suggests that integrin-linked kinase may not directly phosphorylate PKB
at Ser473 but rather promote phosphorylation by an indirect mechanism (Lynch et al.,
1999). PDK1 has also been shown to interact with a fragment of the C-terminus of
PKC-related kinase 2 which has been named PDK1 -interacting fragment (PIF)




























PIF converts PDK1 from an enzyme that phosphorylates PKBa only on Thr to one
that can phosphorylate PKBa at both Thr308 and Ser473. This area needs further work
but it does suggest that PDK1, in complex with another protein, may mediate the
phosphorylation ofPKBa on Ser473 rather than it being phosphorylated by a distinct
enzyme. Very recently this version of events has been challenged by Toker and
Newton, (2000). They suggest that phosphorylation of Thr308 triggers
autophosphorylation of Ser473 both in vitro and in vivo, indicating that PDK2 or
'PDK2-like' activity is not required for PKB activation.
The current model of activation for PKB suggests that upon activation ofPI 3-kinase,
PKB translocates from the cytosol to the plasma membrane and interacts with
PtdIns(3,4,5)P3/PtdIns(3,4)P2 via its PH domain (Figure 1.3). This interaction
induces a conformational change in PKB, which converts it into a substrate for
PDK1, possibly by exposing Thr308 and Ser473 phosphorylation sites. Membrane
localised PDK1 complexes with PIF allowing it to phosphorylate PKB at Thr308 and
Ser473. Activated PKB then translocates to the cytosol and nucleus.
1.7.1b Biological functions of PKB
Since PKB activity is stimulated by a variety of growth factors and insulin, much
effort has focussed on investigating the metabolic effects associated with its
activation. Currently there are no pharmacological inhibitors ofPKB and as a result
the approaches used to assess the role ofPKB have involved expression of activated
alleles or dominant negative mutants.
The majority ofPKB substrates described to date are either involved in the regulation
of insulin metabolism or in cell survival pathways. Figure 1.4 shows the currently
known targets ofPKB. The first direct in vivo substrate to be identified was
glycogen synthase kinase-3 (GSK3). PKB mediated phosphorylation of GSK3 leads
to GSK3 inactivation and the consequent activation of glycogen synthesis (Shaw et
al., 1997a). PKB has also been found to stimulate glucose uptake and GLUT4, a










Targets of PKB phosphorylation. A horizontal bar or an arrowhead indicate an
inhibitory or stimulatory effect ofPKB-mediated phosphorylation respectively. The
absence of a symbol indicates that the effect of PKB-mediated phosphorylation is
unclear at present. FH transcription factors, Forkhead transcription factors; PDE-3B,
phosphodiesterase-3B; mTOR, mammalian target of rapamycin; IRS-1, insulin
receptor-1; eNOS, endothelial nitric oxide synthase; GSK3, glycogen synthase
kinase-3.
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1.7.1c Anti-apoptotic signalling mediated by PKB
It has been demonstrated previously that inhibition ofPI 3-kinase blocks the ability
of survival factors to protect various cell types from programmed cell death (Yao and
Cooper, 1995). Transfection of constitutively active forms ofPI 3-kinase and PKB
can protect Cos-7 epithelial cells from apoptosis induced by ultraviolet irradiation
and neuronal cells from cell death induced by withdrawal of IGF-1 or NGF (Kulik et
al., 1997). Activated PI 3-kinase and PKB have also been shown to protect MDCK
cells from apoptosis induced by detachment of adherent cells from their extracellular
matrix (Khwaja et al., 1997).
The mechanism by which PKB protects cells from apoptosis has received intensive
study. PKB is able to phosphorylate the pro-apoptotic Bcl-2 family member BAD
both in vitro and in vivo (del Peso et al., 1997; Datta et al., 1997). Phosphorylation
ofBAD creates a binding site for 14-3-3, an adapter protein. Binding of 14-3-3
prevents BAD from undergoing heterodimerisation with, and inhibiting the activity
of, Bcl-2 and Bc1-Xl (Zha et al., 1996). However, BAD is only expressed in a
limited range of tissues and cell lines and most of the work reported to date on BAD
has made use of overexpressed protein often in cell lines that do not normally
express it. This suggests that in cells that do not express BAD, another mechanism
must be at work to explain the ability ofPKB to protect cells from apoptosis.
Recently the cysteine protease caspase-9 and the forkhead transcription factor
FKHRL1, both ofwhich are potent inducers of apoptosis, have been found to be
inhibited by PKB-mediated phosphorylation (Cardone et al., 1998; Brunet et al.,
1999).
1.7.2 P7(f6k
P70s6k is a serine/threonine protein kinase that phosphorylates the 40S ribosomal
protein S6. Translation of several hundred mRNAs with 5' oligopyrimidine tracts is
controlled by p70s6k. These mRNAs largely encode for proteins necessary for the
assembly of the translational machinery including ribosomes and elongation factors.
Work on p70s6k has been expedited by the discovery of a specific inhibitor,
rapamycin (Price et al., 1992). Rapamycin is an immunosuppressive macrolide,
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which forms a complex with a specific 12 kDa protein called FK506 binding protein-
12 (FKBP12). The rapamycin-FKBP12 complex binds and inhibits the
autophosphorylation of the mammalian target of rapamycin (mTOR).
P70s6k was the first effector of PI 3-kinase to be described. This work utilised
mutants of the PDGF(3 receptor as well as PI 3-kinase inhibitors to show that
inhibition ofPI 3-kinase activation also impaired p70s6k activation. However,
activation and regulation of p70s6k appears to be far more complex than originally
thought requiring phosphorylation of up to eight sites by at least three signalling
pathways.
The initial step in activating p70s6k seems to be mediated by the MAPK pathway.
This involves a phosphorylation-induced conformational change in the C-terminus of
the kinase domain, revealing additional phosphorylation sites (Dufner and Thomas,
1999). Subsequent phosphorylation is dependent upon the PI 3-kinase/PDKl (Alessi
et al., 1998; Pullen et al., 1998), TOR and PKC^ pathways (Romanelli et al., 1999).
However, the precise mechanism of activation of p70s6k remains elusive and will no
doubt become clearer in the near future.
1.7.3 PI 3-kinase mediated PKC activation
The PKC superfamily which comprises 12 protein kinases subdivided into
conventional PKCs, novel PKCs and atypical PKCs according to their activation
• 9+
profiles and requirement for DAG/phorbol esters, phosphatidylserine and Ca has
been studied extensively (Nishizuka, 1992).
More recently PI 3-kinase has been found to activate members of the PKC family via
PDK1 (Chou et al., 1998). The principal PKC family member involved appears to be
PKC^. PKCi^ has been shown to activate an NF-KB-like activity in vivo and to
phosphorylate a novel IkB kinase leading to gene transcription (L'Allemain et al.,
1989). PKCC, may exert its transcriptional activity via activation of the MAPK
pathway. There have now been several reports of the requirement of functional PI 3-
kinase and PKC^ for MAPK activation (Cai et al., 1997; Takeda et al., 1999).
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Therefore, evidence is now mounting that activation of PKC<^ by PI 3-kinase is
required for many cellular processes including mitogenesis, insulin signalling and
protein synthesis.
1.7.4 Regulation ofMAPK by PI 3-kinase
It is now well established that PI 3-kinase can, in part, activate the MAPK pathway.
This may occur by more than one mechanism and involve both PI 3-kinase, lipid
kinase activity, (via PKC^ as described above) and PI 3-kinase, protein kinase
activity. In addition to being a lipid kinase, PI 3-kinase possesses an intrinsic
Ser/Thr kinase activity. Bondeva et al., (1998) showed that a PI 3-kinase mutant
which had protein kinase activity but no lipid kinase activity could activate MAPK
but not PKB. This suggested that PtdIns(3,4,5)P3 is not required for MAPK
activation. However, the precise target ofPI 3-kinase protein kinase is not known
currently.
1.8 APOPTOSIS
Cells die either by necrosis or apoptosis. Unlike apoptosis or programmed cell death,
necrotic cell death is usually the result of an environmental insult. Necrosis is
characterised by damage to the plasma membrane such that the cell becomes
abnormally permeable to water and ions, swells and disintegrates, resulting in
cellular contents spilling into the extracellular space and causing an inflammatory
response (Wyllie, 1980). By contrast, in apoptosis, the plasma membrane remains
intact so that the cellular contents do not leak into the extracellular space and as a
result, there is no inflammation (Wyllie et al., 1980). This is extremely important to
minimise damage to healthy bystander cells. Macrophages and neighbouring
phagocytic cells rapidly phagocytose the apoptotic cell and its fragments creating
apoptotic bodies.
Apoptotic cells were initially identified by their morphological appearance (Wyllie et
al., 1980). Cells undergoing apoptosis shrink and lose up to one third of their
cytoplasmic and nuclear volume and the plasma membrane becomes ruffled and
blebbed. The nucleus condenses and its chromatin becomes very dense forming
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'pyknotic' spheres. These changes are accompanied by chromatolysis, which
involves the activation of endonuclease activity (Wyllie, 1980).
Apoptosis is essential for correct development and tissue homeostasis. It acts as a
defence mechanism protecting the organism against cells which have undergone
malignant transformation or which have been infected by viruses (Vaux et al., 1994).
Furthermore, cells that migrate to the wrong site during development undergo
apoptosis thereby protecting the correct architecture of tissues (Williams, 1991).
Much of the work elucidating the molecular mechanisms underlying apoptosis has
come from study of the nematode Caenorhabditis elegans. Of the 1090 cells formed
during development of this worm, 131 die by apoptosis (Ellis et al., 1991). Genetic
analysis has identified two genes, ced-3 and ced-4, that must function for these cells
to die (Ellis and Horvitz, 1986). If either gene is inactivated by mutation, death fails
to occur. A third gene ced-9 antagonises the function of ced-3 and ced-4 by
protecting cells from death (Hengartner et al., 1992). Cloning of ced-3 has shown
that its product is similar to the mammalian cysteine protease interleukin-ip-
converting enzyme (ICE) (Yuan et al., 1993). This observation lead to the
identification of a growing family of cysteine proteases with homology to CED-3
that have been designated caspases (Alnemri et al., 1996). To date more than 14
caspases have been cloned and partially characterised in mammals although not all
have been implicated in the apoptotic process. Two main caspase cascades have
been identified in mammalian cells (Figure 1.5). One pathway is activated by a
variety of either intra or extracellular death stimuli whilst the other links caspase-8 to
death receptors expressed at the cell surface including Fas, TNF-related proteins and
DR3. Activated caspase 8 and 9 can cleave and activate the 'effector caspases'
including caspases 3, 6 and 7 which result in increased expression of protease
activity and cell death.
The caspase cascade can be modified by various other factors. In the 1980s, two
































Figure 1.5 The caspase cascade. Apoptosis can be triggered by activation of the
caspase cascade through two linked pathways. Ligation of 'death receptors' such as
Fas, TNFR1 and DR3 activates caspase 8 or 10 via the adapter molecule FADD.
Alternatively, various intra- or extracellular 'death stimuli' trigger the release of
cytochrome c from mitochondria. It is believed that chemotherapeutic agents may
induce opening of the mitochondrial 'megachannel' (also called the permeability
transition pore). The megachannel is regulated by numerous endogenous effectors
including members of the Bcl-2/Bax family, the redox status of the cell, cytosolic
9+
Ca levels, ceramide and amphipathic peptides. Chemotherapeutic agents may
induce opening of the megachannel by modulating some of these endogenous
effectors. Subsequent disruption ofmitochondrial membrane integrity involves loss
ofmetabolic function and the liberation of intermembrane proteins into the cytosol
including cytochrome c. In the cytosol, cytochrome c can bind Apaf-1, which
enhances its ability to associate with procaspase 9. Activated caspase 8 and 9
activate effector caspases such as caspase 3. These caspases promote cleavage of
apoptosis regulators and house-keeping proteins resulting in DNA fragmentation.
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Wild type p53 appears to act as an anti-oncogene, whereas mutant p53 may function
as a dominant oncogene. Of the known tumour suppressor genes, p53 is the gene
most frequently mutated in human malignancies. The highest number ofp53
mutations in lung cancer occur in SCLC in which 70% of tumours have mutations,
followed by 65% of squamous cell, 60% of large cell tumours and 33% of
adenocarcinomas (Greenblatt et al., 1994). The gene product ofp53 is a nuclear
phosphoprotein that is important in cell cycle control. It arrests cells in the
checkpoint for the Gl/S cell cycle which controls genetic stability, growth arrest and
cell death when there has been DNA damage. Through mechanisms which are not
fully understood at present mutant p53 appears to be able to prevent activation of the
apoptotic pathway in response to DNA damage. This can lead to unchecked
progression of the cell cycle before appropriate DNA repair can occur so that the
DNA mutation is passed on to progeny. This may eventually lead to malignant
transformation.
Conversely, work on the Bcl-2 oncogene led to the identification of an important
anti-apoptotic function for this protein. Bcl-2 belongs to a family of related and
interacting family members some ofwhich are anti-apoptotic and some ofwhich are
pro-apoptotic (Chinnaiyan et al., 1996; Shimizu et al., 1996). Pro-caspase-9
activation requires CED-4 oligomerisation. Bcl-2 family members may function by
preventing oligomerisation of CED-4 (Srinivasula et al., 1998; Hu et al., 1998).
Likewise, pro-apoptotic Bcl-2 members can promote apoptosis and to date it is
thought that this group of proteins acts by interacting and antagonising pro-survival
Bcl-2 family members (Adams and Cory, 1998). Bcl-2 family members can, in turn,
be regulated by extracellular factors. Growth factors acting via PKB can
phosphorylate the pro-apoptotic Bcl-2 family protein Bad thereby preventing it from
antagonising Bcl-2 and consequently inhibiting apoptosis (del Peso et al., 1997;
Datta et al., 1997).
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1.9 AIMS
The principal aim of this thesis was to examine the molecular mechanisms regulating
growth, anchorage-dependence, apoptosis and drug resistance in SCLC.
1 Initial studies examined the role of PI 3-kinase and PKB in the regulation of
growth of SCLC. Having established that PI 3-kinase is constitutively active in
SCLC cells, the functional consequences of this upregulation were investigated.
2 The role of SCLC cell adhesion to ECM proteins on chemotherapy-induced
apoptosis was investigated. Having discovered that integrin-dependent adhesion
protects SCLC cells from chemotherapy-induced apoptosis, the mechanism
underlying this phenomenon was examined.
3 Following the identification of CD98 as a highly specific regulator of integrin
affinity, the role of CD98 in SCLC was determined. In particular, the






The following reagents were obtained from Gibco Life Technologies (Paisley, UK):
Dulbecco's Modified Eagles Medium (DMEM); Hanks' buffered salt solution
(HBSS); Penicillin; Streptomycin; dialysed foetal bovine serum (FBS); L-glutamine;
30% (w/v) Acrylamide/bis solution.
The following reagents were obtained from Calbiochem-Novabiochem Corporation
(Nottingham, UK): Wortmannin; Rapamycin; LY294002, Tyrphostin A25;
Fibronectin; Fura-2-tetraacetoxymethylester AME; z-Val-Ala-DL-Asp-
fluoromethylketone (z-VAD).
The following products were purchased from Amersham Life Science Ltd (Cheshire,
UK): [y32P] ATP and Hybond C nitrocellulose membrane.
Antibodies (monoclonals unless stated otherwise) were obtained from the following
sources: Anti-human collagen type IV (COL-94), anti-human fibronectin (FN-3E2),
anti-human laminin (LAM-89), anti-human tenascin (BC-24) and anti-human CD29
(P4C10) were from Sigma Chemical Company (Poole, UK). Phospho-Akt (Ser 473)
was from New England BioLabs (Beverly, USA). Anti-PI 3-kinase p85 N-SH3
antibody and anti-human PKB-PH domain antibodies were purchased from Upstate
Biotechnology (Lake Placid, USA) and anti-human CD29 (4B4) was from Coulter
Immunology (Hialeah, USA). Anti-procaspase-3 antibody (CPP-32) was obtained
from Transduction Laboratories (Lexington, USA). Anti-human topoisomerase Ila
was purchased from TopoGEN (Columbus, USA). Anti-PKBa, P and y antibodies
were kind gifts from Dr D Alessi (Department of Biochemistry, University of
Dundee). Goat polyclonal anti-CD98 antibody (SC-7095) was purchased from Santa
Cruz Biotechnology (Santa Cruz, USA). Horseradish peroxidase-conjugated goat-
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polyclonal anti-mouse secondary antibody and FITC-conjugated goat anti-mouse Ig
polyclonal antibody were obtained from DAKO (Ely, UK).
Crosstide (substrate peptide for PKB) was obtained from Upstate Biotechnology
(Lake Placid, USA). Adenosine 3', 5'-cyclic monophosphate-dependent protein
kinase inhibitor and microcystin-LR were obtained from Alexis Corporation (San
Diego, USA). CIS-4-Sulfoethylthio-cyclophosphamide was from Asta
Pharmaceuticals (Frankfurt, Germany).
All other reagents were obtained from Sigma Chemical Company (Poole, UK).
2.2 METHODS
2.2.1 SCLC cell lines
SCLC cell lines NCI-H69, NCI-H345 and NCI-H510 were purchased from the
American Type Tissue Culture Collection (Rockville, Maryland, USA). All of these
lines have been well characterised (Carney et ah, 1985) - see table 2.1.
Table 2.1 Characteristics of SCLC cell lines.
Cell Line H69 H345 H510
Sex M M M
Prior Treatment Chemotherapy Chemotherapy Radiotherapy
Source PE BM Adrenal
Class C C C
DDC u/mg 240 98 214
CK-BB p/mg 2.2 5.8 2.7
NSE ng/mg 817 4075 491
BLI prnol/mg 1.7 4.7 7.4
Abbreviations: PE, pleural effusion; BM, bone marrow; C, classical; DDC, L-dopa
decarboxylase (elevated > 1.0 u/mg; CK-BB, creatine kinase brain isoenzyme
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(elevated > 0.4 pg/mg); NSE, neurone specific enolase (elevated > 100 ng/mg); BLI,
bombesin-like immunoreactivity (elevated > 0.1 pmol/mg).
SCLC cell lines LS274 and LS310 were a kind gift from Dr J Plumb (Cancer
Research Campaign, Beatson Institute, Glasgow, UK). SCLC cell lines DMS79 and
WX330 were a kind gift from Professor J Smyth (Imperial Cancer Research Fund,
University ofEdinburgh, UK). SCLC cell line GLC19 was a kind gift from Dr de
Leij (Groningen, Holland).
2.2.2 Cell culture
All SCLC cell lines were cultured in Roswell Park Memorial Institute Medium 1640
(RPMI 1640) containing 25 mM HEPES supplemented with 10% (v/v) FBS (heat-
inactivated at 57°C for 1 hour). Cells, which were grown in 25 mis medium to a
• 6 2
density of 1x10 /ml in 75 cm flasks (Costar; Cambridge, USA), were passaged (1:3)
into fresh medium every five days. When the passage number reached forty, fresh
stocks were utilised.
Prior to experimentation SCLC cells were removed from culture medium, washed
twice and subsequently cultured for 24 hours in, either serum-free medium, or in
quiescent medium. Serum-free medium comprised RPMI 1640 medium containing
25 mM HEPES supplemented with 30 nM selenium, 5 pg/ml insulin, 10 pg/ml
transferrin and 0.25% (w/v) BSA (SITA). Quiescent medium comprised RPMI 1640
medium containing 25 mM HEPES supplemented with 0.25% (w/v) BSA.
Swiss 3T3 cells were obtained from the European Cell Culture Collection (Porton
Down, UK) and grown in 162 cm2 flasks (Costar; Cambridge, USA) in DMEM
supplemented with 10% (v/v) heat-inactivated FBS. 3T3 cells were allowed to grow
to confluence and were then quiesced for 24 hours before use in DMEM containing
0.5% FBS.
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Bovine tracheal smooth muscle cells (BTSM) were established in primary culture in
our laboratory by Dr T Walker and grown in DMEM containing 10% (v/v) FBS.
BTSM cells were quiesced for 48 hours before use in DMEM containing 0.5% FBS.
Human alveolar type II epithelial cells (A549) were purchased from the American
Type Tissue Culture Collection and grown in DMEM containing 10% FBS. A549
cells were quiesced in serum-free DMEM for 24 hours before use.
All media contained 50 IU/ml penicillin, 50 IU/ml streptomycin and 5 pg/ml L-
glutamine and all cell lines were maintained in a humidified atmosphere of 5%
CC>2/95% air at 37°C. Culture media for BTSM cells was also supplemented with
amphotericin B to a final concentration of 2.5 pg/ml. All cell lines were regularly
screened for mycoplasma infection and were consistently negative.
2.2.3 Production, isolation andpurification ofntAb 4F2 and 4F2-Fab.
The hybridoma cell line 4F2 (CI3) was purchased from the American Type Tissue
Culture Collection and cultured in DMEM containing 15% FBS, 50 IU/ml penicillin,
50 IU/ml streptomycin and 5 pg/ml L-glutamine and OPI media supplement.
Secreted antibody was purified using protein-A affinity chromatography (Amersham
Pharmacia; Uppsala, Sweden). F(ab)2 fragments were prepared by pepsin digestion
ofpurified 4F2 IgG (2 mg/ml) for 6 hours at 37°C. Digestion was terminated by
adding 1.5 M Tris pH 8.8 to achieve a final pH 7.5. F(ab)2 fragments were dialysed
against 20 mM Tris/0.14 M NaCl pH 7.5 and Fab fragments were produced by
addition of L-cysteine to a final concentration of 10 mM. Digestion was terminated
by the addition of iodoacetamide. Fab fragments were purified on Protein-A
sepharose columns. Fab fragments were characterised by SDS-PAGE and exhibited
characteristic mobilities.
2.2.4 PI 3-kinase activity assay
Cultures of SCLC cells 3-5 days post-passage were washed twice, resuspended in
quiescent medium and incubated at 37°C for 24 hours. The following day cells were
washed twice in pre-warmed HBSS and disaggregated by gentle passage through a
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21-gauge needle prior to aliquoting into 6 well plates (Costar; Cambridge, USA).
Cells were allowed to equilibrate at 37°C for 1 hour prior to the addition of agonist
or antagonist. The plates were then transferred to a water/ice bath at 4°C and the
cells aspirated and centrifuged at 3000 x g for 30 seconds. The supernatant was
aspirated and the cells lysed by addition of 250 pi of ice-cold lysis buffer containing
50 mM HEPES (pH 7.4), 15 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10 mM
sodium pyrophosphate, 100 mM sodium fluoride, 10% (v/v) glycerol, 1% (v/v)
Triton X-100, 0.5 mM dithiothreitol, 1 mM sodium orthovanadate, 50 pM 4-(2-
aminoethyl-benzenesulfonyl fluoride, 5 pg/ml leupeptin, 20 pg/ml aprotinin, and 10
pg/ml soybean trypsin inhibitor. After 30 minutes lysates were clarified by
centrifugation at 13,000 x g for 10 minutes. For each assay point, 0.5 mg of total
protein from the supernatant was incubated with 1.0 pg of p85-SH3 PI 3-kinase
o
antibody overnight at 4 C. 30 pi of goat anti-mouse Ig G agarose beads in lysis
buffer were added for an additional 2 hours. The beads were then pelleted and
washed twice with lysis buffer, once with a high salt buffer containing 100 mM Tris-
HC1 and 500 mM LiCl (pH 7.6) and twice with a solution containing 200 mM
HEPES, 40 mM MgCl2 and 600 mM NaCl (pH 7.4). PI 3-kinase assays were
performed using phosphatidylinositol as substrate in a final volume of 200 pi
containing: (final concentrations) 50 mM HEPES (pH 7.4), 10 mM MgCl2, 150 mM
NaCl, [y32P] ATP (5 pCi, 5000 Ci/mmol), 50 pM ATP, and 0.5 mg/ml sonicated
phosphatidylinositokphosphatidylserine (3:1, w/w). Reactions were carried out for
20 minutes at 37 C and terminated by the addition of chloroform:methanol:0.1 M
HC1 (40:80:1, v/v/v; 750 pi), and a phase-partition was achieved by the addition of
chloroform (250 pi) and 0.1 M HC1 (250 pi). After centrifugation, the lower phase
was washed twice with synthetic upper-phase (methanol: 1 M HCkchloroform,
48:47:3, v/v/v), dried and the lipids were separated by thin layer chromatography
(TLC). TLC plates were obtained from Whatman, Maidstone, UK.. The running
buffer for the TLC consisted of methanol:chloroform:ammonia soln: water, in the
proportions 100/70/15/25 (v/v/v/v). 3'-phosphorylated lipids were identified by
autoradiography using Kodak 'X-OMAT' film and radioactivity was quantified by
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liquid scintillation counting using 'Flo-Scint IV' (Packard, Biosciences; Groningen,
Netherlands) and a Packard 1900 TR liquid scintillation analyser.
2.2.5 HPLC analysis ofphosphorylated lipids
The identity of the 3'-phosphorylated products obtained by TLC was confirmed by
high performance liquid chromatography (HPLC). Labelled lipids were excised
from the TLC plate and subjected to deacylation by adding the dried silica to 3 ml of
25% methylamine in water:methanol:butanol (4:4:1, v/v/v). The resulting mixture
was tightly capped and incubated at 53°C for 30 minutes with 30 second vortexing
every 10 minutes. Following centrifugation at 1000 x g for 3 minutes the deacylated
lipids were dried overnight at room temperature before addition of 1 ml ofwater and
1.2 mis of butanokpetrol ether 40-60 bp:ethyl formate (20:4:1, v/v/v). Following
phase partition the upper phase, containing transacylated lipids, was discarded and
the lower phase was washed with 1.2 ml of butanokpetrol ether 40-60 bp:ethyl
formate (20:4:1, v/v/v). The resultant lower phase containing cleaved lipid head
groups was separated using an HPLC strong anion exchange 5 column (Whatman;
Maidstone, UK) with an (NH^ HPO4 gradient running from 0-10 minutes at 0%
salt, 10-70 minutes at 0-20% salt and from 70-130 minutes at 20-100% salt at a flow
rate of 1 ml/minute. Samples were spiked with adenine and guanine nucleotides and
1 ml fractions collected. Samples were compared with tritiated standards originally
derived from 132 IN astrocytoma cells and validated by Dr I Batty (Dept. of
Biochemistry, University ofDundee).
2.2.6 Assessment ofprotein concentration
Protein concentrations were quantified using a BCA protein assay (Pierce; IL, USA).
This assay relies upon the ability of protein present in the test sample being able to
cause a reduction of Cu2+ to Cu+. Bicinchoninic acid (BCA) chelates Cu+ forming a
purple compound, which can be measured using spectrophotometry (562nM) (Smith
et ah, 1985). Samples were diluted 1 in 10 in dH20 and 10 pi incubated with 200 pi
of test solution (30 minutes, 37°C) in 96 well plates prior to analysis using an
automated plate reader (MRX microplate reader: Dynatech; Chantilly, USA).
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Samples were assayed in triplicate and standard curves formed using pre-made
standard solutions.
2.2.7 Protein kinase B activity assay
Cultures of SCLC cells 3-5 days post-passage were washed twice and resuspended in
quiescent medium and incubated for a further 24 hours. The following day, cells
were washed twice in HBSS at 37°C and disaggregated by gentle passage through a
21-gauge needle prior to aliquoting into 6 well plates. Cells were allowed to
equilibrate at 37°C for 1 hour prior to the addition of agonist or antagonist and then
aspirated, centrifuged at 3000 x g for 30 seconds and lysed using 250 pi of ice-cold
lysis buffer. Lysis buffer contained 50 mM Tris/HCl (pH 7.5), 0.1% (v/v) Triton X-
100, 1 mM EDTA, 1 mM EGTA, 0.27 mM sucrose, 50 mM sodium fluoride, 10 mM
sodium P-glycerophosphate, 5 mM sodium pyrophosphate, 1 mM sodium
orthovanadate, 0.1% (v/v) 2-mercaptoethanol, 1 pM microcystin, 5 pg/ml leupeptin,
20 pg/ml aprotinin, and 10 pg/ml soybean trypsin inhibitor. Lysates were clarified
by centrifugation at 13,000 x g for 10 min, and PKB was immunoprecipitated by
incubating the lysates (containing 150 pg of protein) for 90 minutes at 4 C with 1 pg
of anti-PKBa antibody pre-conjugated to 5 pi of protein G-sepharose in lysis buffer.
Immunoprecipitates were washed twice with lysis buffer containing 0.5 M NaCl and
once with a buffer consisting of 50 mM Tris/HCl (pH 7.5), 0.03% (v/v) Brij-35, 0.1
mM EGTA and 0.1% (v/v) 2-mercaptoethanol. PKB activity was assayed by
incubating washed immunoprecipitates at 30°C for 20 minutes in a thermomixer in
30 pi of kinase assay buffer (50 pM Crosstide, 50 mM Tris/HCl, 0.1 mM EGTA, 20
pM adenosine 3', 5'-cyclic monophosphate-dependent protein kinase inhibitor, 20
pM ATP, 1 pM microcystin and [y-32P] ATP (1.0 pCi 5000 Ci/mmol). The assays
were terminated by placing 40 pi of the assay mixture onto P81 chromatography
paper (Whatman; Maidstone, UK) and washing four times with 0.5% (v/v)
phosphoric acid and once with acetone. Radioactive incorporation was quantified by
liquid scintillation counting.
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2.2.8 Radioligand displacement assayfor mass measurement ofPtdIns(3,4,5)Pi.
The assay is based on radioligand displacement of radiolabelled Ins(l,3,4,5)P4 from
binding sites present in platelets that display high affinity and specificity for
Ins(l,3,4,5)P4. Following a Folch extraction of cellular phospholipids,
Ins(l,3,4,5)P4, the polar headgroup of PtdIns(3,4,5)P3, is released by alkaline
cleavage and its mass can be measured by radioligand displacement using a
calibration curve obtained using unlabelled Ins(l,3,4,5)P4 standards (see below).
The sensitivity limit of the assay is approximately 0.3 pmol and in general lipid
extracts from sample containing 1 mg of cellular protein are sufficient for
determination of the basal level ofPtdIns(3,4,5)P3. The full method has been
described by van der Kaay et al., (1999).
The Ins(l,3,4,5)P4 assay requires:
a. Samples





Ins(l,3,4,5)P4 stock, [32P]Ins(l,3,4,5)P4 and GAP1ip4bp were kindly prepared by Dr J
van der Kaay as described (van der Kaay et al., 1999).
2.2.8a Sample preparation
For adherent cells, such as Swiss 3T3, the medium was aspirated and the cells, which
had been grown in 6 well plates (Costar; Cambridge, USA), were quenched with 1
ml of 10% trichloroacetic acid. After 15 minutes on ice, the wells were scraped and
washed once with 0.5 ml of 10% trichloroacetic acid. The cell lysates were
centrifuged for 5 minutes at 13,000 x g, and the resulting pellet was washed twice
with 0.5 ml of 5% trichloroacetic acid, 1 mM EDTA. Lipids were extracted in 0.75
ml ofCHCU/MeOH/HCl (40:80:1, by volume) for 20 minutes, and phases were then
split by the addition of 0.25 ml of CHCfi and 0.45 ml of 0.1 M HCI. The lower
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phase, obtained after a 1 minute centrifugation at 13,000 x g, was transferred to a
screw cap tube and the upper phase was re-extracted once with 0.45 ml of the
synthetic lower phase. The lower phases were pooled and dried down. Alkaline
hydrolysis of dried lipids was carried out by vortexing in 50 pi of 1 M KOH and
boiling for 30 minutes. Following neutralisation with 50 pi of 1 M acetic acid, the
fatty acids were removed by 2 extractions with 0.5 ml of water-saturated butan-1-
ol/petroleum ether (40-60°C)/ethyl acetate (20:4:1 by volume). Finally, the resulting
water-soluble fractions were dried down by centrifugation and stored at -20°C. Prior
to assaying, samples were resuspended in 110 pi of dilute acetic acid to a final pH of
of 5.0 measured using accurate pH indicator strips. This step is important because
the sample, which now contains approximately 0.5 M KOH/acetic acid, dictates the
pH of the subsequent Ins(l,3,4,5)P4 binding assay. Cells grown in suspension (such
as SCLC cells) were transferred to eppendorf tubes, pelleted by centrifugation at
3000 x g for 2 minutes and killed by the addition of 0.75 ml of CHCIs/MeOH/HCl
(40:80:1, by volume) for 20 minutes. A phase split was then obtained as above and
further sample processing was carried out as above.
2.2.8b Preparation of standards.
Ins(l,3,4,5)P4 standards containing 0.5 M KOH/acetic acid were prepared at the
following concentrations: 8 x 10"6M, 24 x 10"7 M, 8 x 10"7 M, 24 x 10~8 M, 8 x 10"8
M, 24 x 10~9 M, 8 x 10'9 M, 24 x 10"'° M, 8 x 10"'° M, 24 x 10"11 M, 8 x 10"11 M.
2.2.8c [32P]Ins(l,3,4,5)P4label
0.05 pCi [32P]Ins(l,3,4,5)P4 label was used per assay point.
2.2.8d GAP1IP4BP
GAP1ip4bp coupled to agarose beads is stored in high salt buffer with 50% glycerol.
Just before the start of the assay, an appropriate amount of the beads was washed
twice in Ins(l,3,4,5)P4 wash buffer and resuspended in this buffer. The amount of
GAP1IP4BP required for each assay was determined for each new preparation of
GAP11P4BP. Maximal and non-specific binding was determined in 0.5 M KOH/acetic
acid pH 5.0 in the absence or presence of 1 mM Ins(l,3,4,5)P4 respectively. A
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maximal binding of approximately 10% of the total input was aimed for when using
[32P]Ins(l,3,4,5)P4. See van der Kaay et al., (1999) for method.
2.2.8e Wash buffer
25 mM sodium acetate, 25 mM KH2PO4, 1 mM EDTA, 5 mM NaHCC>3, pH 5.0 with
acetic acid.
2.2.8f Assay buffer
0.1 M sodium acetate, 0.1 M KH2PO4, 4 mM EDTA, pH 5.0 with acetic acid.
Each assay sample contained 400 pi final volume and comprised:
100 pi of sample or Ins(l,3,4,5)P4 standard.
100 pi assay buffer.
100 pi [32P] Ins(l,3,4,5)P4(0.05 pCi in H20).
100 pi GAP1IP4BP.
The incubation was started by addition of the binding protein. The samples were
vortexed and incubated on ice for 30 minutes with occasional vortexing as the
agarose beads settled out fairly quickly. Filtration of bound [32P]Ins(l,3,4,5)P4 from
unbound was achieved by filtration through GF/C filters (Whatman; Maidstone,
UK). The samples were filtered onto pre-wetted filters and immediately rinsed twice
with 10 ml of ice-cold wash buffer. The filters were then allowed to air-dry,
transferred to scintillation vials containing 4 mis of 'Floscint V' (Packard
Biosciences; Groningen, Netherlands) and the radioactivity counted in a liquid
scintillation counter. A typical calibration curve obtained using the standards is
shown in Figure 2.1. The Kd for Ins(l,3,4,5)P4 is approximately 3 nM (van der Kaay
et al., 1997). When PtdIns(3,4,5)P3 is subjected to alkaline hydrolysis, the yield of
Ins(l,3,4,5)P4 is 62%. Therefore, for absolute amounts ofPtdIns(3,4,5)P3 to be
calculated, the final values read from the calibration curve need to be corrected by
this factor. Figure 2.2 shows the relative ratios of the side products obtained by















Schematic representation of the products from PtdIns(3,4,5)P3 subjected to alkaline
hydrolysis.
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Van der Kaay et al., (1997) have shown that these products do not interfere with or
contribute to the measured signal. A very important feature of the assay is its
selectivity for Ins(l,3,4,5)P4 over Ins(l,4,5)P3. Ins(l,4,5)P3 is formed by alkaline
cleavage of PtdIns(4,5)P2 which is usually present at 1000-fold higher levels in
resting cells than PtdIns(3,4,5)P3. The Kd for Ins(l,3,4,5)P4 is approximately 5000-
fold lower than the Kd for Ins(l,4,5)P3 so there should be no noise arising from
PtdIns(4,5)P2 also present in lipid extracts from the cells.
2.2.9 Immunoblotting
Whole cell lysates were solubilised in 5 x sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer at 100°C for 5 minutes. Samples
were cooled and undissolved material pelleted at 13,000 x g for 1 minute before
equal amounts ofprotein (50-100 pg) were resolved on SDS polyacrylamide gels for
2-3 hours at 150 volts using tris-glycine gel electrophoresis buffer and an
electrophoresis gel tank (ATTO Corp., Japan). For optimal separation, 8% gels were
used for 60-120 kDa proteins, 10% gels for 40-70 kDa proteins and 12% gels for 10-
40 kDa proteins. The resolved proteins were 'Western blotted' onto Hybond C
nitrocellulose membranes in ice-cold blotting buffer at 100 volts for 1 hour using a
Mini Protean II blotting tank (Biorad Co., UK). Equal protein loading was
confirmed by incubating blots for 5 minutes in Ponceau S which allows visualisation
of protein bands. The membranes were then incubated overnight at 4°C in TBS-
Tween 20 wash buffer in order to prevent subsequent non-specific binding of
primary antibodies prior to addition of the primary antibody (diluted in washing
buffer) for 2 hours. Next, membranes were washed in TBS-Tween 20 (3 x 30 second
vigorous washes and 3x10 minute washes) before species-appropriate horseradish
peroxidase (HRP) conjugated secondary antibody (diluted in washing buffer) was
added for 1 hour. Finally, membranes were rewashed as above and immunoreactive
bands were identified using enhanced chemiluminescence (ECL) (Amersham Life
Sciences; Cheshire, UK) as per manufacturer's instructions. ECL is a high
resolution, non-radioactive method of detecting specific immobilised antigens that
are conjugated (directly or indirectly) to HRP labelled antibodies.
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2.2.9a 5 x SDS-PAGE sample buffer
625 mM Tris HC1 (pH 6.8), 10% SDS (v/v), 25% glycerol (v/v), 0.015%
bromophenol blue (v/v) and 5% 2-mercaptoethanol (v/v).
2.2.9b SDS polyacrylamide gels
Stacking gel:
Stacking gel buffer (1 M Tris base (pH 6.8), 10% SDS) 2.50 ml
30% Acrylamide solution 1.50 ml
Distilled H2O 5.70 ml
25% ammonium persulphate 0.05 ml
TEMED 0.02 ml
Resolving gel:
Resolving gel buffer (1.5 M Tris base (pH 8.8), 10% SDS) 6.25 ml
30% Acrylamide solution 8.33 ml
Distilled H2O 10.38 ml
25% ammonium persulphate 0.10 ml
TEMED 0.02 ml
2.2.9c Gel electrophoresis buffer
25 mM Tris base (pH 8.3), 250 mM glycine and 0.1% SDS.
2.2.9d Blotting buffer
210 mM glycine, 24.7 mM Tris base and 20% methanol.
2.2.9e Wash buffer
20 mM Tris/HCl (pH 7.4), 150 mM NaCl and 0.2% (v/v) Tween-20.
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2.2.10 Determination ofintracellular calcium concentration
Aliquots of4xl06 SCLC cells cultured in SITA for two days were washed and
incubated for 2 hours at 37°C in 10 ml of fresh SITA medium. Cells were then
resuspended in HBSS without Ca2+ and 1 pM fura-2-tetraacetoxymethylester AME,
from a stock of 1 mM in DMSO, was added and the cells were incubated for a
further 10 minutes at 37°C. The cell suspension was centrifuged at 2000 x g for 15
seconds and the cells were resuspended in 2 ml of electrolyte solution (140 mM
NaCl, 5 mM KC1, 0.9 mM MgCl2, 1.8 mM CaCl2, 25 mM glucose, 16 mM HEPES,
16 mM Tris and a mixture of amino acids at pH 7.2), transferred to a quartz cuvette
and stirred continuously at 37°C. Fluorescence was recorded continuously in a
Model F2000 fluorescence spectrophotometer (Hitachi Corp., Japan) with an
excitation wavelength of 340 nM and an emission wavelength of 380 nM. [Ca2+]i
was calculated using the formula:
[Ca2+], = Kd(r-rmin) / (rmax-r)B
where r is the ratio 340/380, rmin is Fmin340/Fmax380, rmax is Fmax340/Fmax380 and B is
Fmin380/Fmax380. F is the fluorescence at the unknown [Ca2+]i, Fmax is the
fluorescence after the trapped fluorescence is released by the addition of 0.02%
Triton-X 100 and Fmjn is the fluorescence remaining after the Ca2+ in the solution is
chelated with 10 mM EGTA. The Kd for fura-2 is 224 nM (Tsien, Pozzan et al.,
1982).
2.2.11 Decatenation assay
Cells were washed twice with ice-cold CMF-PBS and spun at 1,200 rpm for 10
minutes at 4°C. The cell pellet was washed again with 1 ml PBS and spun for 15
seconds at 14,000 rpm at 4°C before being washed in 400 pi of a buffer containing
10 mM HEPES (pH 7.8), 10 mM KC1, 2 mM MgCl2, 1 mM dithiothreitol, 0.1 mM
EDTA, 0.4 mM PMSF, 0.2 mM sodium fluoride, 0.2 mM sodium orthovanadate and
0.3 mg/ml leupeptin. Following a 15 minute incubation on ice the mixture was
vortexed for 15 seconds with 25 pi of 10% Nonidet P-40. Following centrifugation
for 30 seconds at 14,000 rpm at 4°C the supernatant was removed by pipetting and
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the pelleted nuclei resuspended and mixed for 20 minutes in 50 pi of a buffer
containing 50 mM HEPES (pH 7.8), 50 mM KC1, 300 mM NaCl, 0.1 mM EDTA, 1
mM dithiothreitol, 10% (w/v) glycerol, 0.2 mM sodium fluoride and 0.2 mM sodium
orthovanadate. The lysed nuclei were spun for 5 minutes at 14,000 rpm at 4°C and
the resulting supernatant collected and used in the topoisomerase II assay.
Topoisomerase II activity was measured by the ATP-dependent decatenation of
kinetoplast DNA (kDNA) in which an interlocking kDNA network is decatenated to
individual DNA minicircles and small catenanes. Reaction buffer, consisting of 50
mM Tris-HCI (pH 7.5), 10 mM MgCl2, 100 mM KC1, 0.5 mM EDTA, 30 pg/ml
BSA, 1 mM ATP, 0.5 mM dithiothreitol and 100 pg/ml kDNA was mixed with each
sample in a total volume of 45 pL. Reactions were incubated for 30 minutes at 37°C
and then terminated by the addition of 5pl of stop buffer consisting of 50% sucrose,
50 mM EDTA and 0.1% bromophenol blue. Reaction products were analysed by 1%
agarose gel electrophoresis using a buffer consisting of 89 mM Tris-borate (pH 8.3)
and 2 mM EDTA. Following electrophoresis gels were stained with 1 pg/ml
ethidium bromide for 30 minutes, destained with several washings of distilled water
and photographed under UV light.
2.2.12 Adhesion Assay
96 well plates (Costar; Cambridge, USA) were coated with 100 pi of fibronectin,
laminin or collagen IV (see figure legends for details of concentrations) overnight at
4°C and blocked with 1 mg/ml BSA (lh at 25°C). SCLC cells (5 x 105) that had
been washed twice in RPMI 1640 were added to the wells in the presence or absence
of test compounds (see results section and figure legends for details). After 1 hour of
incubation at 37°C, non-adherent cells were removed by gentle washing with PBS
and adherent cells were fixed with 3% formaldehyde and stained with 1% methylene
blue. After several washes with distilled water, 100 pi of 0.1 M HC1 was added to
each well and the absorbance of the resulting solution was measured by
spectrophotometry at 630 nM on an MRX microplate reader plate reader (Dynatech;
Chantilly, USA). Each condition was assayed in triplicate.
60
2.2.13 Flow cytometric analysis ofantigen expression
Aliquots of 5xl05 cells were washed and resuspended in 100 pi PBS containing 0.2%
(w/v) BSA and 0.1% sodium azide (EPICS buffer) and incubated with 10 pi AB
serum for 10 min at 4°C. Primary antibody was then added for a further 30 minutes
followed by two washes with EPICS buffer. Samples were then incubated with
FITC-conjugated goat anti-mouse Ig polyclonal secondary antibody (1:40) for 30
minutes at 4°C and again washed twice in EPICS buffer. Samples were finally
resuspended in EPICS buffer and analysed by flow cytometry using an EPICS profile
2 (Coulter Electronics; Luton, UK).
2.2.14 Liquidgrowth assay
Cultures of SCLC cell lines H69, H345 and H510, 5 days post-passage, were washed
and subsequently incubated in serum-free SITA medium for 24 hours. Before
experimentation cells were washed twice and resuspended in fresh SITA medium
before being gently disaggregated by two passes through a 21-gauge needle into an
essentially single cell suspension as judged by light microscopy. Viability was
determined by trypan blue exclusion on a haemocytometer. Cell number was
determined using a Coulter Counter (Coulter Electronics, Luton, UK) and cells were
diluted using SITA medium to a density of lxl05/ml. Cells were seeded into 24 well
plates and incubated for 4 hours in a humidified atmosphere of 5% CC>2/95% air at
37°C before the addition of agonists or antagonists. Cells were then further
incubated under the same conditions before being removed at various time points and
disaggregated into a single cell suspension for counting using a Coulter Counter.
2.2.15 Clonogenic assay
SCLC cells, 5 days post-passage were washed and subsequently incubated in serum-
free SITA medium for 24 hours. Before experimentation cells were washed twice
and resuspended in fresh SITA medium before being gently disaggregated by two
passes through a 21-gauge needle into an essentially single cell suspension as judged
by light microscopy. Viability was determined by trypan blue exclusion on a
haemocytometer. Cells (lxl 04) were mixed with SITA containing 0.3% (w/v)
agarose and agonist/antagonist (see figure legends for details) and layered over a
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solid base of 0.5% (w/v) agarose in SITA containing the agonist/antagonist at the
same concentration. The cultures were incubated in a humidified atmosphere of 5%
CC>2/95% air at 37°C for 21 days and then stained with the vital stain nitro-blue
tetrazolium. Colonies of >16 cells were counted with a microscope.
2.2.16 Assessment ofSCLC cell apoptosis
2.2.16a Ethidium bromide/acridine orange staining.
1 pi of an ethidium bromide (100 pg/ml) /acridine orange (100 pg/ml) (1/1 v/v) mix
was added to 200 pi SCLC cells and the percentage of cells undergoing apoptosis
was assessed using fluorescent microscopy using an Olympus BH2 fluorescence
microscope (Olympus Optical Co., Japan). This assay is based upon the loss of
plasma membrane integrity when cells die. Acridine orange and ethidium bromide
excite green and orange fluorescences respectively, when they are intercalated into
DNA. Whilst acridine orange can cross the plasma membrane of all cells, ethidium
bromide is excluded from viable and early apoptotic cells which have intact plasma
membranes. Where cells have taken up both dyes (late apoptotic and necrotic cells),
the fluorescence due to ethidium bromide is the stronger and therefore these cells
have an overall orange appearance. Normal healthy cells appear as having a bright
green nucleus with an intact nuclear structure. Early apoptotic cells have a bright
green nucleus but show condensed chromatin as dense areas within the nucleus. Late
apoptotic cells have an orange nucleus and condensed chromatin appears as dense
orange areas. Necrotic cells have an orange nucleus with an intact structure.
2.2.16b Morphological assessment.
Cells were cytocentrifiiged at 300 x g for 3 minutes onto glass slides using a
Cytospin 3 (Shandon; Pittsburgh, USA). Resulting cell preparations were air dried,
fixed in methanol and stained with May-Grunwald-Giemsa stain. Cell morphology
was examined using an Olympus BH2 microscope.
2.2.16c ELISA cell death detection assay.
This commercial assay (Cell Death Detection ELISA from Boehringer Mannheim,
Mannheim, Germany) is based upon a quantitative sandwich-enzyme-immunoassay
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principle using mouse monoclonal antibodies directed against DNA and histones,
respectively. This allows the specific determination ofmono- and oligonucleosomes
in the cytoplasmic fraction of cell lysates.
The assay was performed according to the manufacturer's instructions. Briefly, cell
lysates were placed into a streptavidin-coated microtitre plate. Subsequently, a
mixture of anti-histone-biotin and anti-DNA peroxidase antibodies were added and
incubated for 2 hours. During the incubation period, the anti-histone antibody binds
to the histone component of the nucleosomes and simultaneously fixes the
immunocomplex to the streptavidin coated microtitre plate via its biotinylation.
Additionally, the anti-DNA peroxidase antibody reacts with the DNA component of
the nucleosomes. After removal of unbound antibodies by a washing step, the
amount of nucleosomes is quantified by the peroxidase retained in the
immunocomplex. Peroxidase was determined photometrically with 2, 2' Azino-di
[3-ethylbenzthiazolin-sulfonat] as substrate. Plates were read by spectrophotometry
at 405 nM using an MRX microplate reader (Dynatech; Chantilly, USA) and results
expressed as the increase in absorption of treated cells in comparison to untreated
cells.
2.2.17 Tissue immunohistochemistry
Formalin fixed, paraffin embedded SCLC resection specimens were dewaxed in
xylene and rehydrated through graded alcohols to water. Antigen unmasking was
performed by either pre-incubating sections in 0.1% trypsin (pH 7.6) at 37°C for 15
minutes or microwave-oven boiling for 15 minutes in 0.1 M citrate (pH 6.0).
Sections were processed using a Techmate 500 (DAKO; Ely, UK). Antibody
detection was performed using a multi-link streptavidin biotin complex method and
visualisation was achieved using a diamino benzidine chromagen method as per the
manufacturer's instructions. Slides were counterstained using Harris' haematoxylin.
Negative controls were incubated in primary antibody diluent only. All slides were
reviewed independently by two people.
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2.2.18 StatisticalAnalysis
All data are expressed as the mean ± SEM of the indicated number of experiments or
on occasion as the mean ± SD of 2 experiments each performed in duplicate or
triplicate. Data were analysed by one way analysis of variance with comparison
between groups made using the Newman-Kuels procedure. P values less than 0.05





GROWTH IN SMALL CELL LUNG CANCER
3.1 INTRODUCTION
The main cause of death ofpatients with cancer arises as a result of either primary
tumour invasion or secondary metastatic deposits. Therefore, the ability of tumour
cells to survive and grow in inappropriate environments is central to cancer-related
death.
Transformed cells are characterised by their ability to proliferate, a) in the absence of
serum and, b) in the absence of contact with extracellular matrix, so called
anchorage-independence (Schwartz, 1997). Constitutive stimulation of growth factor
pathways alone is mitogenic rather than oncogenic resulting in benign hyperplasia in
animal models (Chang et al., 1989; Sandgren et al., 1990). For full malignant
transformation to occur, tumour cells also require to be anchorage-independent. In
SCLC cells proliferation is driven by multiple autocrine and paracrine growth loops
involving a variety of hormonal and peptide mitogens including calcium-mobilising
neuropeptides, IGF-1 and NGF (Oelmann et al., 1995; Macaulay et al., 1990;
Nakanishi et al., 1988; Sethi and Rozengurt, 1991).
In vitro, SCLC cells grow as non-adherent, free-floating aggregates. However, the
mechanisms resulting in anchorage-independent growth of SCLC cells are unclear.
Transformation of adherent cells by cytoplasmic oncogenes such as ras or src is
accompanied by the ability to grow in suspension. Cell detachment induced
apoptosis does not occur in epithelial cells expressing activated src or ras (Frisch and
Francis, 1994). These oncogenes appear to provide constitutively activated signals
mimicking those initiated by ligand bound integrins, thereby overcoming the
induction of apoptosis initiated by cell detachment from extracellular matrix. A
recent study has shown that the ability of ras and src to protect epithelial cells from
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cell detachment induced apoptosis is mediated through the PI 3-kinase/PKB pathway
(Khwaja et al., 1997).
PI 3-kinase was initially discovered as a PI kinase activity that co-purified with the
oncoproteins pp60v-,src and polyoma middle T antigen (Sugimoto et al., 1984;
Whitman et al., 1985). Interest in PI 3-kinase increased with the finding that the
transforming ability of several oncoproteins correlated with their ability to associate
with PI 3-kinase and elevate specific lipid products of the enzyme. PI 3-kinase is
involved in the regulation of multiple cellular processes. Early studies using
chemical PI 3-kinase inhibitors and dominant negative or constitutively active
mutations ofPI 3-kinase suggested several distinct functions including mitogenesis,
inhibition of apoptosis, intracellular vesicle trafficking and secretion, and regulation
of actin and integrin functions (reviewed in Carpenter and Cantley, 1996). More
recent studies have begun to explore potential roles for PI 3-kinase in transformed
cells. Shaw et al., (1997b) recently identified a specific integrin-mediated pathway
involving PI 3-kinase that promotes carcinoma invasion while Keely et al., (1997)
have demonstrated that activation ofCdc42 and Racl in mammary epithelial cells
promotes motility and invasion in a PI 3-kinase-dependent manner. In view of these
important physiological and pathological functions much interest has focussed on the
downstream effectors ofPI 3-kinase.
In 1991 the serine/threonine kinase PKB, was identified as the product of the
oncogene v-akt of the acutely transforming retrovirus AKT 8 found in a rodent T-cell
lymphoma (Bellacosa et al., 1991). PKB can be activated by growth factors,
oncogenes and integrins signalling through PI 3-kinase and has been shown to
provide a survival signal that protects cells from apoptosis induced by a variety of
stresses (reviewed in Hemmings, 1997).
These findings suggest that the PI 3-kinase/PKB pathway may be sensitive to
oncogenic conversion and could be important in the development of human cancers.
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The role ofPI 3-kinase-mediated signal pathways in regulating the growth, apoptosis
and anchorage-independence of SCLC cells is unknown.
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3.2 RESULTS
3.2.1 Expression ofp85a, the regulatory subunit ofPI 3-kinase, in SCLC cell
lines
Whole cell lysates prepared from cells that had been incubated in serum-free
'quiescent' medium for 24 hours were resolved on 10% SDS polyacrylamide gels
and transferred to nitrocellulose membrane by 'Western' blotting. P85 expression in
SCLC cells was compared with that in Swiss 3T3 cells. Equal protein loading was
confirmed by incubation of membranes in Ponceau S and p85 expression was
examined using an antibody to the a isoform of the p85 subunit ofPI 3-kinase.
Figure 3.1 shows p85 expression as a single band at 85 kDa. The levels of
expression ofPI 3-kinase in SCLC cells were very similar to that in the Swiss 3T3
cells.
3.2.2 SCLC cells exhibit constitutivePI 3-kinase activity
PI 3-kinase activity was examined in a panel of SCLC cell lines using an in vitro
kinase assay as described in 'Materials and Methods'. In order to examine basal PI
3-kinase activity, SCLC cells 5-7 days post-passage, were taken from growth
medium, washed twice in RPMI 1640 containing 0.25% (v/v) BSA and incubated for
a further 24 hours in the same medium. The following day cells were washed twice
in HBSS, aliquoted and allowed to equilibrate at 37°C for 1 hour prior to lysis.
Initial experiments suggested that basal PI 3-kinase activity in SCLC cells was not
reduced following incubation of cells in quiescent medium. In order to examine this
further, PI 3-kinase activity was measured in several SCLC cell lines and compared
with activity in a panel of untransformed cell lines including human bronchial
epithelial cells, bovine tracheal smooth muscle cells and Swiss 3T3 cells. PI 3-
kinase activity was also measured in a NSCLC cell line (A549).
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Figure 3.1
P85a expression in SCLC cell lines DMS79, LS274, H345, H510, H69 and Swiss
3T3 cells. The blot shown is representative of three independent experiments.
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One of the potential problems of measuring PI 3-kinase activity in a variety of cell
types is that activity levels may vary depending on phase of growth, cell number or
cell density. In order to minimise these potential differences all cell types were
quiesced in serum-free media for 24 hours prior to experimentation. This was
performed to ensure that all growth factors were removed so that basal PI 3-kinase
activity was being measured. Adherent cells were grown to confluence prior to
incubation in serum-free media for 24 hours. Cell lysates were also equilibrated for
protein so that in each experiment identical amounts of protein were being assayed
for PI 3-kinase activity.
Figure 3.2 shows that basal PI 3-kinase activity in all the SCLC cell lines tested
(H69, H345, H510, DMS79 and LS274) was markedly higher than that in human
bronchial epithelial cells, bovine tracheal smooth muscle cells, Swiss 3T3 cells and
A549 adenocarcinoma cells. The addition of either 10% FBS or IGF-1, both potent
growth factors for SCLC, could induce only a modest additional increase in PI 3-
kinase activity (1.51 ±0.19 and 1.82 ± 0.28 fold respectively) (Figure 3.3). Thus,
under conditions where every effort was made to remove all exogenous/autocrine
growth factors, elevated basal PI 3-kinase activity was seen in SCLC cells.
3.2.3 Elevated basal PI 3-kinase activity in SCLC cells can be abrogated by PI 3-
kinase inhibitors
Wortmannin and LY294002 are specific PI 3-kinase inhibitors. We hypothesised
that if SCLC cells display elevated basal PI 3-kinase activity, PI 3-kinase inhibitors
should be able to abrogate this enhanced activity. Therefore, H69 SCLC cells were
treated with increasing concentrations ofwortmannin for 20 minutes prior to cell
lysis. Figure 3.4 shows that wortmannin caused a concentration-dependent inhibition







Comparison of PI 3-kinase activities in SCLC cell lines DMS79, LS274, H345,
H510 and H69, human bronchoepithelial cells (HBE), bovine tracheal smooth
muscle cells (BTSM), NSCLC cell line A549 and Swiss 3T3 cells. The results




















The effect of insulin growth factor 1 (IGF-1) and foetal bovine serum (FBS) on
PI 3-kinase activity in H69 SCLC cells. H69 cells were taken from serum-
containing medium, 'quiesced' in serum-free medium for 24 hours prior to
experimentation and extensively washed before being stimulated with either IGF-1
(100 ng/ml) or 10% FBS for 5 minutes. PI 3-kinase was assayed as described in
'Materials and Methods'. The results, which are expressed as fold increase over
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Figure 3.4
The effect of PI 3-kinase inhibitors on PI 3-kinase activity in SCLC cells.
Concentration response ofwortmannin (left) and LY294002 (right) on PI 3-kinase
activity in H69 SCLC cells. Basal PI 3-kinase activity is expressed as 100%. The
results shown are the means ± SD of two independent experiments performed in
duplicate for experiments using wortmannin and the means ± SEM of three
independent experiments performed in duplicate for experiments involving
LY294002. Representative autoradiographs showing the 3-phosphorylated reaction
product (PtdIns(3)P) are shown for each condition. Experiments involving
LY294002 were performed by Dr S Moore.
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Assay LY294002 (pM) Wortmannin (nM)
PI 3-Kinase 3.4 ± 1.4 8.0 ±2.1
Protein Kinase B 2.7 ±0.1 2.0 ±0.6
Proliferation 10.0 ±0.8 NP
Table 3.1
Comparative IC50 values for LY294002 and wortmannin for PI 3-kinase,
protein kinase B and cell proliferation in H69 SCLC cells. The values shown are
means ± SEM of at least three independent experiments except for PI 3-kinase assays
involving wortmannin which are means ± SD of two independent experiments. NP,
not performed.
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Because LY294002 is a competitive inhibitor for the ATP binding site of PI 3-kinase
and can be competed off during immunoprecipitation, the inhibitor was added
directly to the enzyme assay. LY294002 inhibited PI 3-kinase activity in PI 3-kinase
immunoprecipitates from H69 cells with an IC50 value of 3.4 ± 1.4 pM (Figure 3.4
and Table 3.1). The IC50 values for LY294002 and wortmannin in this system are
very similar to those quoted in the published literature; 1.4 pM for LY294002 and 3
nM for wortmannin (Vlahos et al., 1994b; Powis et ah, 1994). Therefore, SCLC
cells appear to have constitutively active PI 3-kinase, which can be activated by only
1.8-fold above control at maximally effective concentrations of IGF-1 (Figure 3.3).
3.2.4 Basalphosphatidylinositol 3,4,5 trisphosphate levels are elevated in SCLC
cells
Agonist stimulated forms ofPI 3-kinase can phosphorylate Ptdlns, PtdIns(4)P and
PtdIns(4,5)P2 as substrates in vitro, but several lines of evidence suggest that
PtdIns(4,5)P2 is the preferred substrate in vivo, generating PtdIns(3,4,5)P3.
PtdIns(3,4,5)P3 has been shown to increase rapidly and transiently in many cell types
in response to a wide variety of stimuli and since there are no known phospholipases
that can metabolise PtdIns(3,4,5)P3, it has been suggested that PtdIns(3,4,5)P3 is
itself a second messenger.
To date, measuring PtdIns(3,4,5)P3 levels has been done by labelling cells with [3H]
inositol or [32P] orthophosphate. Labelling cells with [3H] inositol is often relatively
• • • 'K')
inefficient, expensive and time consuming and labelling with [ P]-orthophosphate
involves the use of high levels of radioactivity. Both labelling procedures also
require time-consuming HPLC analysis of deacylated lipid extracts that are required
to resolve the glycero derivative, GroPtdIns(3,4,5)P3, from other 32P labelled lipids.
Van der Kaay et al., (1997) have recently described an isotope dilution assay that
detects PtdIns(3,4,5)P3 at sub-picomole levels and can be used for measurements of
PtdIns(3,4,5)P3 from both control and stimulated cells. The full method is described
in 'Materials and Methods' but, in brief, total lipid extracts containing
PtdIns(3,4,5)P3 are subjected to alkaline hydrolysis which results in the release of the
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polar head group Ins(l,3,4,5)P4. Ins(l,3,4,5)P4 is measured by its ability to displace
[32P]Ins(l,3,4,5)P4 from a highly specific binding protein. Using this method basal
PtdIns(3,4,5)P3 levels in H69 and H345 SCLC cell lines were measured and
compared with basal levels of PtdIns(3,4,5)P3 in Swiss 3T3 and Rat-2 fibroblasts.
Figure 3.5 shows PtdIns(3,4,5)P3 levels in basal H69 and H345 SCLC cells and
Swiss 3T3 and Rat-2 fibroblasts. The basal levels of PtdIns(3,4,5)P3 were markedly
higher in the SCLC cell lines compared with the fibroblast cell lines.
In another set of experiments H69 SCLC cells were stimulated with IGF-1. This
resulted in a 1.6 fold increase in PtdIns(3,4,5)P3 levels (Figure 3.6). This figure is
similar to the fold activation ofPI 3-kinase seen with IGF-1 (Figure 3.3).
Taken together these data show that basal PtdIns(3,4,5)P3 levels are elevated in
SCLC cells and support the hypothesis that PI 3-kinase is constitutively active in
SCLC cells.
3.2.5 PKB activity in SCLC cells
PKB can be activated by a wide variety of growth stimuli including PDGF, EGF,
insulin, thrombin and NGF. A number of studies have shown that PI 3-kinase is
involved in the regulation ofPKB (reviewed in Coffer et ah, 1998). Growth factor-
induced activation ofPKB is inhibited by PI 3-kinase inhibitors and by the
expression of a dominant negative form ofPI 3-kinase (Franke et ah, 1995;
Burgering and Coffer, 1995).
It was hypothesised that constitutive PI 3-kinase activity in SCLC cells might lead to
sustained PKB activation. Using monoclonal antibodies to the a, P and y isoforms of
PKB it was found that all three isoforms were expressed in H69 SCLC cells at
similar levels (Figure 3.7). PKB activity was examined using an in vitro kinase
assay as described in 'Materials and Methods'. PKB was immunoprecipitated from
cell lysates using an antibody to the PH domain ofPKB and then assayed by
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Figure 3.5
PtdIns(3,4,5)P3 levels in basal H69 and H345 SCLC cells, Swiss 3T3 fibroblasts
and Rat-2 fibroblasts. In order to measure basal PtdIns(3,4,5)P3 levels cells were
'quiesced' in serum-free media for 24 hours and thoroughly washed prior to
experimentation. PtdIns(3,4,5)P3 levels were measured as described in 'Materials
and Methods'. Results shown are either the mean ± SD of two experiments
performed in triplicate (H69 and Swiss 3T3) or the mean of a single experiment





The effect of IGF-1 and wortmannin on basal PtdIns(3,4,5)P3 levels in H69
SCLC cells. H69 cells were taken from serum-containing medium, 'quiesced' in
serum-free medium for 24 hours prior to experimentation and extensively washed
before being treated with either IGF-1 (100 ng/ml for 5 minutes) (IGF-1), or
wortmannin (lOOnM for 20 minutes) followed by IGF-1 (100 ng/ml for 5 minutes)
(WM) or diluent alone (Basal). PtdIns(3,4,5)P3 levels were measured using an
isotope dilution assay as described in 'Materials and Methods'. The results shown









PKB expression in SCLC cells. Whole cell lysates ofH69 SCLC cells were
resolved on 10% SDS polyacrylamide gels and transferred onto nitrocellulose
membrane by 'Western' blotting. PKB expression was examined using monoclonal
antibodies to the a, P and y isoforms ofPKB. PKB is expressed at 57 kDa. The blot
shown is representative of three independent experiments. Molecular weight
markers in kDa are shown at the left hand margin.
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Initially, basal PKB activity in SCLC cells was compared with basal activity in Swiss
3T3 cells. Prior to experimentation both sets of cells had been maintained in growth
factor-free quiescent medium for 24 hours and thoroughly washed using the same
conditions as described for PI 3-kinase activity measurements. Under basal
conditions PKB activity in H69 SCLC cells was 3.75 fold higher than that in Swiss
3T3 cells despite similar levels of expression ofPKB as determined by 'Western'
blotting (Figure 3.8). These results were confirmed by 'Western' blotting using an
anti-phospho-PKB antibody that recognises phosphorylation ofPKB at serine 473.
Figure 3.8 shows markedly increased phospho-PKB expression in H69 SCLC cells
compared with Swiss 3T3 cells. Figure 3.9 shows that IGF-1 could only induce a
modest additional increase in PKB activity (1.76 fold). This figure is very similar to
the increase in PI 3-kinase activity seen when H69 cells were treated with IGF-1
(Figure 3.3).
The addition of the PI 3-kinase inhibitors LY294002 and wortmannin to H69 SCLC
cells, for 20 minutes prior to cell lysis, caused a concentration-dependent inhibition
of basal PKB activity (Figure 3.10). The IC50 for LY294002 and wortmannin was
2.7 ± 0.1 pM and 2.0 ± 0.6 nM respectively. These values correlate well with those
seen for PI 3-kinase inhibition (Table 3.1). It should also be noted that when
wortmannin and LY294002 were added directly to PKB immunoprecipitates no
inhibition ofPKB activity was seen. This confirmed that these inhibitors were not
acting on PKB activity directly, but rather through PI 3-kinase. Furthermore, PKB
activity was unaffected by the p70s6k inhibitor rapamycin confirming that PKB lies
upstream of p70s6k (Figure 3.9).
These data indicated that basal PKB is elevated in SCLC cells and that this activity is




Comparative PKB expression and activity in H69 SCLC cells and Swiss 3T3
cells. H69 SCLC cells and Swiss 3T3 cells which had been 'quiesced' for 24 hours
prior to experimentation were lysed in PKB lysis buffer and the lysates split. The
bottom panel shows comparative PKB activity. PKB was immunoprecipitated from
cell lysates using an anti-PKB-PH domain antibody and PKB activity was assayed in
an in vitro kinase reaction using 'Crosstide' as substrate as described in 'Materials
and Methods'. PKB activities are expressed in cpm and are the means ± SD of two
independent experiments performed in duplicate. The upper panels show PKB
expression using either an anti-PKB-PH domain antibody (middle panel) or an anti-
phospho-PKB antibody that recognises phosphorylation ofPKB at serine 473 (top
panel). Blots representative of three independent experiments are shown and




PKB activity in SCLC cells. H69 SCLC cells which had been 'quiesced' for 24
hours prior to experimentation were thoroughly washed and then equilibrated in PBS
for 1 hour before being treated with IGF-1 (100 ng/ml for 5 minutes), wortmannin
(WM) (100 nM for 20 minutes) or rapamycin (Rap) (20 nM for 20 minutes) or
diluent alone (basal). PKB was immunoprecipitated from cell lysates using an anti-
PKB-PH domain antibody and PKB activity was assayed in an in vitro kinase
reaction using 'Crosstide' as substrate as described in 'Materials and Methods'.
Results are expressed in cpm and are the means ± SEM of three independent
experiments performed in duplicate. *p < 0.01 compared with basal values.
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Figure 3.10
Concentration dependent inhibition of basal PKB activity by PI 3-kinase
inhibitors in SCLC cells. SCLC cells which had been 'quiesced' for 24 hours prior
to experimentation were thoroughly washed and then equilibrated in PBS for 1 hour
before being treated with wortmannin (left) or LY294002 (right) for 20 minutes
before lysis. PKB was immunoprecipitated from cell lysates using an anti-PKB-PH
domain antibody and PKB activity was assayed in an in vitro kinase reaction using
'Crosstide' as substrate as described in 'Materials and Methods'. Each point
represents the mean ± SEM of three independent experiments performed in
duplicate.
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3.2.6 Functional consequences ofconstitutive PI 3-kinase activity
Having established that PI 3-kinase is constitutively active in SCLC cells, the
biological consequences of blocking this upregulated pathway were examined. It has
been known for several years that PI 3-kinase is involved in cell growth. Studies of
the mutants of the polyoma virus middle T antigen that were defective in
transforming ability initially identified PI 3-kinase as necessary for transformation by
middle T (Whitman et al., 1985; Kaplan et ah, 1986). Subsequent work involving
mutations of \-src and the PDGF receptor correlated the stimulation of PI 3-kinase
activity with transformation and mitogenesis respectively (Cantley et ah, 1991).
There is also evidence for PI 3-kinase regulating pathways controlling apoptosis.
Inhibition ofPI 3-kinase can block the ability of survival factors to protect various
cell types from programmed cell death (Yao and Cooper, 1995; Yao and Cooper,
1996). Recent reports have revealed that PKB is also involved in regulating cell
survival. Activated forms ofPKB have been shown to protect Cos-7 epithelial cells
from apoptosis induced by ultraviolet irradiation (Kulik et ah, 1997) and to protect
neuronal cells from cell death induced by the withdrawal of the survival factor IGF-1
(Dudek et ah, 1997).
3.2.7 SCLC cellgrowth is PI 3-kinase-dependent
SCLC cells were grown in serum-free SITA medium in the presence of increasing
concentrations of LY294002 and cell number was counted at day 9. LY294002
caused a marked concentration-dependent reduction in SCLC cell number in liquid
growth with IC50 values of 10.0 ± 0.8 p.M, 2.9 ± 0.2 pM and 13.3 ± 0.8 pM for H69,
H345 and H510 cell respectively (Figure 3.11) compared with control cells that
received DMSO only (final concentration 0.01%). These figures are similar to the
values obtained for PI 3-kinase and PKB activity inhibition by LY294002 in SCLC
cells (Table 3.1). Similar experiments using wortmannin did not show any inhibition
of growth between treated and control cells. Previous studies have shown that
wortmannin has a relatively short half-life (Powis et ah, 1994; Brown et ah, 1995).
A recent study has shown that although 100 nM wortmannin can completely inhibit
PI 3-kinase activity for the first few minutes following addition, PI 3-kinase activity
can be detected after one hour.
84
H345
Jj L// 1 1 1 U \—// 1 1 L
10"7 10"6 10'5 10"4 10-7 10 "6 10"5 10"4 10 "7 10"6 10 "5 10 "4
Log[LY294002 (M)]
Figure 3.11
The effect of LY294002 on SCLC cell growth. H69, H345 and H510 SCLC cells
(1 x 105) were washed and then incubated in fresh SITA medium in the presence of
increasing concentrations of LY294002 as shown. Cell number was determined on
day 9 using a Coulter counter. The results are expressed as a percentage of cell
growth in the presence of diluent alone (DMSO, final concentration 0.01%). 100%
cell growth represents approximately 1.5 x 106 cells in the H69 cell line and 1.0 x 106
cells in the H345 and H510 cell lines. Each point represents the mean ± SEM of
three to five independent experiments performed in triplicate.
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After 2-3 hours wortmannin is no longer able to inhibit PI 3-kinase activity (Jones et
al., 1999). These findings explain why a single addition ofwortmannin at the
beginning of the experiment was insufficient to inhibit growth over a nine day
period.
Seufferlein and Rozengurt (1996) initially showed that rapamycin was able to inhibit
SCLC cell growth. In order to determine the relative contribution of the p70s6k
pathway to PI 3-kinase-mediated growth in SCLC, SCLC cells were grown in the
presence of LY294002 and rapamycin both alone and in combination. Figure 3.12
shows that the addition of a maximally effective concentration of LY294002 (100
pM) was able to inhibit H69 and H345 SCLC cell growth by 92% over a nine day
period. However, a maximally effective concentration of rapamycin (20 nM) caused
only a 6.5% and 33% reduction in growth over the same time period in H69 and
H345 cells respectively. Incubation of H69 and H345 cells with a combination of 10
pM LY294002 and 20 nM rapamycin caused a 62% and 68% inhibition of growth
respectively over 9 days (Figure 3.12). These results suggest that PI 3-kinase exerts
its growth effects by both p70s6k-dependent and independent pathways in SCLC.
3.2.8 SCLC cell survival is PI 3-kinase-dependent
The effect of PI 3-kinase inhibitors on the rate of SCLC cell apoptosis was
determined using acridine orange/ethidium bromide staining under fluorescent
microscopy. The background level of apoptosis was 8%. Figure 3.13 shows the
dose-dependent increase in apoptosis with increasing concentrations of LY294002.
3.2.9 LY294002 inhibits SCLC cell tumourigenicity and neuropeptide-stimulated
colony growth
The ability to form colonies in agarose semi-solid medium is a marker of anchorage-
independent growth that is characteristic of the transformed phenotype. There is a
positive correlation between the cloning efficiency of cells and the histological
involvement and invasiveness of the tumour in specimens taken from SCLC (Carney
et al., 1980). A number of neuropeptides have been shown to stimulate SCLC cell
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Effect of LY294002 and rapamycin on H69 (left) and H345 (right) SCLC cell
growth. Cells (1 xlO5) were washed and incubated in fresh SITA medium in the
presence of LY294002 (LY) or rapamycin (Rap) alone or in combination, at the
concentrations indicated. On day 9 cell number was measured using a Coulter
Counter. Results expressed as percentage inhibition of growth compared with
control cell growth are the means ± SEM of three to five independent experiments
performed in triplicate.
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Figure 3.13
The effect of increasing concentrations of LY294002 on apoptosis in SCLC cells.
H69 SCLC cells (5 x 104/ml), 3-5 post-passage were incubated in 'quiescent'
medium overnight before being treated with increasing concentrations of LY294002.
After 24 hours cells were removed and apoptosis was determined using ethidium
bromide and acridine orange as described in 'Materials and Methods'. The
basal level of apoptosis was 8%. The results shown are the mean ± SD for two
independent experiments performed in triplicate.
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growth in vivo giving rise to the autocrine and paracrine growth loop theory of
SCLC proliferation (Sethi and Rozengurt, 1991). The effect of LY294002 on SCLC
colony formation in agarose semi-solid medium was studied. LY294002 inhibited
basal colony formation of all three SCLC cell lines by up to 80% (Figure 3.14). As
shown previously, the neuropeptides vasopressin, gastrin and bombesin caused a
marked stimulation of colony formation in H69, H510 and H345 cells respectively.
However, the addition of vasopressin, gastrin or bombesin failed to rescue the
LY294002-induced inhibition of colony formation in these cell lines (Figure 3.14).
Thus, PI 3-kinase appears to play a critical role in sustaining the anchorage-




Effect of LY294002 on SCLC cell growth in semi-solid medium. H69, H345 and
H510 SCLC cells, 3-5 days post passage, were washed and 1 xlO4 viable cells/ml
were plated in SITA medium containing 0.3% agarose on top of a base of 0.5%
agarose in SITA medium as described in 'Materials and Methods'. Both layers
contained either no neuropeptide additions (filled bars) or 50 nM vasopressin (VP),
50 nM bombesin (Bom) or 100 nM gastrin (G) (hatched bars) in the presence (+) or
absence (-) of 10 pM LY294002 (LY). After 21 days, colonies of>120 pm (16
cells) were counted. Results are expressed as colonies/dish and are the means ± SD
from two independent experiments.
90
3.3 DISCUSSION
In this chapter the role ofPI 3-kinase and PKB in the regulation of SCLC cell
proliferation, anchorage-independence and apoptosis have been examined.
Basal PI 3-kinase activity levels in SCLC cell lines are high compared with basal PI
3-kinase activity levels in a panel of untransformed cells types. Furthermore, basal
PtdIns(3,4,5)P3 levels in SCLC cell lines are elevated compared to basal
PtdIns(3,4,5)P3 levels in untransformed cells. Similarly, it has been shown that PKB,
a key effector ofPI 3-kinase, is partially activated in H69 SCLC cells under control
conditions. Taking these data together it is proposed that PI 3-kinase is
constitutively active in SCLC cells and that as a consequence, PKB has elevated
basal activity. We have also demonstrated that inhibition of PI 3-kinase activity
blocked SCLC cell growth in liquid culture and colony formation in soft agarose as
well as stimulating apoptosis.
Although PI 3-kinase activation has been implicated in anchorage-independent
growth, metastasis and cell invasion (Shaw et al., 1997b; Keely et al., 1997) there
has, until recently, been limited evidence for dysregulation of the PI 3-kinase/PKB
pathway in human tumours.
Following the identification of the AKT8 retrovirus from a rodent T-cell lymphoma,
the cellular homologue of w-akt was cloned and found to be a 57 kDa protein
serine/threonine kinase (Coffer and Woodgett, 1991; Jones et al., 1991a; Bellacosa et
al., 1991). The human homologues AKT1 and AKT2 were subsequently identified
and cloned (Staal, 1987) and the human AKT1 locus has been mapped to
chromosome 14q32 (Staal et al., 1988), a region frequently affected by translocations
and inversions in human T-cell leukaemia/lymphoma, mixed-lineage childhood
leukaemia and clonal T-cell proliferations in ataxia telangiectasia (Bertness et al.,
1990). Analysis of a panel of human primary gastric adenocarcinomas showed a 20-
fold amplification ofAKT1. AKT2 has been mapped to the chromosome region
19ql3.1-ql3.2 and has been shown to be amplified and overexpressed in several
ovarian carcinoma and pancreatic cell lines (Cheng et al., 1992; Miwa et al., 1996).
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A large scale study ofAKT2 alterations in ovarian and breast tumours showed
amplification in 12.1% of ovarian and 2.8% of breast carcinomas. Amplification of
AKT2 was more frequent in undifferentiated tumours suggesting that AKT2
alterations may be associated with tumour aggressiveness (Bellacosa et al., 1995).
Although these workers studied AKT expression they did not examine AKT activity
status.
To date, there has been only one other report of increased PI 3-kinase activity in a
human solid tumour. Phillips et al. (1998) examined PI 3-kinase activity in a panel
of 37 human colorectal tumours and compared it to PI 3-kinase activity in normal-
appearing colonic mucosa from the same patients. They found that 86% of tumours
demonstrated increased PI 3-kinase activity with an overall mean increase of 3.8
fold. However, the frequency and extent of increased PI 3-kinase activity in the
tumours did not correlate with the degree of differentiation or tumour stage (Phillips
et al., 1998).
The cause of the elevated PI 3-kinase activity in SCLC cells is unclear. Protein
expression in the SCLC cell lines was similar to that in the untransformed control
cell lines confirming that it was not simply due to an increase in PI 3-kinase
expression.
PI 3-kinase can be activated by a wide variety of growth stimuli including PDGF,
EGF, insulin, thrombin and NGF. Prior to assaying for PI 3-kinase activity every
effort was made to remove all exogenous growth factors by extensive washing prior
to experimentation. Hence, it seems unlikely that exogenous growth factors were
stimulating PI 3-kinase under control conditions. The control cell lines used were
washed and incubated in an identical fashion and under these conditions basal PI 3-
kinase activity levels were very low.
A number of oncogenes including ras and src are able to activate PI 3-kinase.
Transformation ofmany adherent cell types, including fibroblasts and epithelial
cells, by cytoplasmic oncogenes such as ras and src is accompanied by the ability to
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grow in suspension. SCLC cells, in vitro, grow in an anchorage-independent
fashion. However, several studies have failed to show any evidence of activating ras
mutations in SCLC (Mitsudomi et al., 1991; Suzuki et al., 1990). Pp60irc activity has
also been reported as being low in SCLC cells (Budde et al., 1994). Therefore, it
seems unlikely that the elevated basal PI 3-kinase activity in SCLC is due to ras or
src transformation. Interestingly in the study by Phillips et al., (1998) there was no
association between elevated PI 3-kinase activity in colorectal carcinoma and the
frequency of ras mutations, again suggesting that ras mutations are not responsible
for increased PI 3-kinase activity in colorectal cancers.
It is possible that elevated PI 3-kinase activity in SCLC may be due to a gene
mutation. Such a mutation might either encode for a receptor protein that is
continuously switched on, leading to constitutive PI 3-kinase activation, or for one of
the PI 3-kinase subunits. Examples of both types ofmutation have been described
recently. Two groups have published data showing oncogenic mutation of PI 3-
kinase. Jimenez et al., (1998) found that CMN-5 cells from a murine thymic
lymphoma failed to express the p85 regulatory subunit of PI 3-kinase. However, a
65 kDa protein was identified that was not found in untransformed thymocytes.
Analysis ofpi 10a immunoprecipitates from CMN-5 cells indicated that p65
associated with pi 10 in place of p85. Once cloned, expression of p65-PI 3-kinase in
an unrelated cell line showed that p65-PI 3-kinase induced constitutive activation of
PI 3-kinase and contributed to cellular transformation. Shayesteh et al., (1999)
examined PIK3CA, which encodes the pi 10a catalytic subunit of PI 3-kinase. They
showed that PIK3CA is frequently increased in copy number in ovarian carcinomas
and that the increased copy number is associated with increased PIK3CA
transcription, pi 10a protein expression and PI 3-kinase activity. In contrast,
Moscatello et al., (1998) transfected NIH 3T3 cells with a mutated epidermal growth
factor receptor and showed that PI 3-kinase was constitutively activated as a result.
Whether one or more mutations of the types alluded to above are responsible for
constitutive PI 3-kinase activity in SCLC cells remains to be established.
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In addition to examining PI 3-kinase activity in SCLC cells we also measured basal
PtdIns(3,4,5)P3 levels in two SCLC cell lines and compared them to those found in
Swiss 3T3 fibroblasts and Rat-2 fibroblasts. Levels of PtdIns(3,4,5)P3 in the SCLC
cell lines investigated were several fold higher than those in the fibroblast cell lines.
This data supports the hypothesis that PI 3-kinase is constitutively active in SCLC.
Phospholipid levels are regulated on the one hand by kinases and on the other by
phosphatases. PI 3-kinase phosphorylates the 3' position of the inositol head group
ofPtdIns(4,5)P2 to generate PtdIns(3,4,5)P3. PtdIns(3,4,5)P3 can be
dephosphorylated at the 5' position by an SH2-containing 5-phosphatase called SHIP
to generate PtdIns(3,4)P2 (Erneux et al., 1998). Recently a novel 3-phosphatase
called PTEN (phosphatase and tensin homologue deleted on chromosome ten) has
been described which can dephosphorylate the 3' position of both PtdIns(3,4,5)P3
and PtdIns(3,4)P2 to reverse the reactions catalysed by PI 3-kinase. PTEN was
identified by two groups in 1997 as a candidate tumour suppressor gene located at
10q23 (Li et al., 1997; Steck et al., 1997). Initially the PTENcDNA sequence
suggested that it was a member of the protein-tyrosine phosphatase gene superfamily
and PTEN was thought to be a dual-specificity phosphatase (Li et al., 1997; Steck et
al., 1997). However, Maehama et al., (1998) have shown that PTEN can
dephosphorylate the 3' position of Ptdlns phosphates both in vitro and in vivo. This
finding has led to a model for how PTEN acts as a tumour suppressor. Normally
PtdIns(3,4,5)P3 and PKB levels are low in the absence of growth factor stimulation.
However, PTEN-deficient tumour cell lines and tumours derived from PTEN-
deficient mice, exhibit high basal PtdIns(3,4,5)P3 and PKB activity levels (Myers et
al., 1998; Li and Sun, 1998; Haas-Kogan et al., 1998). PTEN mutations have now
been identified in a number of cancers including glioblastoma multiforme,
melanoma, advanced prostate cancers and endometrial carcinoma (Rasheed et al.,
1997; Wang et al., 1997; Guldberg et al., 1997; Cairns et al., 1997; Risinger et al.,
1997). Several groups have sought PTEN mutations in both NSCLC and SCLC.
Although deletions in 10q22-25 are common in SCLC, PTEN mutations appear to be
rather less common. PTEN mutations have been reported as occurring in between 8
and 18% of SCLC cell lines (Forgacs et al., 1998; Kim et al., 1998; Yokomizo et al.,
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1998). Interestingly, neither the H69 nor the H345 cell lines have been shown to
contain PTEN mutations (Yokomizo et ah, 1998). Therefore, it would appear that
the high PtdIns(3,4,5)P3 and increased PKB activity seen in our SCLC cell lines are a
result of constitutive PI 3-kinase activity rather than due to a PTEN mutation.
Recent work has shown that high levels of PKB, either as a result ofPTEN mutation
or constitutive PI 3-kinase activity, may have significant implications for cell
survival both within and outwith their normal environments. Inhibition of PI 3-
kinase is known to block the ability of survival factors to protect various cell types
from apoptosis. Expression of constitutively active PI 3-kinase or PKB protects Cos-
7 epithelial cells from apoptosis induced by ultraviolet irradiation (Kulik et ah, 1997)
and can protect neuronal cells from cell death induced by withdrawal of IGF-1
(Dudek et ah, 1997). Khwaja et ah, (1997) have recently shown that that activated PI
3-kinase and PKB can protect MDCK cells from apoptosis induced by detachment of
adherent cells from their extracellular matrix. Detachment induced apoptosis, which
has been christened 'anoikis', is the mechanism whereby cells are prevented from
surviving outwith their normal environment. In MDCK cells, detachment from
extracellular matrix leads to a rapid decrease in the levels of PI 3-kinase and PKB
and vice versa on re-attachment. Transfection of constitutively active PI 3-kinase or
PKB protects MDCK cells from apoptosis in suspension, while inhibition of PI 3-
kinase caused enhanced apoptosis in adhered cells (Khwaja et ah, 1997). The
finding of constitutively active PI 3-kinase and PKB in SCLC cells provides a
mechanism by which SCLC cells are able to grow in the absence of contact with
extracellular matrix. We propose that constitutive activation of PI 3-kinase/PKB in
SCLC cells may mimic integrin-dependent signal transduction and promote cell
proliferation and protection from apoptosis in the absence of contact with
extracellular matrix.
The addition of the PI 3-kinase inhibitor LY294002 to SCLC cells in liquid culture
resulted in a marked concentration-dependent reduction in cell number. The addition
of LY294002 to SCLC cells showed a modest but consistent increase in the
percentage of cells undergoing apoptosis. Furthermore, LY294002 markedly
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inhibited basal colony formation of SCLC cells in agarose semi-solid medium. The
ability of cells to grow in soft agarose is a feature of anchorage-independence and is
pathognomonic of the transformed phenotype, correlating with tumourigenicity and
invasiveness of the tumour (Carney et al., 1980). Interestingly, the inhibition of
colony formation induced by LY294002 could not be overcome by the addition of
neuropeptides. Neuropeptides are known to be potent growth factors for SCLC,
activating the MAP kinase pathway through G-protein coupled receptors (Seufferlein
and Rozengurt, 1996a). These results suggest that PI 3-kinase may be required for
neuropeptide mitogenic signalling in SCLC. It remains to be established whether
MAP kinase activation can be potentiated by growth factor/integrin-dependent PI 3-
kinase activation. Recent evidence suggests that growth factors do not induce DNA
synthesis in 3T3 cells in the absence of integrin activation (Renshaw et al., 1997).
This appears to result from the inability of growth factors to activate the MAP kinase
pathway in the absence of integrin activation. However, constitutive activation of PI
3-kinase in SCLC cells may mimic integrin-dependent signal transduction and
facilitate growth factor-mediated activation of the MAP kinase pathway.
In addition to using PI 3-kinase inhibitors to study the functional role of the PI 3-
kinase/PKB pathway in SCLC, rapamycin, a specific inhibitor of p70s6k was also
used. P70s6k is implicated in a wide range of cellular processes including protein
synthesis, translation of specific mRNA species and progression from Gi to S phase
of the cell cycle (Chou and Blenis, 1995; Ferrari and Thomas, 1994; de Groot et al.,
1994). P70s6k is known to be an effector of PI 3-kinase and p70s6k has been shown to
be constitutively phosphorylated in SCLC cells (Seufferlein and Rozengurt, 1996b).
Our group has recently shown that p70s6k is also constitutively active in SCLC and
that this is PI 3-kinase-dependent (Moore et al., 1998). Although PKB and p70s6kare
known to be physiological targets ofPI 3-kinase, it is unclear whether these enzymes
lie on the same signalling pathway or parallel pathways. The observation that
constitutively active forms ofPKB led to the activation of p70s6k implied that PKB
may mediate mitogenic signalling through p70s6k (Burgering and Coffer, 1995).
However, the situation is likely to be more complicated since PDK1 has recently
been shown to be capable of inducing p70s6k activation independently ofPKB (Alessi
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et al., 1998; Pullen et al., 1998). Thus PI 3-kinase mediated p70s6k activation may
well occur via alternative pathways. In support of this, certain agonists can
differentially induce PKB and p70s6k (Conus et al., 1998). The data presented here
supports the latter view. It was found that PI 3-kinase regulation of SCLC cell
growth was mediated by both p70s6k-dependent and independent pathways. The
latter pathway may signal through PKB.
In summary it has been shown that constitutive PI 3-kinase activity in SCLC
regulates proliferation, anchorage-independent growth and apoptosis. Recent studies
have suggested that PI 3-kinase activation induces integrin-mediated cell motility
and invasiveness. In addition, PI 3-kinase/PKB activation can promote anchorage-
independent growth, protecting cells in suspension from undergoing apoptosis. The
pathways driven by constitutive PI 3-kinase/PKB may therefore be responsible for
the ability of SCLC cells to survive and proliferate in an anchorage-independent state
leading to the development of a particularly aggressive metastatic phenotype. These
results agree with an increasing cohort of data that points towards the PI 3-
kinase/PKB pathway being upregulated in a number of tumour types and playing a
key role in carcinoma proliferation and metastasis.
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CHAPTER 4
EXTRACELLULAR MATRIX REGULATION OF SMALL
CELL LUNG CANCER CELL APOPTOSIS
4.1 INTRODUCTION
SCLC is characterised by an extremely aggressive clinical course. Untreated, the
median survival from diagnosis is only 5 to 12 weeks depending upon the stage at
diagnosis. Two-thirds of patients will have evidence of distant metastases at the time
of diagnosis thereby excluding the possibility of surgical resection for the majority of
cases. In the 1970s SCLC was a candidate to be the first 'curable' solid malignancy
because of its apparent marked sensitivity to chemotherapy. However, despite initial
response rates of up to 80%, these tend to be short-lived with a median duration of 6-
8 months. Following treatment, the median survival for patients with limited disease
and extensive disease are 14-20 and 8-13 months respectively (Osterlind et al.,
1986).
In the clinic, tumours often shrink dramatically in size following chemotherapy and
may, at the macroscopic level, disappear entirely on chest radiographs and on
conventional cross-sectional scans. However, the recurrence of tumour after
chemotherapy implies the existence of a number of tumour 'stem' cells resistant to
cytotoxic therapy. Apoptosis is now recognised as the predominant mechanism by
which chemotherapeutic agents bring about cell death (Hannun, 1997). An initial
study examining the mechanism of action of etoposide showed that etoposide
induced internucleosomal DNA fragmentation (Kaufmann, 1989). Since then, the
spectrum of chemotherapeutic agents causing apoptosis has expanded progressively.
Vincristine, cis-platinum, cyclophosphamide, adriamycin, paclitaxel and 5'-
fluorouracil have all been shown to exert their effects through apoptosis (reviewed in
Hannun 1997).
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In cancer biology it is becoming increasingly apparent that many tumour cells
circumvent the normal apoptotic mechanisms in order to prevent destruction by
chemotherapeutic drugs. One might hypothesise that, in vivo, some factor(s) in the
local environment is able to provide a survival signal thereby accounting for the
protection of SCLC cells from chemotherapy-induced apoptosis. One possible
candidate to provide such a signal is ECM. Many epithelial and endothelial cell
types are dependent upon adhesion to ECM for their continued survival undergoing
apoptosis on detachment from matrix. Although transformed cells are characterised
by their ability to grow in the absence of contact with a solid ECM, solid tumour
cells exist, in vivo, in a state of dynamic interplay between anchorage-dependence
and independence. Of note is the observation that after chemotherapy recurrent
SCLC frequently occurs at the same sites as the original tumour rather than at distant
sites. This suggests that tumour cells that are adhered to matrix may be relatively
protected from chemotherapy compared with cells that are anchorage-independent.
Tumour stroma varies greatly in amount between different tumours and may make
up more than ninety percent of the total tumour mass in tumours such as scirrhous
carcinomas of the breast and stomach. In such cases almost all of the tumour mass
may be constituted by dense collagenous connective tissue and it may be difficult to
find tumour cells. At the other end of the spectrum, medullary carcinomas may
contain only minimal connective tissue between clusters ofmalignant cells. Up until
now, the ECM composition of SCLC tumours has received little attention.
The aim of this part of the study was to examine the role of anchorage-dependence
on chemotherapy-induced apoptosis in SCLC.
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4.2 RESULTS
4.2.1 Extracellular matrix composition ofSCLC tumours
The ECM composition of 23 SCLC surgical resection specimens from the University
ofEdinburgh pathology files was determined by immunohistochemical staining for
fibronectin, laminin, collagen IV and tenascin.
Normal areas of the lung showed laminin and collagen IV localised to the basement
membranes of alveoli, septae, blood vessels and bronchial glands (Figure 4.1),
whereas fibronectin staining showed diffuse weak positivity throughout the
pulmonary interstitium (Figure 4.1). No tenascin immunoreactivity was seen in
normal lung. In SCLC sections extensive staining for fibronectin, collagen IV and
tenascin was seen in 56%, 87% and 61% of tumours respectively (Table 4.1).
Extensive staining was defined as staining covering more than 50% of the section
area. Furthermore, focal areas of immunoreactivity for fibronectin, collagen IV and
tenascin were seen in 35%, 9% and 39% of sections respectively (Table 4.1).
Fibronectin, collagen IV and tenascin were expressed mainly in areas of reactive host
connective tissue, which were present as extensive areas of scarring or as stromal
bands delineating pockets of invasive tumour cells (Figure 4.2). Furthermore, it was
noted that in SCLC sections the basement membranes of alveoli invaded by tumour
were considerably thickened due to increased expression of fibronectin, laminin and
collagen IV compared with adjacent uninvolved areas (Figure 4.2). In addition to
ECM deposition it was also noted that in 26% and 16% of tumours respectively,
fibronectin and laminin staining was visible within the cells themselves (Figure 4.2)
In three cases matched metastatic lymph nodes were also examined and in all cases
fibronectin, collagen IV and tenascin immunoreactivity was as extensive as in the
primary tumours.








Figure4.2 Immunohistochemicals ainingfECMpr t insarou dS LCcellivivo.Fibron cti(A)anc llagenIVBimmu oreactivity SCLC.,intra/pericellularimmunoreactivityforla nin.Mag ficationX400 102
ECM No of cases STROMA TUMOUR CELLS
Extensive Focal Negative Positive Negative
No (%) No (%) No (%) No (%) No (%)
Fibronectin 23 13 (56) 8 (35) 2 (9) 6 (26) 17 (74)
Laminin 19 0 (0) 0 (0) 19 (100) 3 (16) 16 (84)
Tenascin 23 14 (61) 9 (39) 0 (0) 0 (0) 23 (100)
Collagen IV 23 20 (87) 2 (9) 1 (4) 0 (0) 23 (100)
Table 4.1
Expression of ECM proteins in primary lung SCLC resection specimens. After
immunohistochemistry, ECM protein staining within areas of carcinoma stroma was
recorded on a semi-quantitative scale: no staining, focal staining or extensive
staining (>50% of section). Sections were also assessed for intracellular ECM
protein expression. Data represent numbers of cases, with percentages in
parentheses.
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4.2.2 SCLC cells adhere to extracellular matrixproteins through [31 integrins
In order to investigate the physiological relevance of ECM deposition in SCLC cell
tumours we initially investigated whether SCLC cells are able to bind to ECM
proteins. The principal family of cell surface receptors that are responsible for
anchoring cells to ECM proteins are integrins. The integrin subunit profile of SCLC
cells has been studied previously (Sethi et al., 1999; Hirasawa et ah, 1994; Falconi et
ah, 1994). These studies showed that the predominant beta integrin expressed was
pi. The main alpha integrins expressed on SCLC cells are a2, a3, a6 and
av (Vogel et ah, 1990; Elices et ah, 1991; Hynes, 1992). Figure 4.3 shows that H69
SCLC cells adhered to fibronectin, laminin and collagen IV in a concentration-
dependent manner. The EC50 values for H69 cell adhesion to fibronectin, laminin
and collagen IV were 20 pg/ml, 10 pg/ml and 12 pg/ml respectively. Integrin
function is known to be divalent cation dependent (Humphries, 1996). Therefore, if
SCLC binding to ECM is integrin-mediated, divalent cations such as Mn2+ should
potentiate binding to ECM components and EDTA, a cation chelator, should block
binding. Figure 4.4 shows that when SCLC cells were allowed to adhere to
fibronectin in culture medium (containing 0.65 mM Ca (N03)2 4H2O and 0.54 mM
Mg (SO4) 7H2O) adhesion rates increased from 41 ± 6 % in the absence ofMn2+ to
88 ± 5 % in the presence ofMn2+(1 mM) (p<0.05). Co-incubation with EDTA (1.8
mM) decreased the adhesion level to 6 ± 3 % (p<0.05). Furthermore, when SCLC
cells were incubated on a fibronectin matrix in the presence of a function-blocking
pi antibody adhesion to fibronectin was reduced from 41 ± 6 % to 8 ± 2 % (p<0.05).
Similar results were obtained for laminin. These results show that SCLC cells
adhere to ECM proteins in an integrin-dependent fashion and that pi integrin plays a
significant role.
4.2.3 Extracellular matrix proteins protect SCLC cells from chemotherapy-
induced apoptosis
In order to test the hypothesis that ECM proteins might protect SCLC cells from
chemotherapy-induced apoptosis SCLC cells were treated with a variety of
chemotherapeutic agents in the presence and absence of various ECM proteins.
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Figure 4.3
Adhesion of SCLC cells to ECM proteins. H69 SCLC cells (5 x 105) which had
been washed twice in RPMI 1640 were added to wells which had been pre-coated
overnight with increasing concentrations of fibronectin, laminin or collagen IV as
shown and adhesion measured as described in 'Materials and Methods'. Adhesion is
expressed as a percentage of maximal adhesion, which was defined as adhesion to
poly-L-lysine (10 pg/ml). The results shown are the means ± SEM of three
experiments performed in triplicate.
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Figure 4.4
SCLC adhesion to fibronectin is pi integrin mediated. H69 SCLC cells (5 x 105),
which had been washed twice in RPMI 1640, were added to wells that had been pre-
coated overnight with either BSA 1% or fibronectin 20 pg/ml (Fn) in the absence (-)
or presence ofMn2+ (ImM), a pi function-blocking antibody, P4C10 (1:100) (pi-ve)
or EDTA (1.8 mM) and adhesion measured as described in 'Materials and Methods'.
Adhesion is expressed as a percentage ofmaximal adhesion, which was defined as
adhesion to poly-L-lysine (10 pg/ml). The results shown are the means ± SEM of
three experiments performed in triplicate. *P<0.05 compared with basal fibronectin
values.
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Adhesion of SCLC cells to laminin, fibronectin and collagen IV markedly protected
them against apoptosis induced by chemotherapeutic agents compared to those
grown on plastic as measured using Giemsa staining (Figure 4.5). For example in
H345 cells, in response to 50 pg/ml etoposide, fibronectin reduced apoptosis from
75% to 14% (Figure 4.5). Similar results were seen when H510 cells were treated
with doxorubicin in the presence and absence of fibronectin or laminin (Figure 4.5).
In order to corroborate these findings apoptosis was also assessed by two other
methods. Figure 4.6 shows the effect of etoposide (25 pg/ml) on SCLC apoptosis in
the presence and absence of fibronectin as measured by acridine orange/ethidium
bromide staining (left hand panel) and by immunoassay of cytoplasmic histone-
associated DNA (right hand panel). Using acridine orange/ethidium bromide
staining the basal levels of apoptosis in H69 cells on plastic was 17 ± 2 % and this
increased to 43 ± 3 % in the presence of etoposide. However, for cells plated on
fibronectin the rates were 10 ± 2 % and 13 ± 1 % respectively. Similar results were
obtained using the immunohistochemical method. This data supports our findings
using Giemsa staining.
In order to determine whether ECM-mediated protection from chemotherapy-
induced apoptosis was integrin-mediated or whether it was simply due to a non¬
specific adhesive effect, SCLC cells were plated onto plastic, poly-L-lysine or ECM
and treated with etoposide. Cells adhere to poly-L-lysine in a non-specific fashion
based solely on electrical charge. Figure 4.7 shows that when cells were plated onto
plastic or poly-L-lysine and treated with etoposide (50 pg/ml) the level of apoptosis
was 82 ± 10% and 89 ± 8 % respectively compared with 20 ± 4 % for untreated cells
However, when H69 cells were pre-plated on collagen IV and treated with the same
concentration of etoposide the level of apoptosis fell to 23% (p<0.05). This ECM-
mediated protection from etoposide-induced apoptosis was abolished by the addition
of a function blocking pi antibody.
Taken together, these data show that ECM-mediated protection from chemotherapy-
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Figure 4.5
Effect of ECM proteins on chemotherapy-induced apoptosis in SCLC cells.
SCLC cells (1 x 105/ml) that had been cultured in SITA medium were seeded into 96
well plates pre-coated with fibronectin 20 pg/ml (•), laminin 10 pg/ml (■) or
collagen IV 10 pg/ml (♦) or BSA 1% (□). After 1 hour increasing concentrations of
etoposide or doxorubicin were added as shown and cells further incubated at 37°C.
After 72 hours cells were detached from the plates, aspirated and cytospun onto glass
slides. Apoptosis was detected by Giemsa staining as described in 'Materials and
Methods'. Each point represents the mean ± SEM of quadruplicates performed in
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Figure 4.6
Effect of fibronectin on chemotherapy-induced apoptosis in H69 SCLC cells.
SCLC cells (1 x 105/ml) that had been cultured in SITA medium were seeded into 96
well plates pre-coated with fibronectin (20 pg/ml) or 1% BSA. After 1 hour
etoposide (25 pg/ml) was added and cells further incubated at 37°C. After 24 hours
plates were spun at 200 x g for 4 minutes, supernatant aspirated and apoptosis
detected by either acridine orange/ethidium bromide (left hand panel) or by a
commercial cell death ELISA kit (right hand panel) as described in 'Materials and
Methods'. Each point represents the mean ± SEM of three independent experiments
performed in triplicate. *p< 0.05 compared with cells on plastic treated with
etoposide.
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ECM-mediated protection from chemotherapy-induced apoptosis is mediated
by pi integrins. H69 SCLC cells (1 xlO5) were plated into 96 well plates which had
been pre-coated with either no coating (PLAS), poly-L-Lysine (PLL) (10 pg/ml) or
collagen IV (25 pg/ml) in the presence or absence of a function-blocking pi antibody
(P5D2, 1:100). After 1 hour etoposide (50 pg/ml) was added and cells further
incubated at 37°C for 24 hours. Apoptosis was assessed by Giemsa staining. Each
point is the mean ± SEM of three independent experiments performed in triplicate.
*p<0.05 compared with cells on plastic or PLL treated with etoposide.
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4.2.4 Mechanism ofECM-mediatedprotection ofSCLCfrom chemotherapy-
induced apoptosis
Having made the observation that SCLC cells are protected from chemotherapy-
induced apoptosis by adhesion to ECM proteins the mechanism by which this
protection was occurring was investigated.
4.2.5 Effect offibronectin on SCLC cell growth in liquid culture
We initially considered whether the protective effect conferred by ECM might be
artefactual and simply due to an increase in total cell number when cells were grown
on ECM proteins compared with plastic rather than due to an inhibition of apoptosis.
In order to examine this we incubated SCLC cells in liquid culture on pre-plated
fibronectin under identical conditions to those used for the chemotherapy assays.
Figure 4.8 shows that over the first six days there was no significant difference in
cell number between cells grown in the presence ofECM and control cells grown on
plastic. Over a longer time period (9 days) fibronectin did stimulate a modest
increase in cell number. However, the chemotherapy assays were performed
between 24 and 96 hours. Therefore, it was thought that the survival effect was due
to a true anti-apoptotic effect rather than simply due to an alteration in the growth
rate of cells on matrix compared with those on plastic.
4.2.6 SCLC adhesion to ECM induces tyrosine phosphorylation
Early studies on integrin-dependent cell adhesion and signalling demonstrated that
cell ligation to ECM proteins was accompanied by integrin aggregation and that this
clustering could trigger increased tyrosine phosphorylation of a number of
intracellular proteins (Guan et al., 1991; Kornberg et al., 1991; Hanks et al., 1992).
Tallett et al. (1996) have previously shown that tyrosine phosphorylation is a
mitogenic signal in SCLC cells and that the regulation of the level of protein tyrosine
phosphorylation represents a critical determinant of whether SCLC cells survive and
proliferate, or die by apoptosis. Therefore, the effect of fibronectin on tyrosine




Effect of flbronectin on SCLC liquid growth. H69 SCLC cells (1 xlO5), 3-5 days
post-passage, were washed and then incubated in fresh SITA medium in 24 well
plates which either had no coating (solid line) or had been pre-coated with
flbronectin (20 pg/ml) (dashed line). Absolute cell number was determined at
intervals as shown using a Coulter counter. Data from a representative experiment is
shown.
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Figure 4.9 shows a 'Western blot' using an anti-phosphotyrosine antibody to
determine the effect of fibronectin on tyrosine phosphorylation in H69 SCLC cells.
Figure 4.9 shows that when SCLC cells are adhered to fibronectin there is an
increase in tyrosine phosphorylation of a number of proteins as indicated by an
increase in the number and density of bands (lane 2) compared with those seen in
cells plated on plastic (lane 1). The principal bands affected lay at 58, 60, 75, 85 and
120 kDa. This was unaffected by treatment of cells with etoposide (lane 3).
However, this effect could be completely blocked by pre-treatment with the tyrosine
kinase inhibitor tyrphostin-25 (lane 4) or by pre-treatment with a function-blocking
pi antibody (lane 5).
The inhibition of phosphotyrosine kinase activity seen with tyrphostin-25 was not
simply due to inhibition of SCLC cell adhesion to fibronectin because tyrphostin-25
has been shown not to have any effect on cell adhesion to fibronectin, laminin or
collagen IV over a 24 hour period (Sethi et al., 1999).
These data show that SCLC cell resistance to chemotherapy can be mediated by a
tyrosine phosphorylation-dependent mechanism.
4.2.7 Chemotherapy-induced caspase-3 activation is blocked by ECM-induced
phosphorylation
A wide variety of chemotherapeutic agents have been shown to promote cell death
through apoptosis. It is becoming increasingly clear that chemotherapeutic agents
induce apoptosis via similar mechanisms. The final common pathway for the
induction of apoptosis centres on caspase-3 (see Figure 1.5). Caspase-3 is activated
by proteolytic cleavage of pro-caspase-3. Following activation, caspase-3 cleaves
the chaperone inhibitor of caspase activated deoxyribonuclease releasing DNAase
activity which causes DNA fragmentation in nuclei.
Pro-caspase-3 expression was measured as a marker of caspase-3 activation. When
pro-caspase-3 expression is high, caspase-3 levels are low and vice-versa. Caspase-3




The effect of fibronectin on tyrosine phosphorylation in SCLC cells. H69 SCLC
cells that had been washed and pre-incubated in SITA medium for 12 hours were
seeded at a density of 5 x 106/ml into 24 well plates in the presence or absence of
pre-coated fibronectin (20 pg/ml) with or without etoposide (25 pg/ml), tyrphostin-
25 (25 juM) or a function blocking (31 antibody, 4B4 (10 p.g/ml). After 72 hours cell
lysates were assessed by 'Western' blot analysis as described in 'Materials and
Methods' with antibodies against phosphotyrosine (50:50, PY20:4G10). The gel
shown is representative of three independent experiments. MWM, molecular weight
markers; Tyrph, tyrphostin-25; pi-ve Ab, function blocking pi antibody.
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Figure 4.10 shows that compared with basal untreated cells (column 1), etoposide
markedly stimulated apoptosis and pro-caspase-3 cleavage in H69 SCLC cells grown
on plastic or poly-L-lysine (column 2) increasing the apoptosis rate from 16 ± 0.75%
to 43 ± 1.8%. A similar effect was seen in cells grown in the presence of both
etoposide and the tyrosine kinase inhibitor tyrphostin-25 (column 3). However,
etoposide-induced pro-caspase-3 cleavage was completely blocked by co-incubation
with either the broad-spectrum caspase inhibitor z-Val-Ala-DL-Asp-
fluoromethylketone (z-VAD) (column 4) or the tyrosine phosphatase inhibitor,
sodium orthovanadate (column 5). Sodium orthovanadate and z-VAD reduced the
apoptosis rate from 43 ± 1.8% to 16 ± 0.25% and 15 ± 0.35% respectively, very
similar to basal levels. When SCLC cells were grown on fibronectin, etoposide-
induced pro-caspase-3 cleavage (column 7) was inhibited compared with that seen in
cells grown on plastic (column 2). The apoptosis rate for etoposide treated cells on
fibronectin was 13.4 ± 0.6% compared to 43 ± 1.8% for cells on plastic. However,
this ECM-mediated protection could be completely abrogated either by a function
blocking pi antibody (column 9) or by tyrphostin-25 (column 10). Treatment with
the pi antibody or the tyrosine kinase inhibitor caused the apoptosis rates to rise to
42 ± 0.65% and 44 ± 2.45% respectively. Of note, tyrphostin-25 alone, had no
significant effect on fibronectin plated cells (column 8). Furthermore, the function
blocking pi antibody had no effect on etoposide-induced apoptosis in the absence of
fibronectin. These results show that pi integrin-mediated adhesion to fibronectin
protects SCLC cells from etoposide-induced caspase-3 activation by activating
phosphotyrosine signalling.
4.2.8 Fibronectin protection ofetoposide-induced apoptosis is blocked by a Ptdlns
3-kinase inhibitor
Khwaja et al., (1997) demonstrated that PI 3-kinase mediates matrix-induced
survival of normal epithelial cells. Inhibition ofPI 3-kinase induced apoptosis in
adherent epithelial cells while a constitutively active PI 3-kinase blocked anoikis.
Given that PI 3-kinase requires tyrosine phosphorylation for full activation we
reasoned that PI 3-kinase might be involved in mediating ECM protection from
chemotherapy-induced apoptosis.
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The effect of fibronectin on etoposide-induced apoptosis and caspase-3
activation. H69 SCLC cells that had been washed and pre-incubated in SITA
medium for 12 hours were seeded at a density of 5 x 106/ml into 24 well plates in the
presence or absence of pre-coated fibronectin (20 pg/ml) with or without etoposide
(25 pg/ml), tyrphostin-25 (25 pM), the function blocking pi antibody, (4B4, 10
pg/ml), z-VAD (100 pM) or sodium orthovanadate, (Na3VC>4, 200 pM). After 72
hours apoptosis was determined by acridine orange/ethidium bromide staining. The
data represent the mean ± SEM of three independent experiments performed in
triplicate. *p<0.05 compared with Column 1. #p<0.05 compared with Column 2.
|p<0.05 compared with Column 7. Jp<0.05 compared with column 10. In a parallel
experiment cell lysates were assessed by 'Western' blot analysis with antibodies
against pro-caspase 3. A representative blot is shown. Figures in the left hand
margin are molecular weights in kDa.
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Using an ELISA based system to measure apoptosis it was found that, as before,
etoposide-induced apoptosis was inhibited when cells were plated on fibronectin
compared to those on plastic (Figure 4.11; column 6 versus column 2). The pro-
apoptotic effects of etoposide, LY294002 and tyrphostin-25 alone on ECM plated
cells were similar in magnitude (columns 6, 7 and 8 respectively). However, when
apoptosis was measured in matrix-plated cells that had been co-incubated with either
etoposide and tyrphostin-25 (column 9), or etoposide and LY294002 (column 10) the
ECM-mediated protective effect was lost. These data suggest that PI 3-kinase is one
of the tyrosine-phosphorylated proteins that signals integrin-dependent resistance to
chemotherapy.
4.2.9 Effect offibronectin on topoisomerase IIa expression and activity
Etoposide initiates its cytotoxic action by acting as a specific inhibitor for DNA
topoisomerase II. Topoisomerase II is a nuclear enzyme that effects unknotting and
relaxation of supercoiled DNA molecules by a process of introducing transient
double strand breaks through which the strands of an intact helix can pass.
Topoisomerase poisoning results in the trapping of enzyme molecules on DNA as
cleavable complexes and the generation of potentially lethal lesions.
Therefore the ability of ECM-induced tyrosine phosphorylation to block etoposide-
induced topoisomerase II inhibition was investigated. Topoisomerase II activity was
measured by the ATP-dependent decatenation of a high molecular weight DNA
network. Figure 4.12 shows that while etoposide is able to inhibit topoisomerase II
activity, tyrphostin-25 alone had no effect on either topoisomerase II expression or
activity. Adhesion to fibronectin did not affect the ability of etoposide to inhibit
topoisomerase II activity. Furthermore, adhesion to fibronectin did not alter
topoisomerase II expression. These data suggest that ECM-induced protection from
chemotherapy-induced apoptosis acts at a point downstream ofDNA damage.
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Fibronectin protection of etoposide-induced apoptosis is blocked by a PI 3-
kinase inhibitor. H69 SCLC cells (5 x 104) which had been washed and incubated
in SITA medium for 24 hours were seeded into 96 well plates in the presence or
absence of pre-coated fibronectin (20 pg/ml). One hour after seeding LY294002 (30
pM) or tyrphostin-25 (25 pg/ml) were added and cells were further incubated at
37°C for 24 hours. Apoptosis was assessed using a commercial cell death ELISA kit
as described in 'Materials and Methods'. The data shown are the means ± SEM of
three independent experiments performed in triplicate. *p<0.05 compared with
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Figure 4.12
The effect of fibronectin on topoisomerase Ila expression and activity. H69
SCLC cells that had been washed and pre-incubated in SITA medium for 12 hours
were seeded at a density of 5 x 106/ml into 24 well plates in the presence or absence
of pre-coated fibronectin (20 pg/ml) with or without etoposide (25 pg/ml) or
tyrphostin-25 (25 pM). After 72 hours human topoisomerase Ila expression was
assessed by 'Western' blotting using antibody to human topoisomerase Ila (upper
panel). Topoisomerase Ila activity was measured as described in 'Materials and
Methods' (lower panel). NW, high molecular weight interlocking kDNA network;
MC, decatenated individual DNA mini-circles. The gel shown is representative of
two independent experiments performed in duplicate.
119
4.3 DISCUSSION
The results presented in this chapter show that, in vivo, SCLC cells are surrounded
by an extensive stroma of fibronectin, laminin, collagen IV and tenascin at both
primary and secondary metastatic sites. SCLC cells adhere to ECM proteins in a
predominantly (31 integrin-mediated fashion. When SCLC cells are adhered to ECM
proteins they are protected from the pro-apoptotic effects of chemotherapeutic
agents. The mechanism underlying this phenomenon is due to an ECM-induced
increase in tyrosine phosphorylation, which blocks chemotherapy-induced caspase
activation.
The extent of ECM deposition around SCLC cells, in vivo, has not been appreciated
before. Two other groups have also reported laminin and collagen IV within
basement membrane surrounding tumour cell nests in SCLC (Paakko et al., 1990;
Wetzels et al., 1992). The extent of tenascin deposition in the SCLC sections
examined is notable. Unlike laminin and collagen IV expression, which was
confined to basement membranes, tenascin was expressed in areas of reactive host
tissue scarring and within broad stromal bands around groups of tumour cells.
Tenascin is transiently expressed in many developing organs but is generally absent
in normal adult tissues. However, tenascin is re-expressed in adult tissues that are
actively remodelling following denervation (Gatchalian et al., 1989) and in wound
healing (Mackie et al., 1988) as well as in the stroma of a wide variety of tumours
such as gliomas (Bourdon et al., 1983), breast carcinomas (Mackie et al., 1987) and
basal cell carcinomas (Stamp, 1989). Similarly, neo-expression of some fibronectin
isoforms, while absent in normal interstitium, occurs in tumour stroma (Carnemolla
et al., 1989).
The origin of tumour associated extracellular matrix is unclear. In some sections
stained for laminin and fibronectin, individual cells stained positively for ECM
proteins suggesting that the cells themselves might be synthesising the proteins.
Confirmation of intracellular production of ECM proteins would have to come from
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in situ hybridisation studies or PCR. Mastroianni et al., (1993) noted that 15% of
SCLC sections they examined showed positive cytoplasmic staining for laminin.
Similarly tenascin production by melanoma cells and glioma cells has also been
documented (Herlyn et al., 1991; Bouterfa et al., 1999). Although SCLC cells
appear capable of producing ECM proteins the majority of tumour ECM probably
arises from interstitial fibroblasts. Such a mechanism occurs in gliomas and
malignant melanomas. Chiquet-Ehrismann et al., (1989) showed that the mammary
carcinoma cell line MCF-7 stimulates tenascin production in normal interstitial
fibroblasts by secreting TGF-(3. In cultured fibroblasts TGF-P modulates the splicing
of the primary fibronectin transcript leading to the production of other ECM proteins
including laminin and tenascin (Borsi et al., 1990). Our group and others have found
that SCLC cell lines are able to produce TGF-P in vitro (Fischer et al., 1994) and
personal communication from Dr T Sethi).
The neo-expression of tenascin and fibronectin in the interstitium of tumours
suggests that tumour cells may condition their stroma in order to support their growth
and modulate their propensity to invasion. In addition to TGF-P, SCLC cells
produce a variety of growth factors, cytokines and inflammatory mediators including
IGF-1, gastrin-releasing peptide and IL-8, which may, through complex autocrine
and paracrine interactions, be able to modulate the immediate environment of SCLC
cells (Macaulay et al., 1990; Sethi and Rozengurt, 1991). IGF-1 and gastrin-
releasing peptide are mitogenic for both SCLC cells and fibroblasts. IL-8 is an
essential angiogenic factor for non-small cell lung cancer in nude mice (Arenberg et
al., 1996). Therefore, in vivo, SCLC may create a specialised environment as a
consequence of autocrine and paracrine effects that, using an analogy to
inflammation, likens SCLC to 'a wounding reaction' with the laying down and
remodelling ofECM, growth factor release and neo-vascularisation.
Integrins are the principal family of cell surface receptors that mediate the
attachment of cells to extracellular matrices. The main beta integrin expressed by
SCLC cells is pi and the principle alpha integrins expressed are a2, a3, a6 and av
(Falconi et al., 1994). Therefore, SCLC cells express the appropriate integrins for
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binding to fibronectin (a3[31 and otv[31) and collagen and laminin (a2(31, a3pi and
a6pi).
Although different tumour types display a great deal of heterogeneity in integrin
expression it is now generally accepted that the up- or downregulation of some
integrins in poorly differentiated tumours may represent a hallmark of invasive and
metastatic behaviour (reviewed in Varner and Cheresh 1996). Decreased expression
of integrin a2pi has been observed in poorly differentiated breast carcinomas (Zutter
et al., 1995) and increased expression of avP3 is consistently observed in human
metastatic melanomas (Albelda et al., 1990; Danen et al., 1995). Interestingly, while
normal bronchial epithelial cells express a5, SCLC cells do not (Koukoulis et al.,
1997). Furthermore, the pi subunit has been shown to be necessary for lung cancer
cell migration towards fibronectin, laminin and collagen IV in an in vitro hapto- and
chemotaxis assay system (Bredin et al., 1998). Although not conclusive, these
findings do suggest that SCLC cells express an integrin profile that is in keeping with
an aggressive phenotype.
Apoptosis is the process whereby cells are induced to activate their own death and it
is crucial for maintaining appropriate cell number and tissue organisation.
Extracellular matrix is known to play a crucial role as a survival factor since the
disruption of integrin-mediated cell-matrix interactions induces apoptosis (Frisch and
Francis, 1994). In a mammary epithelial cell model, addition of an antibody to (31
integrin led to disruption of cell-ECM interactions and to an increase in apoptosis
(Boudreau et al., 1995).
We have found that extracellular matrix proteins are able to protect SCLC cells from
chemotherapy-induced apoptosis. There has been one other report of laminin-
induced chemoresistance of SCLC cells (Fridman et al., 1990). These findings have
now been extended to show that this is a general property of several ECM proteins
found in increased amounts in SCLC tumours in vivo. The finding that ECM-
mediated chemoresistance could be abrogated by a function-blocking [31 antibody
showed that the effect is (31 integrin-mediated. One other group has also recently
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reported that etoposide-induced DNA strand breakage in xenograft tumour-derived
endothelial cells (TDECs) could be inhibited by culturing TDECs on gelatin,
collagen IV, laminin, fibronectin or the integrin ligand hexapeptide GRGDSP but not
on the integrin peptide GRADSP (Hoyt et al., 1996). DNA damage was also
inhibited when TDECs were plated on surfaces coated with antibodies to a5, pi and
(33 integrin subunits and by clustering integrins with soluble antibodies.
Adhesion of SCLC cells to ECM proteins induced tyrosine phosphorylation and
inhibition of tyrosine kinase activity abrogated ECM-induced chemoresistance and
promoted apoptosis. Furthermore, etoposide-induced apoptosis could be blocked in
the presence of the tyrosine phosphatase sodium orthovanadate. Protein tyrosine
phosphorylation has been described previously in response to cell attachment to
ECM proteins (Hanks et al., 1992) and on integrin clustering (Kornberg et al., 1991;
Kornberg et al., 1992). Recently, protein tyrosine kinase activity has been reported
to regulate apoptosis. Abl protein, a non-receptor type tyrosine kinase, inhibited
cytokine withdrawal-mediated (Evans et al., 1993) or Fas-mediated apoptosis
(McGahon et al., 1995). Inhibition of protein tyrosine kinase activity by its
inhibitors such as erbstatin, genistein or tyrphostin-25 has been shown to induce
apoptosis in SCLC cells (Tallett et al., 1996; Simizu et al., 1996).
With the developing understanding of mechanisms regulating apoptosis it is
becoming increasingly clear that chemotherapeutic agents act through similar
mechanisms. Kaufmann et al., (1993) identified proteolytic cleavage of poly (ADP)
ribose polymerase (PARP) in response to etoposide. Subsequently this was shown to
be due to activation of a specific protease and that it preceded endonuclease
activation and DNA fragmentation (Lazebnik et al., 1994). It now appears that many
inducers of cell death, including cytokines and chemotherapeutic agents, ultimately
converge on the activation ofPARP and related proteases, which then trigger the
terminal and execution stages of apoptosis. The data presented in this chapter shows
that etoposide-induced caspase-3 activation is modulated by ECM-induced tyrosine
phosphorylation. ECM-mediated protection from etoposide-induced caspase-3
activation could be blocked by either a pi function-blocking antibody or by a
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tyrosine kinase inhibitor. Boudreau et al., (1995) reported that apoptosis ofCID-9
mammary epithelial cells could be induced by antibodies to (31 integrins or by
overexpression of stromelysin-1 which degrades ECM. Expression of interleukin-l(3
converting enzyme (ICE) correlated with the loss of ECM and inhibitors of ICE
activity prevented apoptosis. These results suggested that ECM regulates apoptosis
in mammary epithelial cells through an integrin-dependent negative regulation of
ICE expression. Similarly, Simizu et al., (1998) showed that induction of apoptosis
by erbstatin in SCLC cells resulted in the activation of caspase-3 (-like) proteases.
They too concluded that since erbstatin and herbimycin A do not inhibit other protein
kinases, such as protein kinases A and C, tyrosine kinase activity or tyrosine
phosphorylated proteins may be a negative regulator of caspase activity. The exact
mechanism by which this occurs is not known. It would seem likely that there may
be one or more tyrosine phosphorylated proteins involved. We studied PI 3-kinase
as a possible candidate. All class la PI 3-kinases contain adapter subunits containing
SH2 domains. These adapters bind phosphorylated tyrosine residues, thereby linking
class la PI 3-kinase subunits to tyrosine kinase signalling pathways. Recently there
have been a number of publications linking the PI 3-kinase/PKB pathway to cell
survival and protection from apoptosis (Khwaja et al., 1997; Kulik et al., 1997;
Farrelly et al., 1999). We found that the PI 3-kinase inhibitor LY294002 was able to
block the ECM-mediated protective effect against chemotherapy-induced apoptosis
in the same way that tyrphostin-25 did. This suggested that PI 3-kinase is one of the
tyrosine-phosphorylated proteins that signals integrin-dependent resistance to
chemotherapy. One could argue that rather than blocking the ECM-mediated
protective pathway with LY294002 or tyrphostin-25, our results simply show the
additive effect on apoptosis of etoposide and LY294002 or etoposide and tyrphostin.
However, the same effect can be obtained by blocking the ECM-mediated pathway
with a function blocking p 1 antibody. Furthermore, adding a tyrosine phosphatase
inhibitor to cells on plastic mimicked the ECM effect. Therefore, we think it more
likely that our results do show that blocking tyrosine kinases or PI 3-kinase abrogates
the ECM protective effect against chemotherapy-induced apoptosis.
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Interestingly, another group has reported that IGF-1 and the IGF-1 receptor can
prevent etoposide-induced apoptosis in BALB/c 3T3 cells (Sell et al., 1995).
Although they did not examine the mechanism underlying this effect it is likely to be
mediated by the PI 3-kinase/PKB pathway, as IGF-1 is a major activator of this
pathway. Taken together it would seem likely that PI 3-kinase and PKB are involved
in mediating integrin-dependent resistance to chemotherapy. One might speculate
that the final mediator inhibiting caspase-3 activation is one of the Bcl-2 family of
proteins. PKB phosphorylates BAD thereby preventing BAD from inhibiting the
anti-apoptotic proteins Bcl-2 and Bcl-XL. Recently it has been demonstrated that
Bc1-Xl can inhibit caspase-3 activation (Suzuki et ah, 1998). Although our group
has not been able to demonstrate any alteration in Bcl-2 expression in SCLC cells
adhered to fibronectin (personal communication from Dr T Sethi), Simizu et al.,
(1998) demonstrated that Bax mediated erbstatin-induced caspase-3 activation. Bax,
another member of the Bcl-2 family promotes apoptosis and antagonises the function
of Bcl-2.
The mechanisms involved in the acquisition of drug resistance by SCLC cells are
still unclear. Several drugs used in the treatment of SCLC such as etoposide,
teniposide and doxorubicin act on the nuclear enzyme DNA topoisomerase Ila by
freezing an enzyme-DNA cleavable complex, thereby creating DNA breaks and
eventually leading to cell death. Several cellular resistance mechanisms towards
topoisomerase II poisons have now been identified. The first mechanism called the
altered topoisomerase II multi-drug resistance phenotype, described either a
reduction and/or mutation in the enzyme itself (Pommier et al., 1986; Danks et al.,
1988). Such a mechanism has been described in an adriamycin-resistant SCLC cell
line (de Jong et al., 1990). Two well characterised drug efflux pumps, P-
glycoprotein (P-gp) (Borst et al., 1993) and the multi-drug resistance protein (MRP)
(Cole et al., 1992) also occur in both SCLC and NSCLC and have been shown in
transfection studies to be sufficient to confer resistance. However, their clinical
importance is still unclear (Narasaki et al., 1996; Nooter et al., 1996). Of note, H69
SCLC cells, which were used for all experiments examining the mechanism of
chemoresistance, do not express P-gp or MRP (Kreisholt et al., 1998).
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Hannun (1997) proposed a three phase hypothesis to explain how many disparate
chemotherapeutic agents can bring about apoptosis: In phase I each class of
chemotherapeutic agent interacts with a specific target such as DNA or RNA,
bringing about target injury or dysfunction. In phase II the cell, through as yet
poorly defined mechanisms, is able to decipher and assess the specific injury to the
chemotherapy target. In the final phase (III) a decision point may exist such that
susceptible cells react to the signals generated in response to chemotherapy-induced
injury as a go-ahead for the execution phase of apoptosis. Other cell types may
preferentially enter programmes of cell cycle arrest or damage repair in response to
the same signals.
Based on existing work and the data presented here, the following model for the
development of chemoresistance in SCLC cells is proposed (see figure 4.13).
Etoposide acts by inhibiting the re-annealing action of topoisomerase II causing
multiple DNA nicks. This persistent DNA damage results in cell cycle delay in S
phase and G2/M with subsequent caspase-3 activation leading to apoptosis.
However, (31-integrin-mediated cell adhesion to ECM proteins results in tyrosine
phosphorylation, which, despite persistent chemotherapy-induced DNA damage,
prevents caspase activation and apoptosis. In this way, tumour cells bound to ECM
escape chemotherapy-induced cell death and then, with subsequent genetic damage,
drug resistant clones may be selected. The mechanism described here may be
responsible for the initial resistance of SCLC cells to chemotherapy.
The exact point at which the ECM-mediated tyrosine phosphorylation pathway
impinges upon the chemotherapy-induced pro-apoptotic pathway is unclear
currently. Increased tyrosine phosphorylation had no effect on etoposide-induced
topoisomerase II inhibition indicating that it acts downstream ofDNA damage. One
possible mechanism is that ECM-induced tyrosine phosphorylation prevents cell
cycle arrest by modulating cyclin-dependent kinase activity. Progression from G2
into M phase is controlled in part by a cyclin-dependent kinase (cyclin B/Cdk I) that





Proposed mechanism by which SCLC cell adhesion to ECM proteins can
promote chemoresistance. See text for details.
x2'
with Hannun's hypothesis. In Hannun's hypothesis the 'phase III decision point' is
akin to the presence or absence of the ECM-mediated tyrosine kinase pathway. In
the absence ofECM, susceptible cells undergo chemotherapy-induced apoptosis but
in the presence of the ECM-mediated 'rescue pathway' cells may enter a period of
temporary cell cycle arrest or damage repair before continuing to cycle normally
albeit having sustained some genetic damage.
In summary it has been shown that SCLC cells are surrounded by a stroma ofECM
proteins, the origin ofwhich are likely to be fibroblasts and other surrounding cells.
SCLC cells secrete a variety ofmitogenic growth factors and cytokines including
IGF-1, neuropeptides, TGF-p and IL-8. TGF-|3 can modulate the primary fibronectin
transcript leading to production of other ECM proteins while IL-8, an angiogenic
factor, likely facilitates neovascularisation. Our working hypothesis is that, in vivo,
SCLC creates a specialised environment that, using an analogy to inflammation
likens SCLC to a 'wounding reaction' with the laying down and remodelling of
ECM, growth factor release and neovascularisation. Thus, at primary and secondary
metastatic sites, by the mechanisms described above there seems to be a permissive
environment for SCLC cell proliferation, protection from apoptosis and resistance to
chemotherapy. We believe that this is a good model to explain the partial responses
and local recurrence of tumour often seen after chemotherapy.
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CHAPTER 5
CD98: ROLE IN INTRACELLULAR SIGNALLING AND
ANCHORAGE-INDEPENDENCE OF SCLC
5.1 INTRODUCTION
The processes of cell migration and adhesion are central, not only to tumour
metastasis, but also to a range of physiological processes such as embryogenesis,
haemostasis, the immune response and the maintenance of tissue integrity. The
regulation of cell migration is dependent upon rapid, controlled alterations of the
affinity of integrins for their extracellular ligands. Integrins are capable ofmediating
bi-directional transmembrane signalling from the outside to the inside of the cell
('outside-in' signalling) and from the inside to the outside of the cell ('inside-out'
signalling) (Dedhar and Hannigan, 1996). The former is initiated by integrin
clustering at focal sites of the plasma membrane and results in the propagation of
signals into the cytoplasm. Inside-out signalling regulates the affinity state for a
ligand through the propagation of conformational changes from the integrin
cytoplasmic domain to the extracellular binding site. The classical example of this is
platelet aggregation, a physiological process dependent upon integrin affinity
modulation. Platelet aggregation relies upon fibrinogen cross-linking the platelet
integrin allbp3. Resting platelets are unable to aggregate because their allb(33 is in
a partially active conformation that has a low affinity for fibrinogen. Following
activation by specific agonists such as thrombin, allbp3 undergoes a conformational
change that dramatically increases its binding affinity for fibrinogen resulting in
platelet aggregation (Shattil et al., 1998). In addition to integrin affinity modulation,
cells can use integrin clustering or avidity modulation to regulate ligand binding.
Changes in both integrin affinity and avidity are not mutually exclusive and the
relative contributions of each to ligand binding vary with integrin type.
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At present the signalling pathways regulating integrin affinity are poorly understood.
Recent studies indicate that the small GTP binding proteins H-ras and R-ras and their
effectors play a role in regulating integrin affinity. Whereas activated H-ras and its
effector Raf-1 inhibit integrin activation in CHO cells (Hughes et al., 1997), R-ras
(which is highly homologous to H-ras) stimulates integrin binding affinity (Zhang et
al., 1996). These proteins may act together to modulate integrin affinity.
In the last few years work in several laboratories has pointed to CD98 involvement in
regulating adhesive interactions mediated by integrins. Initially, Ito and colleagues
(1992) showed that antibodies to CD98 promote integrin-mediated virus-induced cell
fusion. Subsequently, Fenczik et al., (1997) identified CD98 as a unique and highly
specific regulator of integrin affinity. They showed that an anti-CD98 heavy chain
mAb increased P1 integrin-dependent adhesion of a SCLC cell line to the ECM
proteins laminin and fibronectin.
CD98, a ubiquitously expressed cell surface antigen, is an early marker ofT cell
activation (Diaz, Jr. et al., 1997), which is highly conserved between species
(Parmacek et al., 1989). CD98 is a cell surface heterodimer formed by the covalent
linkage ofCD98 heavy chain with up to five different light chains. (Quackenbush et
al., 1987; Teixeira et al., 1987; Warren et al., 1996, Kanai et al., 1998;
Mastroberardino et al., 1998; Nakamura et al., 1999). Sequence analysis has not
suggested a function for the heavy chain, but the light chain has been demonstrated
to function as an amino acid transporter.
CD98 is expressed at low levels on the surface of quiescent cells but is rapidly
upregulated early in transition from GO to G1 phase and remains at elevated levels
until the cell cycle is complete (Suomalainen, 1986; Parmacek et al., 1989). CD98 is
strongly expressed on adherent human embryonic and newborn fibroblasts but
expression gradually diminishes on cells from older individuals. While 100% of
embryonic and newborn fibroblasts express CD98, less than 1% of adherent human
fibroblasts from normal adults do so. However, expression is reconstituted to high
levels on sarcomatous cell lines and is present constitutively on the surface of
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activated and proliferating cells (Azzarone et al., 1985). These expression patterns
suggest that the function ofCD98 is coupled to cellular activation.
A number of studies have shown that perturbation ofCD98 function with
monoclonal antibodies (mAbs) has profound effects on cellular proliferative
responses, but none have been definitive. Anti-CD98 heavy chain mAbs block
differentiation ofmurine foetal liver, bone marrow, peripheral blood, pluri-potent
progenitor cells and erythroid lineages (Warren et al., 1996). In LIN haemopoietic
progenitor cells (cells lacking lineage specific surface markers), anti-CD98 heavy
chain mAbs trigger DNA fragmentation (Warren et al., 1996). The effects of anti-
CD98 heavy chain mAbs on T-cell proliferative responses are controversial, with
studies describing both inhibitory and stimulatory effects (Spagnoli et al., 1991;
Diaz, Jr. et al., 1997; Warren et al., 2000).
Early studies suggested that an intracellular signalling pathway mediates the action
ofCD98 (Warren et al., 1996; Okamoto et al., 1997; Tabata et al., 1997). Tyrosine
kinase inhibitors such as genistein and herbimycin inhibit CD98 activity in
haematopoietic cells (Warren et al., 1996) suggesting that tyrosine kinase activation
may be an early signal transduction pathway activated by CD98. CD98 may also
2 j 2~F ~E 0-f
regulate the intracellular Ca concentration [Ca ]j through the Na /Ca exchanger
in a cell type-specific manner (Michalak et al., 1986; Posillico et al., 1987; Freidman
2~F
et al., 1994). Anti-CD98 heavy chain mAbs trigger a transient increase of [Ca ]j in
human parathyroid adenoma cells resulting in a decrease in the basal level of PTH
secretion (Posillico et al., 1987). In contrast, anti-CD98 heavy chain mAbs inhibit
90% of the Na+-dependent Ca2+ uptake by rabbit skeletal muscle or bovine cardiac
sarcolemmal vesicles (Michalak et al., 1986). However, anti-CD98 heavy chain
mAbs have no effect on [Ca2+]i in peripheral blood lymphocytes or T cell lines
(Freidman et al., 1994). CD98 has also been implicated in transport of amino acids
and recently the light chain of CD98 has been isolated and identified as an E16/TA1
amino acid transporter (Mannion et al., 1998). Finally, overexpression of CD98 in
the murine fibroblast cell line NIH3T3 has been shown to result in cellular
transformation (Hara et al., 1999).
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Therefore, CD98 appears to modulate several basic cellular signal transduction
pathways and functions during activation. One could hypothesise that CD98 is a
central regulator of cellular activation that governs passage through the G1 phase of
the cell cycle. However, a definitive role for CD98, its mechanism of action in
cellular activation and transformation and its relevance in human cancer has not been
determined. The aim of this part of the study was to examine the expression of
CD98 in SCLC cells in vivo and in vitro and to determine the intracellular signalling
and functional consequences of cross-linking CD98 in SCLC.
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5.2 RESULTS
5.2.1 CD98 expression in SCLC cells
CD98 expression on SCLC cells, in vivo, was examined by immunohistochemical
staining of SCLC specimens from the University ofEdinburgh pathology files. In all
samples examined, high levels ofCD98 expression were seen on SCLC cells.
Furthermore, CD98 expression on SCLC cells was markedly upregulated compared
with that on normal bronchial epithelium (Figure 5.1).
CD98 expression was also determined on several SCLC cell lines by flow cytometric
analysis using an indirect immunofluorescence technique with the monoclonal
antibody 4F2 directed against the heavy chain ofCD98. Figure 5.2A shows that
CD98 is highly expressed on H69 SCLC cells. Mean fluorescence intensity was 79.4
arbitrary units (AU) compared to an IgG2a isotype matched control of 14.2 AU.
When FI69 SCLC cells were incubated in the presence of increasing concentrations
of 4F2, a dose-dependent increase in binding was seen with a half maximal value of
6.5 pg/ml (Figure 5.2B). Saturated binding occurred between 30-100 pg/ml (Figure
5.2B). Furthermore, high levels of expression of CD98 were seen in all SCLC cell
lines examined including H345, H510, LS310, WX330 and GLC19 (Figure 5.3).
The expression level ofCD98 on these SCLC cell lines was compared with that on
untransformed cell lines including human bronchoepithelial cells, Swiss 3T3 cells
and bovine tracheal smooth muscle cells. In all cases, the expression ofCD98 on the
SCLC cell lines was significantly higher than that on the untransformed cell types
(Figure 5.3).
Thus high expression of CD98 on the surface of SCLC cells is a general
phenomenon both in vitro and in vivo.
5.2.2 Mobilisation of intracellular calcium
2+Several groups have previously investigated the role ofCD98 on [Ca ]i with
variable results suggesting that this response may be cell type specific (Michalak et
al., 1986; Posillico et al., 1987; Freidman et ah, 1994). Figure 5.4 shows that 4F2, at
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Figure 5.1
CD98 expression in SCLC. Immunohistochemical staining for CD98 in normal
bronchial epithelium (upper panel) and SCLC cells in vivo (lower panel). Areas of
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CD98 expression in H69 SCLC cells. (A) CD98 expression in H69 SCLC cells (in
blue) was determined by flow cytometric analysis using an indirect
immunofluorescence technique with the monoclonal antibody 4F2 to the heavy chain
ofCD98. Binding using a control IgG2a antibody is shown in green. (B) A dose-




Comparison of CD98 expression on SCLC cell lines (H69, H345, H510, LS310,
WX330, GLC19) with human bronchoepithelial cells (HBE), bovine tracheal
smooth muscle fibroblasts (BTSM) and Swiss 3T3 fibroblasts (3T3). Each value
represents the mean fluorescence intensity, arbitrary units (AU) ± SEM of three
independent experiments. Background control values were 2.4 ± 0.2 AU.
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concentrations up to 20 pg/ml did not stimulate mobilisation of [Ca ]j in fura-2
loaded SCLC cells. However, [Ca ]\ mobilisation was seen in response to FBS or
neuropeptides as previously demonstrated.
5.2.3 Cross-linking CD98 stimulates PI 3-kinase activation
Previous studies have suggested that tyrosine kinase activation might be an early
signal transduction pathway activated by CD98 (Warren et al., 1996). Class la PI 3-
kinases interact with adapter subunits containing SH2 domains. These adapters bind
phosphorylated tyrosine residues, thereby linking class la PI 3-kinase subunits to
tyrosine kinase signalling pathways. Therefore, the effect of cross-linking CD98 on
PI 3-kinase activity was examined using an in vitro kinase assay as described in
'Materials and Methods'.
The addition of 4F2 (20 pg/ml) caused a 2.5-fold increase in PI 3-kinase activity,
first evident within 2 minutes, maximal at 5 minutes and returning to baseline by 50
minutes (Figure 5.5). Cross-linking of the cytoplasmic tails ofCD98 is believed to
be important to its mechanism of action (Fenczik et al., 1997). If this is the case, one
would hypothesise that 4F2-Fab fragments, that are unable to cross-link CD98,
would have no effect on PI 3-kinase activation. Indeed, monoclonal 4F2-Fab
fragments did not have any effect on PI 3-kinase activity, confirming that cross-
linking ofCD98 was required for PI 3-kinase activation (Figure 5.6). Furthermore,
pre-incubation with 4F2-Fab antibody blocked subsequent 4F2 stimulation of PI 3-
kinase supporting this hypothesis. Importantly, isotype matched control IgG2a
antibodies failed to activate PI 3-kinase indicating that this was not a non-specific
effect (Figure 5.6). Thus cross-linking CD98 stimulates PI 3-kinase activation.
In chapter 3 it was shown that PI 3-kinase activity in SCLC cells is sensitive to the
effect of the PI 3-kinase inhibitor wortmannin. IfCD98 does activate PI 3-kinase,
wortmannin should block this effect. Figure 5.6 shows that wortmannin did
completely inhibit CD98-stimulated PI 3-kinase activity in PI 3-kinase
immunoprecipitates from H69 cells.
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Figure 5.4
Effect of 4F2 on intracellular calcium concentration in SCLC cells. H69 SCLC
cells, loaded with fura-2/AME, were resuspended in electrolyte solution and placed
in a quartz cuvette. Fluorescence was monitored and basal and peak [Ca2+]i
calculated as described in 'Materials and Methods'. The concentrations of 4F2
(pg/ml) are shown. FBS was used at a final concentration of 1%.
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Figure 5.5
Effect of cross-linking CD98 on PI 3-kinase activity. H69 SCLC cells were
'quiesced' in serum-free media for 24 hours and thoroughly washed prior to
experimentation. Cells were treated with 4F2 (20 pg/ml) for variable times as shown
prior to lysis. PI 3-kinase activity was measured as described in 'Materials and
Methods'. All data are the mean of four independent experiments performed in
triplicate ± SEM. An autoradiograph showing the 3-phosphorylated reaction product




The effect of 4F2-Fab and wortmannin on 4F2-induced PI 3-kinase activity.
H69 SCLC cells which had been quiesced overnight and thoroughly washed in
serum-free medium were treated with 4F2 (20 pg/ml) or 4F2-Fab (20 qg/ml) having
been pre-treated with wortmannin (100 nM), 4F2-Fab (20 pg/ml) or diluent as
indicated. PI 3-kinase activity was assayed as described in 'Materials and Methods'.
An isotype matched IgG2a control antibody (20 pg/ml) is shown for comparison.
All data are the mean of three independent experiments performed in triplicate ±
SEM. *p<0.05 compared with control cells.
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5.2.4 Cross-linking CD98 activates PKB.
PKB has been identified as a key downstream effector of PI 3-kinase (Hemmings,
1997). We therefore examined the effect of 4F2 on PKB activity using an in vitro
kinase assay as described in 'Materials and Methods'. Figure 5.7 (upper panel)
shows that cross-linking CD98 with 4F2 antibody stimulated PKB activity in a time-
dependent fashion. An increase in PKB activity was first evident at 2 minutes (1.3
fold), maximal by 10 minutes (2.5 fold) and had returned to baseline by 20 minutes.
This magnitude of response, and time course, was very similar to that seen for PI 3-
kinase activation.
These results were confirmed by 'Western' blotting using an anti-phospho-PKB
antibody that recognises phosphorylation ofPKB at serine 473. Figure 5.7 (lower
panel) shows that 4F2 caused an increase in phosphorylation ofPKB at 5 and 10
minutes compared with that in untreated control cells or 4F2-Fab treated cells.
Therefore, in addition to activating PI 3-kinase, cross-linking CD98 also activates its
principal downstream effector, PKB.
5.2.5 Functional effects ofcross-linking CD98 with 4F2
PI 3-kinase and PKB have both been shown to be involved in regulating cell growth
and survival (Khwaja et al., 1997). Therefore, the functional consequences of cross-
linking CD98 with 4F2 in SCLC cells were examined. The ability of cells to grow in
soft agarose is a feature of anchorage-independence and is pathognomonic of the
transformed phenotype, correlating with tumourigenicity and invasiveness of the
tumour (Carney et al., 1980). Cross-linking CD98 with 4F2 markedly enhanced the
ability of SCLC cell lines H69, H345 and H510 to form colonies in semi-solid
agarose. SCLC basal colony growth was stimulated 200-300% by the addition of 20
pg/ml 4F2 (Figure 5.8). This effect could be blocked by co-incubation with the PI 3-
kinase inhibitor, LY294002 (lOpM). Furthermore, addition ofmaximal clonal-
stimulating concentrations of neuropeptide growth factors galanin (50nM) and
bombesin (lOnM) in H510 and H345 cells respectively, caused a supra-maximal
























Cross-linking CD98 activates PKB. Upper Panel: Time course ofPKB activation
by 4F2 (20 jag/ml). PKB was immunoprecipitated from cell lysates using an anti-
PKB PH-domain antibody. PKB activity was assayed as described in 'Materials and
Methods'. The figure shows data from a representative experiment. Lower Panel:
Western blot ofphospho-PKB. H69 SCLC cells were incubated in the presence or
absence of 4F2-Fab (20 pg/ml 10 minutes), 4F2 (20 pg/ml for 5 and 10 minutes) or
10% FBS (5 minutes). 'Western' blots ofH69 SCLC cells were probed with an
antibody, which recognises phosphorylation ofPKB at serine 473 at 60kDa.
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Figure 5.8
Cross-linking CD98 stimulates SCLC clonal growth. H69, H345 and H510 SCLC
cells were plated in SITA medium containing 0.3% agarose in the presence or
absence of 4F2 (20 pg/ml) or LY294002 (lOpM) over a base of 0.5% agarose in
culture medium as described in 'Materials and Methods'. After 21 days colonies of
>120 pm (16 cells) were counted. Results are expressed as mean ± SEM
colonies/dish of three independent experiments performed in triplicate.
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Figure 5.9
The effect of cross-linking CD98 on neuropeptide-stimulated clonal growth in
SCLC cells. H345 and H510 SCLC cells were plated in SITA medium containing
0.3% agarose, in the presence or absence of bombesin 10 nM (BN), galanin 50 nM
(Gal) and 4F2 20 pg/ml, over a base of 0.5% agarose in culture medium as described
in 'Materials and Methods'. After 21 days colonies of >120 pm (16 cells) were
counted. Results are expressed as mean ± SEM colonies/dish of three independent
experiments performed in triplicate. (Experiments performed by Dr T Sethi).
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5.3 DISCUSSION
Until now little has been known about the signalling pathways activated by CD98.
Early studies suggested that tyrosine kinase activation may be an early signal
transduction pathway activated by CD98 (Warren et al., 1996). This study shows for
the first time that cross-linking CD98 with the mAb 4F2 stimulates PI 3-kinase and
PKB activity. Furthermore, 4F2 SCLC colony growth in soft agarose. 4F2-mediated
colony growth could be blocked by LY294002 showing that it is a PI 3-kinase-
dependent pathway. Taken together these data show that PI 3-kinase-dependent
signalling is playing a central role in CD98 mediated SCLC cell growth.
The finding that cross-linking CD98 stimulates anchorage-independent growth
suggests that it promotes 'integrin-like' intracellular signalling. However, as
discussed previously, full oncogenic transformation is believed to require both serum
and anchorage-independent growth (Schwartz, 1997). SCLC cell growth is
promoted by multiple autocrine and paracrine growth loops involving calcium
mobilising neuropeptides (Sethi and Rozengurt, 1991) which activate MAP kinase
through G-protein coupled receptors (Seufferlein and Rozengurt, 1996a). Recent
work suggests that for full activation of the MAPK pathway by growth factors an
integrin-mediated co-signal is required (Renshaw et al., 1997). The finding that
CD98 augments neuropeptide-mediated SCLC colony growth supports this
hypothesis although it is conceivable that 4F2 and neuropeptides are working
through unrelated pathways but having an additive effect on colony cell growth.
However, we propose that the CD98-mediated stimulation of PI 3-kinase activity in
SCLC cells by 4F2 is mimicking integrin-dependent signal transduction and thereby
facilitates neuropeptide-mediated cell growth.
What are the possible mechanisms by which CD98 could generate 'integrin-like'
signals? One possibility is that CD98 may physically associate with integrins,
providing a mechanism whereby cross-linking ofCD98 modifies integrin activity as
a consequence of their close proximity. Alternatively, CD98 cross-linking may
generate signalling intermediates, which subsequently activate integrin-signalling
145
pathways. Such a mechanism would not be without precedent. The transmembrane-
4 superfamily (TM4SF or tetraspans) associate with a subset of integrins. For
example CD9 associates with a2(31 (Jones et al., 1996) and a5pi (Rubinstein et al.,
1994) and CD151 associates with a3pi (Hemler et al., 1996; Yanez-Mo et al., 1998).
An emerging model is that TM4SF proteins recruit signalling enzymes such as PI 4-
kinase and PKC into complexes with integrins (Berditchevski et al., 1997; Hemler,
1998). PI 4-kinase mediated PtdIns(4)P and PtdIns(4,5)P2 are both substrates for PI
3-kinase and regulators of the actin cytoskeleton.
Recent work suggests that CD98 associates either directly or indirectly with pi
integrin. First to demonstrate this were Fenczik et al., (1997) who showed that 4F2
antibody promoted pi integrin-mediated adhesion of a SCLC cell line to fibronectin
and laminin. The same group has subsequently reported that CD98 associates with
integrin pi cytoplasmic domains with a unique integrin class and splice variant
specificity. CD98 interacts with the ubiquitous piA integrin but not the muscle
specific splice variant pio or leukocyte specific P7 cytoplasmic domains (Zent et al.,
2000). Furthermore, Warren et al., (2000) have shown that CD98 co-stimulation of
T-lymphocyte activation could be blocked by antibody to pi integrin indicating a
functional association between CD98 and pi integrin. However, further work is
required to determine which of the mechanisms outlined above mediates CD98/p 1
integrin signalling.
There is now increasing evidence that CD98 has oncogenic potential. A recent study
by Hara et al., (1999) showed that human CD98 transfected NIH3T3 cells were
capable of anchorage-independent growth and that CD98 transfected clones led to
tumour development in athymic mice. The data presented here showing that cross-
linking CD98 promotes anchorage-independent growth supports this idea. It has
previously been shown that constitutively active PI 3-kinase can transform chick
embryo fibroblasts (Chang et al., 1997) and that a mutant p85 can transform
fibroblasts in vitro (Jimenez et al., 1998). Furthermore, recent studies suggest that
integrin-mediated PI 3-kinase activation is important for cell migration and can
promote carcinoma invasion (Renshaw et al., 1997; Keely et al., 1997). Constitutive
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activation of PI 3-kinase as a result of overexpression ofCD98 may explain the
transformation seen in NIH3T3 cells overexpressing CD98. PI 3-kinase activation
may also account for the implication that CD98 is involved in the regulation of
cellular activation and progression through the G1 phase of the cell cycle
(Suomalainen, 1986; Parmacek et al., 1989). PI 3-kinase regulates progression from
G1 to S phase of the cell cycle via its downstream effector p70S6k (Takuwa et al.,
1999).
CD98 is transpiring to be a multifunctional molecule: fusion regulator, amino acid
transporter, Na+/Ca2+ exchanger, co-mitogen and now an integrin regulator and
potentially an oncogenic protein. The data presented here support the hypothesis that
CD98 is able to transmit 'integrin-like' signals and, given what is known about its
ability to modulate integrin affinity, it seems likely that it does indeed play a major
role in regulating adhesion.
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CHAPTER 6
SUMMARY, CONCLUDING COMMENTS AND FUTURE
DIRECTIONS
6.1 DISCUSSION
Over the last 20 years medical and surgical intervention has resulted in little change
in the five-year survival for lung cancer, with approximately 90% of patients dying
within one year of diagnosis. The major breakthrough for management of SCLC
occurred in 1969 with the finding that this tumour is particularly sensitive to
chemotherapy and radiotherapy. However, despite high initial response rates with
combination chemotherapy the majority of patients relapse, so that the five-year
survival rate is only 3-8%. Despite multiple trials examining new chemotherapy and
radiotherapy regimens current therapies seem to have reached something of a
plateau. More and more it is being realised that in order to make further progress
towards the development of novel therapies for lung cancer a better understanding of
the cellular and molecular processes that govern their growth is required.
If lung cancers did not metastasise far more would be potentially curable by surgery
and if SCLC did not relapse and become insensitive to chemotherapy cure rates
would be much higher. Thus, the early dissemination ofmetastases and the
development of resistance to chemotherapy are two fundamental processes
responsible for the highly malignant phenotype of SCLC. In this thesis the
molecular mechanisms that underlie anchorage-dependence, chemoresistance and
apoptosis of SCLC have been examined.
PI 3-kinase is now recognised to play a role in multiple cellular processes including
several central to the process of tumourigenesis. We have shown that SCLC cells
exhibit constitutively active PI 3-kinase and that, as a result, PKB has elevated basal
activity. Furthermore, PtdIns(3,4,5)P3 levels are also elevated in SCLC lines
compared with control cells. It is proposed that constitutive activation of PI 3-kinase
148
may mimic integrin-dependent signal transduction thereby promoting cellular
proliferation, anchorage-dependence and tumourigenicity in SCLC. Over the last
year a number of other groups have also reported high PI 3-kinase activity in a
variety of tumour types. As discussed in Chapter 3, high PI 3-kinase activity can
probably occur in several ways. Certain oncogenes such as ras and src can activate
PI 3-kinase, although neither has been described in SCLC. Recently, a novel
oncogene, PIK3CA, located in 3q26.3 has been described in ovarian and more
recently, cervical carcinomas (Shayesteh et al., 1999; Ma et al., 2000).
Amplification of 3q26.3 in primary cervical carcinomas and cervical cancer cell lines
results in increased copy number ofPIK3CA and elevated levels of its gene product,
pi 10a. This is associated with high PI 3-kinase activity. At present, the cause of
constitutive PI 3-kinase activity in SCLC cells is not known. The next step might be
to use single strand conformational polymorphism to see if there are any mutations
present in the coding sequences of the p85 and pi 10 subunits of PI 3-kinase in our
SCLC lines. If any mutations are identified sequencing would be performed to
determine the nature of these mutations.
The central role of PI 3-kinase in tumourigenesis makes it a potential target for drug
development. Recently two groups have reported the use of either inositol
phosphates or phosphatidylinositol analogues to inhibit the growth of various cancer
cell lines including the same SCLC cell lines that we utilised. Razzini et al., (2000)
showed that inositol 1,3,4,5,6 pentakisphosphate and inositol 1,4,5,6
tetrakisphosphate inhibited IGF-1 induced [ H]-thymidine incorporation in a human
breast cancer cell line and also blocked the ability ofH69 SCLC cells to grow in
liquid medium and form colonies in semi-solid agarose medium. Hu et al., (2000a)
obtained similar results using phosphatidylinositol analogues. While these results are
very interesting it remains to be seen whether they can be replicated in animal
models. In another approach the PI 3-kinase inhibitor LY294002 was used to treat
athymic mice that had been inoculated intraperitoneally with an ovarian cancer cell
line (Hu et al., 2000b). In the LY294002 treated group mean tumour burden and
ascites production was markedly reduced compared with controls. This is the first
description of an animal model to test the efficacy of LY294002 in vivo. Although
149
LY294002 is a 'broad-spectrum' PI 3-kinase inhibitor there were apparently no
systemic side effects in the control group. An animal model for SCLC has been
described previously and it would be most interesting to replicate this type of
experiment in such a model (Fridman et al., 1990).
In vivo, tumour cells exist in a state of dynamic interplay between anchorage-
dependence and independence. The ability of a cell to regulate adhesion and de-
adhesion is central to the processes ofmigration and metastasis. The mechanisms
regulating these processes are poorly understood at this time. In this thesis it has
been shown that cell-matrix adhesion appears to be critical to the ability of SCLC
cells to survive the effects of chemotherapy. Although we have begun to dissect the
basic protective mechanism, many questions remain unanswered. For instance, what
are the identities of the various tyrosine phosphorylated proteins that mediate ECM
protection? Preliminary data suggests that one is PI 3-kinase. This is supported by
recent data that links the PI 3-kinase/PKB pathway to cell survival and protection
from apoptosis (Khwaja et al., 1997). However, it is likely that a number of other
factor(s) are also involved. Whilst constitutive PI 3-kinase activity in SCLC cells
seems to be sufficient to allow anchorage-independent growth, it does not appear to
be sufficient to prevent chemotherapy-induced apoptosis because non-adhered cells
are chemosensitive. Integrin engagement also appears to be required. At least
twenty different proteins including Rho, Ras, FAK, MAPKs and PI 4-kinase as well
as PI 3-kinase can be recruited to the ECM ligand/integrin binding site. It is quite
possible that two or more pathways may contribute to the ECM-mediated protective
effect. Recently, specific inhibitors for a number of tyrosine kinases have been
described (Levitzki and Gazit, 1995). Ifwe can define the exact pathways mediated
by ECM it may be possible to selectively target key signalling molecules and block
the 'protective pathway' thereby augmenting the effects of conventional
chemotherapeutic drugs. Further work is also required to dissect the mechanism by
which the ECM-mediated tyrosine phosphorylation pathway impinges upon the
chemotherapy-induced pro-apoptotic pathway. Preliminary data suggests that ECM-
induced tyrosine phosphorylation may prevent cell cycle arrest by modulating cyclin-
dependent kinase activity and thus maintaining cell cycling. However, certain
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cyclins such as cyclin B/cdk-1 are tyrosine phosphorylation dependent and it might
be possible, using selective tyrosine kinase inhibitors, to arrest the cell cycle and
thereby induce apoptosis.
In Chapter 5 the role ofCD98 in SCLC was examined. CD98 has recently been
implicated as a regulator of integrin affinity and may be central to the control of
anchorage-dependence. The finding that cross-linking CD98 stimulates anchorage-
independent growth suggests that it can mimic integrin-like intracellular signalling.
Integrins are unique in their ability to mediate bi-directional signalling. The ability
ofCD98 to mimic integrin-like signalling is an example of'outside-in' signalling.
As discussed in Chapter 5, the exact mechanism by which cross-linking CD98
activates PI 3-kinase is not known and work is currently in progress to try and
elucidate this. Hara et al., (1999) have also shown that CD98 transfected fibroblasts
are capable of anchorage-independent growth. However, at present little is known
about how CD98 regulates integrin affinity. It has now been shown that cross-
linking CD98 can enhance both integrin-dependent adhesion of SCLC cells to ECM
proteins (Fenczik et al., 1997) and also promote anchorage-independent growth.
Much work remains to be done in order to dissect out the mechanism by which CD98
regulates integrin affinity and avidity by 'inside-out' signalling. As we learn more
about the mechanisms regulating integrin adhesion it may become possible using
selective antibodies to artificially switch integrins 'on' or 'off in order to promote or
prevent adhesion and thus manipulate the ability of tumour cells to metastasise.
In conclusion one can hypothesise that SCLC cells, in vivo, exist in a state of
dynamic flux between anchorage-dependence and independence. The regulation of
integrin adhesion is governed by complex signalling pathways and feedback loops
involving, among others, PI 3-kinase and CD98. At any one time a proportion of
cells are anchorage-independent and therefore can potentially migrate and
metastasise while others are adhered to ECM proteins and are protected from the
effects of chemotherapy. Furthermore, within this specialised microenvironment
there exist a variety of mitogenic growth factors, cytokines and angiogenic factors as
well as serine proteases and MMPs. This would appear to be a good model to
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explain the aggressive nature of SCLC accounting for this tumour's propensity to
metastasise early and relapse following chemotherapy.
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The Presence of a Constitutively Active Phosphoinositide 3-Kinase in Small Cell
Lung Cancer Cells Mediates Anchorage-independent Proliferation via a
Protein Kinase B and p70s6k-dependent Pathway1
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ABSTRACT
Small cell lung cancer (SCLC) is characterized by early and widespread
metastases. Anchorage-independent growth is pivotal to the ability of
tumor cells to survive and metastasize in vivo and, under in vitro condi¬
tions, allows transformed cells to form colonies in semisolid medium.
Here, we report that of five SCLC cell lines tested, all exhibited high basal
constitutive phosphoinositide 3-kinase (PI 3-kinase) activity, which results
in high basal protein kinase B (PKB) and ribosomal p70 S6 kinase activity
(p70s6k). Inhibition of PI 3-kinase activity markedly inhibited SCLC cell
proliferation in liquid culture as a result of stimulating apoptosis and
promoting cell cycle delay in G,. Furthermore, PI 3-kinase inhibition
reduced basal SCLC cell colony formation in agarose semisolid medium
that could not be overcome by the addition of neuropeptide growth
factors. Thus, constitutive PI 3-kinase activity in SCLC cells plays an
important role in promoting the growth and anchorage independence of
SCLC. This is not due to activating ras mutations or increased basal sre or
focal adhesion kinase activity. These data represent the first description of
constitutively activated PI 3-kinase/PKB in any human cancer. Constitu¬
tive activation of these integrin-dependent signaling events provides a
molecular explanation for the anchorage-independent growth of SCLC
cells and may account for the nonadherent phenotype and highly meta¬
static nature of this aggressive cancer. Up-regulation of the PI 3-kinase/
PKB pathway may, therefore, represent a novel target for therapeutic
intervention in SCLC.
INTRODUCTION
Lung cancer is the commonest fatal malignancy in the developed
world. SCLC4 constitutes 25% of all lung neoplasms and is charac¬
terized by early and widespread metastasis with a 5-year survival of
3-8% (1). The aim of our work has been to devise novel and more
rational therapeutic strategies based on a better understanding of the
molecular events that are responsible for metastasis and sustaining the
growth and preventing the death of SCLC cells.
The molecular mechanisms regulating SCLC cell proliferation and
apoptosis are beginning to be elucidated. We have shown recently that
tyrosine phosphorylation and tyrosine kinase activation is an impor¬
tant mitogenic signal in SCLC cells and that the regulation of the level
Received 4/29/98; accepted 9/18/98.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance with
18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by the University of Edinburgh (Ph.D. studentship to
S. M. M.) and the Scottish Hospital Endowment Research Trust and Medical Research
Council U.K. (Clinical Training Fellowship to R. C. R.).
2 Both authors made an equal contribution to this work.
3 To whom requests for reprints should be addressed, at Respiratory Medicine Unit.
Rayne Laboratory. University of Edinburgh Medical School, Teviot Place. Edinburgh
EH8 9AG, Scotland, United Kingdom. Phone: 44 131 650 6946; Fax: 44 131 650 4384;
E-mail: tsethi@ed.ac.uk.
4 The abbreviations used are: SCLC, small cell lung cancer; PI, phosphatidylinositol;
PI(4)P, phosphatidylinositol 4-phosphate; PI(4,5)P2, phosphatidylinositol 4,5-bisphos-
phate; PI(3,4,5)P3, phosphatidylinositol 3,4,5-triphosphate; SH, Src homology; FAK,
focal adhesion kinase; LY294002, 2-(4-morpholinyl)-8-phenyl-4//-l-benzopyran-4-one;
PKB. protein kinase B; BTSM, bovine tracheal smooth muscle; FBS, fetal bovine serum;
p70s6k, ribosomal S6 kinase; MAP. mitogen-activated protein; SITA. RPMI 1640 medium
with 25 mM HEPES supplemented with 30 nM selenium, 5 /xg/ml insulin, 10 jig/ml
transferrin; 0.25% (w/v) BSA; 5 p.g/ml L-glutamine; 50 pJml penicillin, and 50 /xg/ml
streptomycin; ECL, enhanced chemiluminescence.
of tyrosine phosphorylation may represent a critical determinant of
whether SCLC cells survive and proliferate or die by apoptosis (2).
However, little is known about the precise nature of the tyrosine
kinases involved or the downstream signaling pathways that may be
involved in these responses.
The PI 3-kinase family of enzymes phosphorylate inositol contain¬
ing phospholipids on the 3' position of the nonpolar inositol head
group. Although PI 3-kinase can phosphorylate PI, PI (4)P, and PI
(4,5)P2 in vitro, PI (4,5)P2 is believed to be the preferred substrate in
vivo generating the second messenger PI (3,4,5)P3 (3-6). PI 3-kinase
is an enzyme that acts as a direct biochemical link between a phos¬
phoinositide pathway and a number of proteins cbntfcjning intrinsic or
associated tyrosine kinase activities including the receptors for insulin
and colony-stimulating factor and the products of the oncogenes \-src
and v-abl (7). Phosphorylation of specific tyrosine residues on acti¬
vated polypeptide growth factor receptors activates the p85-pl 10 PI
3-kinase heterodimeric complex via an SH2 domain of the p85 reg¬
ulatory subunit (8). In addition, adhesion to extracellular matrix
stimulates the integrin-dependent interaction of the p85 PI 3-kinase
complex with FAK, causing increased accumulation of PI (3,4)P2 and
PI (3,4,5)P3 (9). Thus, PI 3-kinase is a critical component of signaling
pathways that can be activated by a variety of growth factors, onco¬
genes, chemokines, cell surface receptors, and integrins. Use of the
selective PI 3-kinase inhibitors wortmannin (10) and LY294002 (11)
and dominant-negative or constitutively active mutants of PI 3-kinase
have shown that this enzyme plays a key role in a variety of distinct
cellular functions including the mitogenic response, apoptosis, intra¬
cellular vesicle trafficking/secretion, and regulation of actin and inte-
grin function (reviewed in Ref. 12). Furthermore, recent studies sug¬
gest that integrin-mediated PI 3-kinase activation is important for cell
migration and can promote carcinoma invasion (13, 14).
In view of these important physiological functions, much interest
has focused on potential downstream effectors of PI 3-kinase. Evi¬
dence is accumulating to show that PI 3-kinase is a crucial mediator
of ribosomal S6 kinase (p70s6k) activation in response to serum and
growth factors (15). Activation of p70s6k regulates a wide variety of
cellular processes involved in the mitogenic response including pro¬
tein synthesis, translation of specific mRNA species, and progression
from G, to S phase of the cell cycle (16-18). Seufferlein and Rozen-
gurt (19) demonstrated recently that p70s6k is constitutively phospho-
rylated in SCLC cells and that the p70s6k inhibitor rapamycin inhibits
SCLC cell proliferation. Rapamycin inhibits p70s6k indirectly, form¬
ing a complex with FK-506-binding protein, which in turn interacts
with RAFT/mTOR, a lipid kinase that is a putative upstream regulator
of p70s6k (17).
The serine/threonine proto-oncogene PKB is the cellular homo-
logue of the transforming oncogene product v-Akt (20). PKB has been
shown to be activated by growth factors, oncogenes, and integrins,
signaling through PI 3-kinase (reviewed in Ref. 21). PKB has been
shown to be overexpressed in 12% of ovarian, 3% of breast, and 10%
of pancreatic cancers, where it has been associated with a poor
prognosis and increased tumorigenicity (22. 23). However, the activ¬
ity state of PKB in tumor cells has not been examined previously.
5239
CONSTITUTIVE PI 3-K1NASE ACTIVITY IN SCLC CELLS
The ability of cancer cells to grow in the absence of cell adhesion
to extracellular matrix has been shown to correlate closely with
tumorigenicity in animal models (24). The main cause of death in
patients with cancer arises as a result of either primary tumor invasion
or secondary metastatic deposits. Therefore, the ability of tumor cells
to survive and grow in inappropriate environments is central to
cancer-related death.
The induction of complete oncogenic transformation appears to
require both serum and anchorage-independent growth (25). Consti¬
tutive stimulation of growth factor pathways by ectopic growth factor
expression is mitogenic rather than oncogenic, resulting in benign
hyperplasia in animal models (26-28). In vivo, autocrine growth
factor expression can also be associated with accelerated or serum-
independent growth of otherwise normal cells (29). Our previous
work suggests that the unrestrained proliferation of SCLC cells is
driven by multiple autocrine and paracrine growth loops involving
calcium-mobilizing neuropeptides (30). SCLC cells grow as nonad¬
herent, free-floating aggregates in vitro\ however, the mechanisms
resulting in anchorage-independent growth of SCLC cells are unclear.
The fact that integrins transmit intracellular signals that protect cells
from apoptosis suggests that constitutive activation of these down¬
stream second messengers may mediate anchorage independence.
Transformation of adherent cells by cytoplasmic oncogenes such as
ras or src is accompanied by the ability to grow in suspension. Cell
detachment-induced apoptosis does not occur in epithelial cells ex¬
pressing activated src or ras (31). These oncogenes appear to provide
constitutively activated signals, mimicking those initiated by ligand-
bound integrins, thereby overcoming the induction of apoptosis initi¬
ated by cell detachment from extracellular matrix. A recent study has
shown that the ability of ras and src to protect epithelial cells from
cell detachment-induced apoptosis is mediated through PI 3-kinase
and PKB (32). However, neither high src activity nor activating ras
mutations have been found in SCLC cells (33-35).
These preliminary findings suggest that the PI 3-kinase pathway
may be sensitive to oncogenic conversion and could be important in
the development of human cancers. The role of PI 3-kinase-mediated
signal pathways in regulating the growth, apoptosis, and anchorage
independence of SCLC cells is unknown. Here we demonstrate that all
five SCLC cell lines tested have high basal constitutive PI 3-kinase
activity. This results in high levels of basal PKB and p70s6k activity.
Furthermore, our results suggest that PI 3-kinase activity plays an
important role in promoting the growth and anchorage independence
of SCLC cells and may account for the highly metastatic and aggres¬
sive nature of this tumor. We believe that this is the first description
of constitutively active PI 3-kinase/PKB in a human cancer.
MATERIALS AND METHODS
Cell Culture. SCLC cell lines NCI-H345, NCI-H69, and NCI-H510 and
human alveolar type II epithelial cells (A549) were purchased from the
American Type Tissue Culture Collection (Rockville, MD). Swiss 3T3 cells
were from the European Cell Culture Collection (Porton Down, United King¬
dom). SCLC cell lines LS274 and DMS79 were kind gifts from Professor J.
Smyth (1CRF, Edinburgh, Scotland). BTSM cells were established in primary
culture in our laboratory. 16HBE140 cells were originally from D. Gruenert
(University of California, San Francisco, CA). All SCLC cell lines were grown
in RPMI 1640 with 25 mM HEPES supplemented with 10% (v/v) heat-
inactivated FBS. BTSM, A549, and Swiss 3T3 cells were grown in DMEM
containing 10% (v/v) FBS. 16HBE140 cells were cultured in MEM supple¬
mented with 10% FBS and 1% nonessential amino acids. All media contained
50 units/ml penicillin, 50 /xg/ml streptomycin, and 5 /xg/ml L-glutamine, and
cells were cultured in a humidified atmosphere of 5% CCL/95% air at 37°C.
For experimental purposes, SCLC cells 5 days after passage were trans¬
ferred into SITA medium and cultured for another 2 days before use. Alter¬
natively, cells were taken from growth medium, washed thoroughly with
quiescent medium, and incubated in fresh quiescent medium for 24 h before
experimentation. Quiescent medium comprised RPMI 1640 with 25 mM
HEPES supplemented with 0.25% (w/v) BSA, 50 units/ml penicillin, 50 /xg/ml
streptomycin, and 5 /eg/ml L-glutamine. BTSM cells were quiesced for 48 h
before use in DMEM containing 0.5% FBS. 16HBE140 and A549 cells were
quiesced for 24 h in serum-free MEM and DMEM, respectively. Cell viability
was confirmed by trypan blue exclusion and was always >95%.
PI 3-Kinase Activity Assay. Adherent cells were washed three times with
PBS at 37°C, transferred to ice, and Iysed using ice-cold lysis buffer containing
50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10 mM
sodium PPh 100 mM sodium fluoride, 10% (v/v) glycerol, 1% (v/v) Triton
X-100, 0.5 mM DTT, 1 mM sodium orthovanadate, 50 /xm 4-(2-aminoethyl-
benzenesulfonyl fluoride, 5 jixg/ml leupeptin, 20 /xg/ml aprotinin, and 10 /xg/ml
soybean trypsin inhibitor. SCLC cells (1 X 107) that had been washed three
times with PBS at 37°C were transferred to 24-well plates in 1 ml of PBS and
allowed to equilibrate at 37°C for 1 h before the addition of varying concen¬
trations of wortmannin or DMSO vehicle (final concentration, 0.1 % v/v) for 20
min. Cells were then transferred to ice, pelleted, and lysed. Lysates were
clarified by centrifugation at 13,000 X g for 10 min. For each assay point, 1
mg of total protein from the supernatant was incubated with 2.5 /xg of p85-Pl
3-kinase antibody for 90 min at 4°C. Thirty /xl of goat anti-mouse IgG agarose
beads in lysis buffer were added for an additional 2 h. The beads were then
pelleted and washed sequentially with: lysis buffer, 100 mM Tris-HCl, and 500
mM LiCl (pH 7.6), once; and twice with 200 mM HEPES, 40 mM MgCl2, 600
mM NaCl (pH 7.4). PI 3-kinase assays were performed using phosphatidyli-
nositol as substrate in a final volume of 200 /xl containing: (final concentra¬
tions) 50 mM HEPES (pH 7.4), 10 mM MgCL, 150 mM NaCl, [y-32P]ATP (10
/xCi, 3000 Ci/mmol), 50 /xm ATP, and 0.5 mg/ml sonicated phosphatidyli-
nositobphosphatidylserine (3:1, w/w). Reactions were carried out for 20 min at
37°C and terminated by the addition of chloroform:methanol:0.1 M HC1
(40:80:1, v/v/v; 750 /xl), and a phase-partition was achieved by the addition of
chloroform (250 /xl) and 0.1 M HC1 (250 jtxl). After centrifugation. the lower
phase was washed twice with synthetic upper phase, dried, and the lipids were
separated by TLC. Phosphorylated lipids were identified by autoradiography
and radioactivity quantified by liquid scintillation counting. For assays involv¬
ing LY294002, immunoprecipitates from untreated cells were prepared as
above, washed, and incubated with varying concentrations of LY294002 for 20
min at 37°C before PI 3-kinase activity assays as above.
p70s6k Activity Assay. p70s6k activity was assayed essentially as described
by Scott et al. (36) with some minor modifications. Cells cultured in SITA
medium were washed and plated as outlined above before the addition of
varying concentrations of inhibitors at 37°C for 20 min. Cells were solubilized
for 30 min at 4°C in a buffer containing 50 mM Tris/HCl (pH 8.0), 120 mM
NaCl. 20 mM NaF, 5 mM EGTA, 1 mM EDTA, 10 mM sodium PP^ 10 mM
p-nitrophenyl phosphate, 1 mM benzamidine, 0.1 mM phenylmethylsulfonyl
fluoride and 1% (v/v) NP40. Lysates were clarified at 13,000 X g for 10 min
and equal quantities of protein equilibrated supernatant incubated with 2 /xg
polyclonal anti-p70s6k antibody. After 90 min, the lysates were further incu¬
bated with 25 /xl of Pansorbin. The immunoprecipitates were washed twice in
lysis buffer and twice in the same buffer without detergent. This was followed
by two washes in a buffer containing 25 mM HEPES (pH 7.4), 20 mM
^-glycerophosphate, 20 mM MgCL, 3 mM EGTA, 0.2 mM sodium orthovana¬
date, and 2 mM dithiotreitol and then incubated in the same buffer containing
100 /xm S40 substrate peptide, 10 /xm adenosine 3',5'-cyclic monophosphate-
dependent protein kinase inhibitor and [y-32P]ATP (10 /xm; 1 /xCi, 3000
Ci/mmol) in a volume of 30 /xl for 20 min at 30°C. The reaction was
terminated by the addition of 10 /x 1 of 300 mM phosphoric acid, and the
mixture was spotted onto P81 chromatography paper. The papers were washed
twice with 0.5% (v/v) phosphoric acid, allowed to dry, and phosphorylation ol
the S40 substrate peptide was quantified by liquid scintillation counting as an
index of enzymatic activity.
PKB Activity Assay. SCLC cells (1 X 106) cultured in quiescent medium
for 24 h before experimentation were washed three times in PBS and aliquoted
as outlined above before the addition of varying concentrations of inhibitor foi
20 min. Cells were then lysed using 250 /xl of ice-cold buffer containing 50 mv
Tris/HCl (pH 7.5), 0.1% (v/v) Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.27
M sucrose, 50 mM sodium fluoride, 10 mM sodium ^-glycerophosphate, 5 mM
sodium PPh 1 mM sodium orthovanadate, 0.1% (v/v) 2-mercaptoethanol, 1 /xv
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microcystin, 5 j.ig/ml leupeptin, 20 /xg/ml aprotinin, and 10 jJ-g/ml soybean
Irysin inhibitor. Lysates were clarified by centrifugation at 13,000 X g for 10
min, and PKB was immunoprecipitated by incubating the lysates (containing
150 /xg of protein) for 90 min at 4°C with 1 p.g of anti-PKBa antibody
preconjugated to 15 pi of protein G-Sepharose in lysis buffer. Immunopre-
cipitates were washed twice with lysis buffer containing 0.5 M NaCl and once
with a buffer consisting of 50 mM Tris/HCl (pH 7.5), 0.03% (v/v) Brij-35, 0.1
mM EGTA, and 0.1% (v/v) 2-mercaptoethanol. PKB activity was assayed by
incubating washed immunoprecipitates at 30°C for 20 min in a thermomixer in
30 pi of kinase assay buffer (50 pM Crosstide, 50 mM Tris/HCl, 0.1 mM
EGTA, 20 pM adenosine 3',5'-cyclic monophosphate-dependent protein ki¬
nase inhibitor, 20 mM MgAc, 0.2 mM ATP, 1 pM microcystin, and [y-32P]ATP
(1.0 pCi, 3000 Ci/mmol). The assays were terminated by placing 40 pi of
assay mixture onto P81 chromatography paper and washing four times with
0.5% (v/v) phosphoric acid and once with acetone. Radioactive incorporation
was quantified by liquid scintillation counting.
Immunoblotting. Cell pellets were lysed at 4°C in PI 3-kinase lysis buffer
(see above) for 30 min. Lysates were clarified by centrifugation at 13,000 X g
for 10 min at 4°C. Twenty pg of protein were solubilized in SDS-PAGE
sample buffer and resolved on 10% gels. The proteins were transferred to
nitrocellulose membranes, blocked using 5% (w/v) nonfat milk in TBS-Tween
[20 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.02% (v/v) Tween 20)
overnight at 4°C and then incubated sequentially with primary and secondary
antibodies diluted in blocking buffer for 1 h each at room temperature. Primary
antibodies (used at a 1:1000 dilution) were the same as those used in the
activity assays. The secondary antibodies were species appropriate horseradish
peroxidase-conjugated antibodies. Immunoreactive bands were identified us¬
ing ECL according to the manufacturer's instructions.
Liquid Growth Assay. Cultures of SCLC cell lines H345, H69, and H510
at 5 days after passage were grown for 2 days in SITA medium. Before
experimentation, cells were washed twice and resuspended in fresh SITA
medium before being gently disaggregated by two passes through a 21-gauge
needle into an essentially single-cell suspension as judged by light microscopy.
Viability was determined by trypan blue exclusion on a hemocytometer. Cells
(1 X 10s) were seeded into 24-well plates in SITA medium and incubated for
4 h in a humidified atmosphere of 5% C02/95% air at 37°C before the addition
of inhibitors (see figure legends); cells were then further incubated under the
same conditions before being removed at various times and disaggregated into
a single-cell suspension using a 21-gauge needle, and cell number was deter¬
mined using a Coulter Cell Counter (Coulter Electronics, Luton, United
Kingdom).
Clonogenic Assay. SCLC cells, 3-5 days after passage, were washed and
resuspended in SITA medium. Cells were then disaggregated into a single-cell
suspension by two passes through a 21-gauge needle. Viability was judged by
trypan blue exclusion. Cell number was determined with a Coulter cell counter
and 1 X 10J viable cells mixed with SITA containing 0.3% (w/v) agarose and
agonist/antagonist at the concentrations indicated (see Fig. 8) and layered over
a solid base of 0.5% (w/v) agarose in SITA with agonist/antagonist at the same
concentration, in 35-mm plastic dishes. The cultures were incubated in humid¬
ified 5% C02/95% air at 37°C for 21 days and then stained with the vital stain
nitroblue tetrazolium. Colonies of >I20-/xm diameter (16 cells) were counted
with a microscope.
Morphological Assessment of SCLC Cell Apoptosis. SCLC cells
(1 X 105) were seeded into 96-well plates in 200 p.1 of SITA medium and
incubated in the presence or absence of 10 /xM LY294002, 100 nM wortman-
nin, or appropriate diluent for 24 h. One p.1 of an ethidium bromide (100
/xg/ml):acridine orange [100 p.g/ml; 1:1 (v/v)] mixture was added to each well,
and the percentage of cells undergoing apoptosis was assessed using fluores¬
cent microscopy as described previously (37).
Flow Cytometric Assessment of Cell Cycle Phase. Cells (1 X 10s) were
cultured in SITA medium in the presence or absence of LY294002 (10 p.M).
After 24 h, cells were washed twice in PBS and fixed in 70% ice-cold ethanol.
Cellular DNA content was determined by staining with 50 (U.g/ml of propidium
iodide and analyzed according to forward and side scatter properties using an
EPICS Profile II (Coulter Electronics, Luton, United Kingdom). The propor¬
tion of cells in G,, S, and G2-M phases (minimum of 3000 cells analyzed per
condition) was calculated using standard methods.
Materials. RPMI 1640, BSA agarose, IgG protein agarose, rapamycin, and
wortmannin were purchased from Sigma Chemical Co. (Poole, United King¬
dom). Monoclonal p85-SH3 antibody and the S40 peptide substrate were from
TCS (Buckingham, United Kingdom); polyclonal p70s6k antibody was ob¬
tained from Santa Cruz Biotechnology (Santa Cruz, CA). Adenosine 3',5'-
cyclic monophosphate-dependent protein kinase inhibitor and LY294002 were
from Calbiochem-Novabiochem Corp (Nottingham, United Kingdom).
[y-,2P]ATP (3000 p.Ci/mmol) and Hybond C nitrocellulose membranes were
purchased from Amersham International (Amersham, United Kingdom), and
horseradish peroxidase-conjugated antibodies were obtained from DAKO UK.
PKBa antibody and Crosstide substrate peptide were a kind gift from Dr. D.
Alessi and Professor P. Cohen (University of Dundee, Dundee, United King¬
dom). All other reagents were of the purest grade available.
RESULTS
SCLC Cells Display Constitutive PI 3-Kinase Activity, Which Is
Inhibited by Wortmannin and LY294002. PI 3-kinase is known to
be critically involved in cell proliferation and anchorage-independent
growth (32). We therefore tested whether the highly aggressive phe-
notype of SCLC might, in part, result from constitutive PI 3-kinase
activity. Western blot analysis of lysates from H69, H345, H510,
LS274, and DMS79 SCLC cell lines showed expression of the p85a
subunit of PI 3-kinase (Fig. M).
B
Fig. 1 .A, PI 3-kinase expression and activity in
SCLC cell lines. Upper panel, Western blots of
SCLC cell lysates (DMS79, LS274, H69, H345,
and H510) and Swiss 3T3 lysates were probed with
a monoclonal anti-p85a-SH3 antibody and visual¬
ized using ECL. Lower panel, for activity assays,
PI 3-kinase was immunoprecipitated from cell ly¬
sates using an anti-p85a-SH3 antibody. PI 3-kinase
activity was assayed (as described in "Materials
and Methods") using phosphatidylinositol as sub¬
strate. 3-Phosphorylatcd lipids were resolved using
TLC, identified by autoradiography, and quantified
by liquid scintillation counting. Results are the
means of two independent experiments; bars, SD.
HBE, human bronchial epithelial cells; A549, hu¬
man alveolar type II epithelial cells; 3T3, Swiss
3T3 fibroblasts. B, basal PI 3-kinase activity in
SCLC cells. SCLC cells grown in serum-free SITA
medium or quiescent medium (Q) were washed
three times in PBS and then equilibrated in fresh
PBS for 1 h. Ten % FCS indicates cells taken from
quiescent medium and stimulated with 10% FCS
for 10 min before lysis.
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Fig. 2. Effect of PI 3-kinase inhibition on PI 3-ki-
nase activity in SCLC cells. Concentration response of
wortmannin {left) and LY294002 (right) on PI 3-kinase
activity in H69 (upper) and H345 (lower) SCLC cells.
Values shown are the means of two to three independ¬
ent experiments performed in duplicate; bars, SE. Ba¬
sal PI 3-kinase activity is taken as 100%. Representa¬
tive autoradiographs showing the 3-phosphorylated
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To examine basal PI 3-kinase activity, SCLC cells were cultured in
serum-free SITA medium for 48 h and then maintained for an addi¬
tional 24 h in growth factor-free quiescent medium. The cells were
then washed extensively in PBS and allowed to equilibrate in PBS for
1 h to remove exogenous/autocrine growth factors. PI 3-kinase activ¬
ity from p85a immunoprecipitates was measured as described in
"Materials and Methods." The identity of the PI (3)P was confirmed
by monomethylamine deacylation and HPLC analysis using a SAX 5
column and (NH4)2HP04 gradient and authentic tritiated standards as
markers (data not shown). Fig. 1A shows a markedly elevated basal PI
3-kinase activity in all of the SCLC cell lines tested (H69, H345,
H510, DMS79, and LS274) compared with human bronchial epithe¬
lial cells (16HBE140), BTSM cells, human alveolar type II epithelial
cells (A549), and Swiss 3T3 cells. Fig. IS shows that SCLC cells
grown in either serum-free SITA medium or growth factor-free qui¬
escent medium have equally high basal PI 3-kinase activity. Thus,
under conditions where every effort was made to remove all exoge¬
nous/autocrine growth factors, high basal PI 3-kinase activity was
seen in SCLC cells. Furthermore, 10% FCS could induce only a
modest additional increase in PI 3-kinase activity (151 ± 19.4%; Fig.
IS). We therefore concluded that SCLC cells possess a constitutively
active PI 3-kinase. This was further supported by data using the PI
(3,4,5)P3 mass assay (38), which showed that SCLC cells in a basal
state have elevated levels of PI (3,4,5)P3 (4.5 ± 2.1 pmol/mg) com¬
pared with a number of other cell types including Swiss 3T3 and
1321N1 astrocytoma cells (2.16 ± 1.0 pmol/mg).5
Wortmannin and LY294002 (at concentrations up to 100 nM and
100 p,M, respectively) are specific PI 3-kinase inhibitors and have
5 J. van der Kaay, personal communication.
emerged as useful tools to elucidate the cellular function and signal
transduction pathways of PI 3-kinase (10, 11). Treatment of SCLC
cells with wortmannin for 20 min (Fig. 2, left panels) or the addition
of LY294002 directly to immunoprecipitates 20 min before assaying
for PI 3-kinase activity (Fig. 2, right panels) caused a concentration-
dependent inhibition of basal PI 3-kinase activity in three SCLC lines
examined. The IC50 of PI 3-kinase activity by wortmannin in H69 and
H345 cells was 8.0 ± 2.1 nM and 0.27 ±1.1 nM, respectively, and for
LY294002, 3.4 ± 1.4 and 0.85 ± 0.41 /lim, respectively (mean ± SE;
n = 2-4). Similar results were also seen in H510 cells (IC50,
11.1 ± 4.1 nM and 1.2 ± 0.4 pm for wortmannin and LY294002,
respectively).
p70s6k Activity Is PI 3-Kinase-dependent. The molecular targets
of PI 3-kinase are being defined by studies using PI 3-kinase inhibi¬
tors. Evidence is accumulating that PI 3-kinase is a crucial mediator
of p70s6k activation (15). Fig. 3A shows a Western blot analysis of
p70s6k expression in SCLC cell lines H69, H345, and H510. We
therefore investigated the possibility that the constitutive phosphoryl¬
ation of p70s6k described previously in SCLC cells (19) causes high
basal p70s6k activity that is driven by constitutive PI 3-kinase activity.
Immunoprecipitation of p70s6k from SCLC cells maintained under
conditions identical to those described by Seufferlein and Rozengurt
(Ref. 19; see "Materials and Methods") showed a high level of basal
p70s6k activity. For H69 cells, basal activity was 4317 ± 346 cpm,
and in H345 cells, basal activity was 4417 ± 897 cpm (mean ± SE;
n = 3-4). Preincubation of intact SCLC cells with the PI 3-kinase
inhibitors wortmannin (Fig. 3B, left panels) and LY294002 (Fig. 3B,
right panels) for 20 min caused a concentration-dependent inhibition
of p70s6k activity in FI69 cells (IC50, 1.3 ± 0.73 nM and 0.9 ± 0.68
ju.m, respectively) and H345 cells (IC50, 14.6 ± 5.5 nM and 4.2 ± 1.2
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Fig. 3. A, expression of the p70 isoform of ribosomal s6
kinase in SCLC cell lines H69, H345, H510 and Swiss 3T3.
Cell lysates were Western blotted and probed using a rabbit 75
polyclonal anti-p70s6k antibody. Immunoreactive bands were
visualized by ECL. B, p70s6k activity in SCLC. Well-washed
H69 (upper) and H345 (lower) SCLC cells were equilibrated in 50
fresh PBS for l h and treated with wortmannin (left) or
LY294002 (right), at concentrations indicated, for 20 min be¬
fore lysis. p70shk was immunoprecipitated from cell lysates, > ^5
and activity was assayed in an in vitro kinase reaction using S40
peptide as substrate (as described in "Materials and Methods").
Values shown are the means of three to four independent
experiments performed in duplicate; bars, SE. Basal p70s6k
activity is expressed as 100%. For H69 experiments, basal Jj\
activity was 4317 ± 346 cpm, and nonspecific background O100
activity was 698 ± 158 cpm; in H345 experiments, basal
activity was 4417 ± 897 cpm, and background activity was
392 ± 90 cpm. ^ ®
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pM, respectively; mean ± SE; n = 3-4). Similar results were seen in
H510 cells with wortmannin and LY294002 (IC50, 4.1 nM and 1.0 pM,
respectively). These results are similar to the IC50s obtained for
wortmannin and LY294002 inhibition of PI 3-kinase. The maximal
inhibition of p70's6k activity achieved using either 100 nM wortmannin
or 10 pM LY294002 was 75%. The addition of rapamycin, a highly
potent inhibitor of p70s6k, to intact SCLC cells for 20 min caused a
100% inhibition of p70s6k activity (data not shown). The addition of
either 100 nM wortmannin or 10 pM LY294002 to the in vitro kinase
reaction had no effect on the kinase activity of p70s6k immunopre-
cipitates (data not shown). Thus, wortmannin and LY294002 do not
affect p70s6k activity directly but regulate p70sSk activity via wort-
mannin/LY294002 sensitive PI 3-kinase activity.
Constitutive PKB Activity in SCLC Cells Is PI 3-Kinase-de-
pendent. In integrin and growth factor signal transduction, PKB has
been identified as a key downstream effector of PI 3-kinase (21).
Western blot analysis of SCLC cell lines H510, H69, and H345
revealed expression of the a isoform of PKB (Fig. 4A). Hence, we
examined basal PKB activity in SCLC cells. SCLC cells that had been
maintained in growth factor-free quiescent medium for 24 h before
experimentation were thoroughly washed, and PKB activity was de¬
termined using an in vitro kinase assay as described in "Materials and
Methods." Fig. 45 shows that under basal conditions, SCLC H69 cells
display constitutive PKB activity that could be completely inhibited
by 100 nM wortmannin. The p70s6k inhibitor rapamycin had no effect
on PKB activity (Fig. 45). Similar results were seen in H345 and
H510 cells (results not shown). Under identical conditions, very low
levels of basal PKB activity was seen in Swiss 3T3 cells despite a
similar level of expression of PKBa as judged by Western blot
analysis (Fig. 4, A and 5). The addition of LY294002 (Fig. 4C, left)
or wortmannin (Fig. 4C, right) to H69 cells for 20 min caused a
concentration-dependent inhibition of basal PKB activity. The IC50
for LY294002 and wortmannin was 2.7 ± 0.1 pM and 2.0 ± 0.6 nM,
respectively (mean ± SE; n = 3). These values correlate well with
those seen for PI 3-kinase inhibition. When added directly to PKB
immunoprecipitates, wortmannin and LY294002 had no effect on
PKB activity. These results suggest that the elevated basal PKB
activity in SCLC cells is a direct downstream consequence of consti¬
tutive PI 3-kinase activity in these cells.
SCLC Cell Growth in Liquid Culture Is PI 3-Kinase-depen-
dent. We went on to examine the biological consequences of block¬
ing constitutive PI 3-kinase signaling. SCLC cells were grown in
SITA in the presence of increasing concentrations of LY294002, and
the cell number was counted at day 9. LY294002 caused a marked
concentration-dependent reduction in SCLC cell number in liquid
culture (IC50s, 10.0 ± 0.8, 2.9 ± 0.2, and 13.3 ± 0.8 pM for H69,
H345, and H510 cells, respectively; mean ± SE; n = 3-5; Fig. 5).
These results are in good agreement with data obtained for inhibition
of PI 3-kinase, PKB, and p70s5k activity by LY294002. Thus, consti¬
tutive PI 3-kinase activity appears to play an important role in the
proliferation of this aggressive cancer.
To determine the relative contribution of the p70s6k pathway to PI
3-kinase-mediated growth in SCLC, SCLC cells were grown in the
presence of the specific inhibitors LY294002 and rapamycin both
alone and in combination, as described in "Materials and Methods."
Fig. 6 shows that the addition of a maximally effective concentration
of LY294002 (100 pM) was able to inhibit H69 and H345 SCLC
growth by 92% over a 9-day period, whereas a maximally effective
concentration of rapamycin (20 nM; Ref. 19) caused a 6.5 and 33%
reduction in growth over the same time period in H69 and H345 cells,
constitutive pi 3-kinase activity in sclc cells
Fig. 4. A, PKBa expression in SCLC cell lines
H69, H345, H510, and Swiss 3T3. Western blots of
cell lysates were probed with an anti-PKBa anti¬
body and visualized by ECL. B, PKB activity in
SCLC cells. SCLC cells grown in quiescent me¬
dium were well washed and then equilibrated in
fresh PBS for 1 h. PKB was immunoprecipitated
from cell lysates, and activity was assayed in an in
vitro kinase reaction using Crosstide as substrate
(as described in "Materials and Methods"). Basal
PKB activity was measured in H69 SCLC cells
preincubated with diluent (O), 100 nM wortmannin
(WM), or 20 nM rapamycin {Rap). Basal 3T3 shows
PKB activity in Swiss 3T3 cells under identical
conditions as described above. Results expressed
as percentage of PKB activity above nonspecific
background are the means of two independent ex¬
periments in duplicate; bars, SD. C, concentration-
dependent inhibition of basal PKB activity by PI
3-kinase inhibitors in SCLC cells. SCLC cells were
treated with LY294002 (left) or wortmannin {right)
for 20 min before lysis. Each point represents the
mean of three independent experiments performed
in duplicate; bars, SE. Basal PKB activity is ex¬
pressed as 100% (1824 ± 241 cpm; nonspecific
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respectively. Incubation of H69 and H345 cells with a combination of
10 /am LY294002 (a value close to the IC50) and 20 nm rapamycin (a
maximally effective concentration) caused an —61—68% inhibition of
SCLC cell growth over 9 days (Fig. 6). Similar results were seen in
H510 cells. These results suggest that PI 3-kinase exerts its growth
effects by both p70s6k-dependent and independent pathways in SCLC.
However, it appears that the majority of the PI 3-kinase effect is
mediated via a p70s6k-independent pathway, potentially signaling
through PKB.
SCLC Cell Survival Is PI 3-Kinase-dependent. Activation of PI
3-kinase and PKB activity has been implicated in the protection of
cells from apoptosis. The effect of PI 3-kinase inhibitors on the rate of
SCLC cell apoptosis was determined using acridine orange/ethidium
bromide staining under fluorescent microscopy. The background level
of SCLC cell apoptosis in these experiments was 8%. H345 cells
treated with 10 /am LY294002 or 100 nM wortmannin for 24 h showed
a 41 ± 12 and 31 ± 13% increase in the percentage of cells
undergoing apoptosis, respectively. The figures for H69 cells were
82 ± 30% and 95 ± 22%, respectively (mean ± SE; n = 3; Fig. 7A).
These data were corroborated using an immunoassay that detected
cytoplasmic histone-associated DNA fragments (data not shown).
During this time course, trypan blue positivity remained consistently
<5%. Thus, although inhibition of PI 3-kinase activity in SCLC cells
caused a marked inhibition of cell growth in liquid culture, this did not
occur as a result of increased cell necrosis but was due, in part, to an
increase in apoptosis. Because the proapoptotic effect due to PI
3-kinase inhibition was relatively modest, we examined the effect of
PI 3-kinase inhibitors on cell cycle kinetics. Fig. IB shows that 10 /am
LY294002 causes a cell cycle delay in G, and a decrease in the
number of cells entering mitosis. Therefore, the growth-inhibitory
effects induced by LY294002 are due to a combination of an increase
in apoptosis and a delay in the cell cycle.
LY294002 Inhibits SCLC Cell Tumorigenicity and Neuropep-
tide-stimulated Colony Growth. The ability to form colonies in
agarose semisolid medium is a marker of anchorage-independent
growth that is characteristic of the transformed phenotype. There is a
positive correlation between the cloning efficiency of cells and the
histological involvement and invasiveness of the tumor in specimens
taken from SCLC (39). We therefore examined the effect of 10 /am
LY294002 on SCLC colony formation in agarose semisolid medium.
LY294002 (pM)
Fig. 5. Concentration-dependent effect of LY294002 on H69, H345, or H510 SCLC growth. SCLC cells (1 X 105) were washed and incubated in fresh SITA medium in the presence
of increasing concentrations of LY294002 as shown. Cell number was determined on day 9, and results are expressed as a percentage of cell growth in the presence of diluent alone.
Each point represents the mean of three to five independent experiments performed in triplicate; bars, SE.
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Fig. 6. Effect of LY294002 and rapamycin on H69 (left) and H345 (right) SCLC cell
growth. Cells (1 X 105) were washed and incubated in fresh SITA medium in the presence
of LY294002 (LY) and rapamycin (Rap) alone or in combination, at the concentrations
indicated. On day 9, cell number was measured. Results expressed as percentage inhibi¬
tion of growth compared with control cell growth are means of three to five independent
experiments performed in triplicate; bars, SE.
Fig. 8 shows that 10 jxm LY294002 inhibited basal colony formation
of all three SCLC cell lines by up to 80%. Our previous work has
suggested that SCLC cell growth is sustained by multiple autocrine
and paracrine growth loops involving calcium mobilizing peptides. As
shown previously, the neuropeptides vasopressin (50 nM), gastrin (100
nM), and bombesin (50 nM) caused a marked stimulation of colony
formation in H69, H510, and H345 cells, respectively (30). However,
the addition of vasopressin, gastrin, or bombesin failed to rescue the
LY294002-induced inhibition of colony formation in these cell lines
(Fig. 8). Thus, PI 3-kinase appears to play a critical role in sustaining
the anchorage-independent growth of SCLC.
DISCUSSION
SCLC has the highest metastatic potential of any of the solid tumors
with >90% of patients having widespread metastases at presentation.
A characteristic feature of cancer cells is their ability to grow in the
absence of cell adhesion to extracellular matrix. The development of
secondary metastatic deposits at sites remote from the primary tumor
is one of the main causes of death in patients with cancer. Therefore,
the ability of tumor cells to survive and proliferate in inappropriate
environments is central to cancer-related death. Thus, anchorage-
independent growth is pivotal to the highly proliferative and meta¬
static nature of this cancer.
The novel findings of this study are that in all five SCLC cell lines
examined, constitutive PI 3-kinase activity was found that results in
high levels of basal PKB and p70s6k activity. Inhibition of PI 3-kinase
activity blocks SCLC cell growth in liquid culture and colony forma¬
tion in semisolid medium. We show that this occurs due to a combi¬
nation of a stimulation of apoptosis and a delay in the cell cycle in G,
with a consequent decrease in the number of cells entering mitosis.
Our results also show that SCLC growth and survival is mediated both
by p70s6k-dependent and -independent pathways, the latter potentially
acting through PKB. Thus, downstream pathway(s) driven by a con-
stitutively active PI 3-kinase appear to play an important role in
promoting the growth and anchorage independence of SCLC. Re¬
cently, PI 3-kinase activation has been implicated in anchorage-
independent growth, metastasis, and cell invasion (13, 14). To our
knowledge, this is the first description of constitutively activated PI
3-kinase/PKB in any human cancer. Constitutive activation of these
integrin-dependent signaling events may provide a molecular expla¬
nation for anchorage-independent growth and account for the highly
metastatic nature of SCLC. We propose that anchorage independence
mediated by constitutive PI 3-kinase activity, in concert with serum
independence mediated by multiple autocrine/paracrine growth loops
driven by calcium-mobilizing neuropeptides, is responsible for the
very aggressive nature of SCLC.
The origin of this constitutive PI 3-kinase activity in SCLC cells is
unclear. Before analysis of PI 3-kinase activity, every effort was made
to remove exogenous growth factors by extensive cell washing.
Hence, we feel that it is unlikely that exogenous growth factor
stimulation is mediating this high PI 3-kinase activity, and further¬
more, under identical conditions PI 3-kinase activity is low in control
cells. PI 3-kinase can be activated by intracellular second messengers
such as ras, FAK, and sre, which are also able to promote anchorage-
independent growth (24, 32, 40, 41). However, several studies have
failed to show any evidence of activating ras mutations in SCLC (33,
34). In addition, we have shown previously that under the basal
conditions described above, FAK phosphorylation is low (2). Further¬
more, pp60 sre activity is low in SCLC cells (35). This suggests the
possibility of a novel mechanism of PI 3-kinase activation or a
mutationally activated PI 3-kinase in SCLC cells.
The molecular targets of PI 3-kinase are being defined by studies
using PI 3-kinase inhibitors. In this study, we used the PI 3-kinase
inhibitors wortmannin and LY294002. To ensure the specificity of
effects seen with pharmacological agents, it is important that inhibi¬
tors with differing mechanisms of action produce similar effects
within the concentration range described for other cell systems. Wort¬
mannin (IC50, 3 nM) is noncompetitive with respect to ATP, binding
irreversibly to the pi 10 catalytic subunit of PI 3-kinase (10), whereas
LY294002 (IC50, 1.4 /xm) behaves as a competitive inhibitor for the
ATP binding site of PI 3-kinase (11).
PKB and p70s6k have been identified as downstream effectors of PI
3-kinase (15, 21). Our results may underlie the constitutive basal
Fig. 7. A, effect of the PI-3 kinase inhibitors LY294002 and
wortmannin on H69 (left) and H345 (right) SCLC cell apop¬
tosis. Cells (1 X 10s) were washed and incubated in fresh SITA
for 24 h in the presence of either diluent or 10 /am LY294002
(LY) or 100 nM wortmannin (W\f). Apoptotic cells were iden¬
tified using acridine orange/ethidium bromide under fluores¬
cence microscopy. The results that are expressed as a percent¬
age of stimulation of apoptosis over control cells are the means
of six independent experiments performed in triplicate; bars,
SE. B, effect of LY294002 on SCLC cell cycle. H69 cells that
had incubated for 24 h in the presence or absence of 10 /am
LY294002 (LY) were washed in PBS and fixed with 70%
ice-cold ethanol. Cellular DNA content was determined by
staining with propidium iodide, and cell cycle phase was ana¬
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Fig. 8. Effect of LY294002 on SCLC clonal growth in semisolid medium. H69, H345.
and H510 SCLC cells, 3-5 days after passage, were washed, and l X I04 viable cells/ml
were plated in SITA medium containing 0.3% agarose on top of a base of 0.5% agarose
in culture medium as described in "Materials and Methods." Both layers contained either
no neuropeptide additions (■) or 50 nM vasopressin (VP), 50 nM bombesin (Bom), or 100
nM gastrin (G; in the presence ( + ) or absence (-) of 10 /xm LY294002 (LY). After 21
days, colonies of >120 /xm (16 cells) were counted. Results are expressed as colonies/
dish, means of triplicates of two independent experiments: bars, SD.
phosphorylation of p70s6k noted previously in SCLC cell lines H510,
H69, and H345 (19). This constitutive basal phosphorylation is re¬
flected in the high basal activity of p70s6k. Wortmannin and
LY294002 inhibit p70s6k activity by 70-80% with IC50s similar to
those seen for both PI 3-kinase and p7CPftk inhibition. Thus, the
constitutive phosphorylation and kinase activity of p70s6k is, in part,
driven by constitutive PI 3-kinase activity. However, even when high
concentrations of wortmannin (100 nM) and LY294002 (100 p.M) were
used, residual p70s6k activity was noted. This may be due to activation
of p70s6k by other pathways, e.g., the PKC pathway as described in
other cell systems (17). This may also explain why H345 cell p70s6k
was more resistant to the effects of PI 3-kinase inhibitors than in H69
cells with an IC5„ shifted to the right and higher residual p70s6k
activity, despite maximal PI 3-kinase inhibition. Constitutive activa¬
tion of the e isoform of PKC has been described in a SCLC cell line (42).
PKB overexpression in human ovarian, breast, and pancreatic can¬
cers has been shown to be associated with a poor prognosis and
increased tumorigenicity (22, 23). However, these studies did not
examine PKB activity. All three SCLC lines that we examined ex¬
pressed the a isoform of PKB and had elevated basal PKB activity
that could be completely inhibited by wortmannin and LY294002 in
a concentration-dependent manner similar to PI 3-kinase. Therefore,
the high basal PKB activity in SCLC cells occurs as a consequence of
constitutive PI 3-kinase activity. The doublet band for PKBa was only
seen in H510 cells and was a constant finding (n = 3). The reason is
obscure but may be due to a posttranslational modification or an
alternatively spliced form of the protein.
To examine the functional importance of this up-regulated pathway,
we used the PI 3-kinase inhibitor LY294002. The addition of
LY294002 to SCLC cells in liquid culture resulted in a marked
concentration-dependent reduction in cell numbers. The IC5ns are
very similar to the IC50s for inhibition of PI 3-kinase, PKB, and p70s6k
activity by LY294002. PI 3-kinase inhibition can almost totally block
SCLC cell proliferation. Thus, constitutive PI 3-kinase-dependent
signaling is playing a critical role in SCLC growth.
The addition of PI 3-kinase inhibitors, wortmannin, and LY294002
to SCLC cells showed a modest but consistent increase in the per¬
centage of cells undergoing apoptosis. In addition, PI 3-kinase inhi¬
bition causes a cell cycle delay, and the combination of cell cycle
delay and stimulation of apoptosis appear to be responsible for the
growth inhibition seen. Studies using trypan blue and acridine orange
excluded a toxic effect being responsible. PI 3-kinase inhibition may
arrest growth by preventing normal growth factor signaling. Recent
evidence suggests that growth factors do not induce DNA synthesis in
3T3 cells in the absence of integrin activation (43). This appears to
result from the inability of growth factors to activate the MAP kinase
pathway in the absence of integrin-mediated second messenger sig¬
nals. We propose that constitutive activation of PI 3-kinase in SCLC
cells may mimic integrin-dependent signal transduction and facilitate
growth factor-mediated activation of the MAP kinase pathway. When
this second messenger pathway is blocked, growth factors can no
longer activate MAP kinase, leading to SCLC cell growth arrest.
PI 3-kinasc acting through PKB has been shown to promote
anchorage-independent growth (32). This may be central to the survival
and growth of tumor cells in inappropriate environments. The ability of
cells to grow in soft agar is a feature of anchorage independence and
pathognomonic of the transformed phenotype, correlating with tumori¬
genicity and invasiveness of the tumor (39). SCLC basal colony growth
can be stimulated by neuropeptide growth factors (30, 44). These obser¬
vations, along with the finding that SCLC cells produce a variety of
neuropeptides and hormones (45), gave rise to the autocrine/paracrine
theory of SCLC growth. LY294002 markedly inhibited basal colony
formation of SCLC cells in agarose semisolid medium. This block could
not be overcome by the addition of vasopressin, gastrin, or bombesin in
H69, H510, and H345 cells, respectively. This shows that PI 3-kinase
activity is crucial for anchorage-independent growth in SCLC cells.
Furthermore, these results suggest that PI 3-kinase activity is required for
neuropeptide mitogenic signaling. In SCLC cells, neuropeptides have
been shown to activate MAP kinase through G-protein-coupled receptors
(46). PI 3-kinase activity may be necessary for neuropeptide activation of
MAP kinase in SCLC. It remains to be established whether MAP kinase
activation can be potentiated by growth factor/integrin-depcndent PI
3-kinase activation and whether this underlies our observations of the
effects of PI 3-kinase inhibition on SCLC growth.
Although both PKB and p70s6k arc known to be physiological targets
of PI 3-kinase, it is unclear whether these enzymes lie on the same
signaling pathway or on parallel pathways. Observations that constitu-
tively activated forms of PKB led to the activation of p70s6k implied that
PKB may mediate mitogenic signaling through p70s6k activation (47).
Recently, PDK1, the enzyme that phosphorylates Thr308 of PKB, has
been shown to directly phosphorylate and activate p70s6k, resulting in a
PI 3-kinasc-dependent mechanism of activation that may circumvent
PKB in the proliferative pathway (48). Differential activation of PKB and
p70'sSk can be achieved under distinct cellular calcium levels; this may be
important for integrating signals from multiple signaling inputs (49). Our
results support these latter findings. PI 3-kinase regulation of SCLC cell
growth is mediated both by p70s6k-dependent and -independent path¬
ways. It appears that p70s6k activation makes approximately a 20-30%
contribution to the PI 3-kinase effect, with a 70-80% contribution from
another pathway, potentially signaling through PKB. H69 cells were
noted to be less sensitive to rapamycin than H345 cells, and this may be
due to different cell line growth rates. Similar effects were seen by
Seufferlein and Rozengurt (19). Because the principle mechanism of
action of rapamycin is G, cell cycle delay rather than apoptosis or
necrosis, we propose that the faster growth rate and cell cycling of H69
cells diminishes the growth-inhibitory effect of rapamycin at longer time
points compared with H345 cells. This is supported by the observation
that at shorter time points the effect of rapamycin on H69 and H345 cell
growth is similar (38 ± 1.3% versus 29 ± 2.7% growth inhibition,
respectively).
We have shown that constitutive PI 3-kinase activity in SCLC
regulates proliferation, anchorage-independent growth, and apoptosis.
Recent studies have suggested that PI 3-kinase activation induces
CONSTITUTIVE PI 3-KINASE ACTIVITY IN SCLC CELLS
integrin-mediated cell motility and invasiveness (13, 14). In addition,
PI 3-kinase/PKB activation can promote adhesion-independent
growth, protecting cells in suspension from undergoing apoptosis
(32). The pathways driven by constitutive PI 3-kinase in SCLC cells
may therefore be responsible for the highly metastatic and nonadher¬
ent phenotype of SCLC cells. We predict that constitutive PI 3-kinase
activation may be a late event in the development of SCLC, allowing
transformed cells to become locally invasive and metastatic. Given the
likely importance of growth and survival in suspension for mainte¬
nance of the transformed phenotype, and particularly for metastatic
spread of cancer cells within the body, an understanding of the
mechanisms that result in constitutive activation of PI 3-kinase and of
its downstream effectors could be of benefit in designing novel
therapies for SCLC.
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Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer
(SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix
(ECM) at both primary and metastatic sites. Adhesion of SCLC cells to ECM enhances tumori-
genicity and confers resistance to chemotherapeutic agents as a result of (31 integrin-stimulated
tyrosine kinase activation suppressing chemotherapy-induced apoptosis. SCLC may create a spe¬
cialized microenvironment, and the survival of cells bound to ECM could explain the partial re¬
sponses and local recurrence of SCLC often seen clinically after chemotherapy. Strategies based
on blocking (31 integrin-mediated survival signals may represent a new therapeutic approach to
improve the response to chemotherapy in SCLC.
Lung cancer is the most common fatal malignancy in the devel¬
oped world. Small cell lung cancer (SCLC), which constitutes
25% of all lung neoplasms, is characterized by early and wide¬
spread metastases. Etoposide is the most effective drug for use
against SCLC and is commonly used in combination with dox¬
orubicin and cyclophosphamide or platinum-based drugs'.
However, despite initial sensitivity to chemotherapy, this tumor
almost invariably relapses and becomes resistant to further treat¬
ment: thus, the patient 2-year survival rate remains less than 5%
(ref. 2). New therapeutic strategies are urgently needed, and
these will most likely result from a better understanding of the
cell biology of SCLC.
The integrin family of receptors represents the main extracel¬
lular matrix (ECM) receptors. The growth and survival of un-
transformed epithelial and endothelial cells requires adhesion
to ECM proteins. When displaced from ECM. these cells un¬
dergo apoptosis. This phenomenon is called 'anchorage depen¬
dence'. After being activated by an ECM ligand, integrins
stimulate intracellular signals, which can prevent entry into the
cell death program31. Integrins regulate many intracellular sig¬
naling pathways, such as tyrosine phosphorylation and inositol
lipid metabolism5. This can lead to negative regulation of inter-
leukin-l|3 converting enzyme expression6, an essential effector
of apoptosis. A characteristic feature of cancer cells is their abil¬
ity to grow without the requirement of adhesion to ECM. This
correlates closely with tumorigenicity in animal models7.
Cytoplasmic oncogenes may provide a constitutively activated
signal, usually initiated by ligand-bound integrins, thereby
overcoming anchorage dependence. Anchorage-independent
662
growth is seen in vitro in SCLC cells, which grow as non¬
adherent, free-floating aggregates.
Some forms of chemotherapy exert their cytotoxic effects
mainly by inducing apoptosis89. Tumor mass is a balance be¬
tween cell proliferation and cell death (necrosis and apoptosis),
and factors affecting this balance have a profound effect on
tumor growth. Regulation of apoptosis in tumor cells remains
poorly understood. However, the level of protein tyrosine kinase
(PTK) activity may determine whether SCLC cells survive and
proliferate or die by apoptosis'0. SCLC cell growth in vitro may be
sustained by multiple autocrine and paracrine loops involving
calcium-mobilizing neuropeptides". This discovery led to the
development of agents to block these growth loops for use in
clinical trials in patients with SCLC, for example, neuropeptide
receptor antagonists such as |D-Arg6, D-Trp'-9, NmcPhe8]-
substance P (6-11) (ref. 12) and monoclonal antibodies against
the growth factor gastrin-releasing peptide13. The aim of our
study here was to determine if the local environment of SCLC
cells in vivo could provide a survival signal, or block a death sig¬
nal, thereby accounting for the protection of SCLC cells from
chemotherapy-induced apoptosis.
SCLC cells are surrounded by ECM proteins
We determined the ECM composition of unselected SCLC spec¬
imens from pathology files by immunohistochemical staining
for fibronectin (Fn), laminin (Ln), collagen IV and tenascin.
Normal areas of the lung showed Ln and collagen IV localized to
the basement membranes of alveoli, septae, blood vessels and
bronchial glands, whereas Fn staining showed diffuse weak pos-
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Fig. 1 Immunohistochemical stain¬
ing of ECM proteins around SCLC
cells in vivo. Fibronectin (a) and colla¬
gen IV (b) immunoreactivity in SCLC
lung, c, lntra-/pericellular immunore¬
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itivity throughout the pulmonary interstitium. No tenascin im¬
munoreactivity was seen in normal lung. In contrast, extensive
(> 50% of section area) Fn, collagen IV and tenascin staining
were seen in 56%, 87% and 61% of tumors, respectively, with
focal areas of immunoreactivity seen in another 35%, 9% and
39% of sections, respectively (Table 1). Fn, collagen IV (Fig. 1)
and tenascin (not shown) were expressed mainly in areas of re¬
active host connective tissue, which were present as extensive
areas of scarring or as stromal bands delineating packets of inva¬
sive tumor cells. Intracellular staining for Fn and Ln was seen in
26% and 16% of tumors, respectively (Fig. 1 and Table 1). In
SCLC sections, the basement membranes of the alveoli were
considerably thickened compared with adjacent uninvolved
areas, with increased expression of Fn, Ln and collagen IV. In
three cases in which matched metastatic lymph nodes were
available for examination, Fn, collagen IV and tenascin im¬
munoreactivity was as extensive there as in the primary tumors
(data not shown). Thus, in vivo, SCLC cells exist in an ECM-rich
environment.
SCLC cells adhere to ECM proteins through p1 integrins
We next determined the physiological relevance of these in vivo
results using the classical SCLC cell lines H69, H345 and H510.
Expression of individual integrin subunits on SCLC cells was
homogeneous with an almost unimodal distribution. The main
beta integrin expressed was pi. The alpha integrins were those
known to be involved in adhesion to collagen and Ln; (a2pi,
a3pi and a6pl) and Fn: (a3pl and avpi)(refs. 14-16; Table 2).
These results were in agreement with those described in other
SCLC cell lines17. In keeping with this, H69 cells adhered to Fn,
Ln and collagen IV in a concentration-dependent manner (data
not shown). Adhesion induced a profound change in SCLC cell
morphology, with reorganization of the actin cytoskeleton. The
cells adopted a flattened conformation and formed actin-rich
filopodia (Fig. 2a), giving the appearance of differentiation to a
neuron-like morphology. However, adhesion to ECM proteins
had no effect on the expression of neuroendocrine markers chro-
mogranin A, dopa-decarboxylase and neuron-specific enolase
Table 1 Expression of ECM proteins in primary lung SCLC resection specimens
ECM Number Stroma Tumor cells
of cases Extensive Focal Negative Positive Negative
number (%) number (%) number (%) number (%) number (%)
Fibronectin 23 13 (56) 8 (35) 2 (9) 6 (26) 17 (74)
Laminin 19 0 (0) 0 (0) 19 (100) 3 (16) 16 (84)
Tenascin 23 14 (61) 9 (39) 0 (0) 0 (0) 23 (100)
Collagen IV 23 20 (87) 2 (9) 1 (4) 0 (0) 23 (100)
After immunohistochemistry, ECM protein staining within areas of carcinoma stroma was recorded on a semi-quantitative
scale: no staining, focal staining or extensive staining (> 50% of section). Sections were also assessed for intracellular ECM
protein expression. Data represent numbers of cases, with percentages in parentheses.
(results not shown). Adhesion was stimulated by 1 mM Mn2*
(similar results were seen with 1 mM Mg2*) and was inhibited by
the function-blocking pi antibodies P5D2 and 4B4 (Fig. 2b; simi¬
lar results were obtained in H510 and H345 cells). These results
demonstrate that SCLC cells adhere to Fn, Ln and collagen IV in
a mostly pi integrin-dependent manner.
ECM protects SCLC cells from chemotherapy-induced apoptosis
The addition of the chemotherapeutic agents doxorubicin, CIS-
4-sulfoethylthio-cyclophosphamide (cyclophosphamide) and
etoposide induced a concentration-dependent increase in SCLC
cell apoptosis, as judged by morphology, electron microscopy,
acridine orange/propidium iodide staining and immunoassay of
cytoplasmic histone-associated DNA fragments. Adhesion of
SCLC cells to Ln, Fn or collagen IV substantially protected H69,
H345 and H510 cells against the apoptosis induced by these
chemotherapeutic agents, reducing both the percentage and
number of cells undergoing apoptosis (Fig. 2c). For example, in
H345 cells, in response to 50 pM etoposide, Fn reduced apoptosis
from 75% to 14%, which corresponded to a reduction from 1.05
x 105 to 0.33 x 10s apoptotic cells (similar results were obtained
with cis-platinum). Nonspecific adhesion of H69 cells to poly-
L-lysine did not protect cells from etoposide-induced apoptosis.
Furthermore, the addition of the (31 function-blocking antibody
P5D2 abolished the ECM-mediated protection from etoposide-
induced apoptosis (Fig. 2d). The addition of conditioned
medium (from SCLC cells grown in the presence of collagen IV
or Fn) did not protect SCLC cells adhered to poly-L-lysine from
chemotherapy-induced apoptosis (data not shown). Thus, ECM-
mediated protection from apoptosis was not mediated by the
release of soluble autocrine growth factors. Therefore, ECM pro¬
teins acting through pi integrins protect SCLC cells from
chemotherapy-induced apoptosis.
In liquid culture, the presence of Fn stimulated a 150-200% in¬
crease in SCLC cell number. Furthermore, Fn also reduced the cy¬
totoxicity of cyclophosphamide and cis-platinum in H345 cells
(50% inhibitory concentration (IC50): 1.0-200 pM and 92-450
pg/ml, respectively; (n = 3; Fig. 3a). Similarly, the presence of Ln,
Fn or collagen IV substantially reduced
the sensitivity of all SCLC cell lines to
the cytotoxic agents doxorubicin, cis-
platinum, etoposide and cyclophos¬
phamide (results not shown).
Adhesion to Fn. Ln and collagen IV
had no effect on cell-cell aggregation
up to 24 hours, but at later time points,
a small increase in cell aggregation was
seen, which was abolished by function-
blocking pi antibodies. Treating SCLC
cells with either pi function-blocking
or -stimulating antibodies in the ab-
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Fig. 2 pi-integrin-mediated adhesion to ECM
proteins protects SCLC cells from chemother¬
apy-induced apoptosis. a, Adhesion of H69
SCLC cells to ECM. Confocal fluorescence mi¬
croscopy of cells stained with rhodamine phal-
loidin after 4 h of attachment to poly-L-lysine
(left) or collagen IV (right), b, Effect of Mn!l and
the pi function-blocking antibodies (pl-ve Ab)
P5D2 or 4B4 on SCLC cell adhesion to laminin
(Ln) fibronectin (Fn) and collagen IV (C IV).
negative control. Data represent the mean ±
s.e.m. of three to six independent experiments
done in quadruplicate on duplicate plates.
c. Effect of ECM proteins on chemotherapy-in¬
duced apoptosis in SCLC cells. SCLC cells were
seeded in the presence of pre-coated fi¬
bronectin (•), laminin (■) or collagen IV (♦) or
in the absence of ECM (□), then increasing con¬
centrations (horizontal axes) of chemothera-
peutic agents were added. Apoptosis was
determined by acridine orange or Giemsa stain¬
ing. Each point represents the mean ± s.e.m. of
two to four independent experiments, d, The
effect of etoposide on H69 SCLC cell apoptosis in the presence of no coat¬
ing matrix (-), poly-L-lysine (PLL) or collagen IV in the presence or absence
K|» hPfmk'ial fdlpi
Collagen IV
jjjdnu Mm vtM m
g> of yP <v" yP a*
^4° ***• ^4*
Ln Fn C IV
Doxorubicin (pM) Etoposide (pM) Collagen IV
of the function-blocking antibody P5D2. Each bar represents the mean ±
s.e.m. of three independent experiments.
sence of ECM had no effect on SCLC cell growth, cell-cell aggre¬
gation or chemotherapy-induced apoptosis (data not shown).
Tumor and transformed cells, including SCLC, are able to form
colonies in agarose medium. Indeed, there is a positive correla¬
tion between the cloning efficiency of cells and the histological
tumor involvement of SCLC cells'8. The presence of Fn or Ln in
the clonogenic assay caused a 200-300% stimulation of H69 cell
colony formation (Fig. 36). Further addition of neuropeptide
growth factors bradykinin (10 nM) and galanin (50 nM) caused
an additive effect. Moreover, Fn also reduced the cytotoxicity of
etoposide in the clonogenic assay in H69 cells (IC50: 3.2-9.3
pg/ml; n- 2; Fig. 3c). These data indicate that in vivo pi integrin-
mediated adhesion of SCLC cells to ECM proteins around the
tumor is associated with enhanced tumorigenicity and increased
resistance to standard chemotherapeutic agents.
PTK activation prevents chemotherapy-induced caspase activation
PTK activity in SCLC cells may be essential in determining
whether they survive and proliferate or die by apoptosis10.
Adhesion of H69 SCLC cells to Fn stimulates PTK activity in both
basal cells (not treated with etoposide) and etoposide-treated
cells. This effect was completely blocked by pretreatment with
tyrphostin-25 (a selective PTK inhibitor) or a function-blocking
pi antibody (Fig. 4a). The presence of Fn reduced the cytotoxic¬
ity of H69 SCLC cells to etoposide, shifting the concentration-
response curve to the right (IC50: 2.2-25 pg/ml). This effect was
blocked by the addition of function-blocking pi antibodies (Fig.
46). Addition of tyrphostin-25 (25 pM) also blocked the Fn-me-
diated reduction in cytotoxicity shifting the concentration-
response to etoposide back to the left. As a consequence, in the
presence of tyrphostin-25, the IC50 for etoposide was the same (5
pg/ml) in the presence or absence of ECM (Fig. 46). Similar re¬
sults were obtained with Ln and collagen IV (results not shown).
The addition of 25 pM tyrphostin-25 to SCLC cells for 24 hours
had no effect on SCLC cell adhesion to ECM (data not shown).
These data show that pi integrin-dependent resistance to
chemotherapy is mediated by a PTK-dependent mechanism.
Several of the chemotherapeutic agents used here, including
etoposide, function specifically by inhibiting the re-annealing
action of topoisomerse II, resulting in DNA damage and apopto¬
sis'9. Caspase-3, one of the essential mediators of apoptosis, is ac¬
tivated by proteolytic cleavage of pro-caspase-3 (ref. 20). After
being activated, caspase-3 cleaves the chaperone inhibitor of cas¬
pase activated deoxyribonuclease, releasing the DNAase activity,
which causes DNA fragmentation in nuclei2'. In H69 SCLC cells,
the etoposide (25 pg/ml)-induced pro-apoptotic effect and pro-
caspase-3 cleavage was completely blocked by co-incubation
with either the tyrosine phosphatase inhibitor sodium vanadate
(200 pM) or the broad-spectrum caspase inhibitor z-Val-Ala-DL-
Asp-fluromethylketone (z-VAD: 100 pM) without affecting the
level of pro-caspase-3 expression (Fig. 4c). In addition to block¬
ing pro-caspase-3 cleavage. Fn reduced both the percent (43% to
11%) and number (4.8 x 10" to 1.45 x 101) of cells undergoing
apoptosis in response to 25 pg/ml etoposide. Furthermore, the
Fn-mediated protection of H69 SCLC cells from etoposide-
Table 2 Integrin expression in SCLC cell lines
Cell line H69 H345 H510
Integrin subunit
PI 30.8 ± 3.5 17.1 ± 1.4 42.3 ±3.9
(32 5.0 ± 0.3 1.4 ± 0.2 4.2 ± 0.4
P3 6.8 ± 0.5 6.8 ±0.6 4.5 ± 0.7
P4 6.7 ± 0.9 4.6 ± 0.5 6.0 ± 0.1
P5 5.6 ± 0.8 3.8 ± 0.2 6,8± 0.6
P6 5.6 ±0.6 5.9 ± 0.4 2.5 ± 0.1
a1 4.3 ± 0.2 6.1 ± 0.5 4.9 ±0.8
a2 2.3 ± 0.3 7.1 ± 0.6 17.4 ± 2.2
a3 36.4 ± 2.5 38 ± 2.2 30 ± 1.8
a4 5.7 ± 0.4 6.5 ± 0.3 3.2 ±0.
a5 3.0 ± 0.2 2.4 ± 0.4 4.4 ± 0.4
a6 32.4 ± 2.8 22.5 ± 2.5 17.1 ± 2.9
av 20.6 ± 3.1 14.7 ± 2.8 26.3 ± 1.2
Integrin expression was determined by flow cytometric analysis using an indirect im-
munofluorescent technique with monoclonal antibodies against integrin subunit. Each
value represents the mean fluorescence intensity, arbitrary units (AU) ± s.e.m., of three
to four independent experiments. Background control antibody mean fluorescence val¬
ues were 2.4 ± 0.2 AU.
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Fig. 3 ECM proteins stimulate SCLC cell growth and tumorigenicity.
a, The chemosensitivity of H345 SCLC cells to increasing concentrations
(horizontal axes) of chemotherapeutic agents was assessed in the presence
(•) or absence (□) of fibronectin. Live cells were assessed by trypan blue
exclusion. Data represent mean ± s.e.m. of three independent experiments
done in quadruplicate in duplicate plates, b, The effect of ECM proteins
laminin (Ln) and fibronectin (Fn) on H69 SCLC cell colony formation in the
presence of bradykinin (BK) or galanin (Gal). The clonogenic assay was
done in triplicate in two independent experiments. Data represent mean ±
s.d. c, Inhibition of H69 cell colony formation by increasing concentrations
(horizontal axis) of etoposide, in the presence (•) or absence (□) of
fibronectin. Data represent mean (of two independent experiments done
in triplicate) ± s.d.
induced apoptosis and pro-caspase-3 cleavage was abrogated by
either the addition of a function-blocking (3, antibody or the PTK
inhibitor tyrphostin-25 (25 pM). This tyrphostin effect was
blocked by 100 pM z-VAD without affecting the level of pro-
caspase-3 expression. The function-blocking (3, antibody had no
effect on etoposide-induced apoptosis in the absence of Fn.
Apoptosis induced by DNA damage can be suppressed by Bcl-2
(ref. 22) through a mechanism that prevents caspase-3 activa¬
tion23. Adhesion to Fn or treatment with etoposide has no effect
on the level of Bcl-2 expression in SCLC cells (data not shown).
Adhesion to Fn or treatment with tyrphostin-25 did not substan¬
tially alter either the expression or activity of topoisomerase II in
basal or etoposide-treated cells (Fig. 4d). Furthermore, treatment
with z-VAD did not affect etoposide-inhibition of topoisomerase
II (results not shown). Thus adhesion to Fn through pi integrins
protects SCLC cells from etoposide-induced caspase-3 activation
and apoptosis by activating PTK signaling downstream of DNA
damage. In addition, z-VAD prevents apoptosis at a point down¬
stream of DNA damage, preventing activation and cleavage of
pro-caspase-3 by upstream caspases.
Discussion
This study shows that SCLC, in vivo, is surrounded by an exten¬
sive stroma of ECM at both primary and secondary metastatic
sites. This stroma contains, in part, Fn, Ln, collagen IV and
tenascin. The extent of ECM deposition around SCLC cells in
vivo has not generally been appreciated. The origin of ECM pro¬
teins in SCLC stroma is unclear, but may be the consequence of
complex autocrine and paracrine interactions involving fibrob¬
lasts and other surrounding cells. SCLC cells secrete many
growth factors, including insulin-like growth factor and neu¬
ropeptides such as gastrin-releasing peptide, which are mito-
genic both for SCLC cells and fibroblasts24"26. In addition, a basal
'feeder' layer of human fibroblasts can stimulate the clonal
growth of SCLC cells. Furthermore, SCLC cell lines also secrete
many inflammatory cytokines and mediators involved in tissue
repair (T.S., S.C.D. & R.S., unpublished results). These include
TGF-fS and IL-8 (an essential angiogenic factor for non-small cell
lung cancer growth in nude mice27). In cultured fibroblasts, TGF-
(3 modulates the splicing of the primary Fn transcript, leading to
the production of other ECM proteins, including Ln and
tenascin28 29. SCLC cell lines secrete Fn, as shown by western blot
analysis (T.S. & R.C.R., unpublished results), and the detection
of intracellular and pericellular staining for Fn, collagen IV, Ln
and tenascin in pathological samples raises the possibility that,
at least in some cases, SCLC cells may secrete these ECM pro¬
teins. ECM may also be a substrate for neovascularization30 fur¬
ther facilitating metastasis. Therefore, in vivo, SCLC may create a
specialized environment as a consequence of autocrine and
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paracrine effects that, using an analogy to inflammation, likens
SCLC to 'a wounding reaction' with the laying down and remod¬
eling of ECM, growth factor release and neovascularization.
The exact function of tenascin is unclear. It is known to be an
oncodevelopmental protein expressed in fetal tissue31 and in
adult tissues that are actively remodeling, where it is often co-ex-
pressed with matrix metalloproteases32, supporting the idea that
the local environment around SCLC is like an ongoing inflam¬
matory reaction. Tenascin may facilitate growth factor-depen¬
dent proliferation and protect cells from apoptosis, possibly in
conjunction with other ECM proteins33.
Doxorubicin, cyclophosphamide, etoposide and cis-platinum
caused a concentration-dependent stimulation of apoptosis in
SCLC cells. Overexpression of the multidrug resistance gene
MDR1 is not common in SCLC, indicating that, unlike in other
tumors, this is not an important mechanism for drug resistance
in these tumors34. The binding of SCLC cells to laminin reduces
the cytotoxicity of certain chemotherapeutic agents35. We have
shown here that this is a general property ofmany ECM proteins
found in increased amounts around SCLC in vivo. This occurs as
a result of (31 integrin-dependent adhesion to Ln, Fn and colla¬
gen IV. Despite their anchorage independence, the binding of
SCLC cells to ECM proteins confers protection from chemother¬
apy-induced apoptosis. Furthermore, Ln and collagen IV are the
main glycoproteins of basement membranes, and induce migra¬
tion, probably by haptotaxis36. This seems to be important in
metastasis in many tumor cell lines. Thus, at primary and sec¬
ondary metastatic sites, there seems to be a permissive environ¬
ment for SCLC cell proliferation, protection from apoptosis and
resistance to chemotherapy.
ECM suppression of cytotoxicity is not due to differentiation
to a chemoresistant phenotype, a lower growth rate or ECM-
stimulated autocrine secretion. Function-blocking (31 and func¬
tion-stimulating (31 antibodies did not substantially affect SCLC
cell-cell adhesion. The small increase in cell aggregation seen
after prolonged contact with Fn is therefore most likely due to
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Fig. 4 Chemotherapy-induced caspase-3 activation is blocked by (51 inte-
grin-stimulated tyrosine kinase activation, a, The effect of fibronectin on tyro¬
sine phosphorylation in SCLC cells. H69 SCLC cells were seeded in the
presence or absence of fibronectin as indicated with or without the function-
blocking pi antibody 4B4 (pi-ve Ab), tyrphostin-25 (Tyrph) or etoposide.
Cell lysates were assessed by western blot analysis with antibodies against
phosphotyrosine (PY20 and 4G10). The gel is representative of three inde¬
pendent experiments. Left margin, molecular weight markers in kDa. b, H69
SCLC cells were seeded in the absence (□) or presence of fibronectin alone
(•) or fibronectin plus a function-blocking pi antibody (♦ and discontinous
line). Etoposide (concentrations, horizontal axis) and diluent (upper) or tyr¬
phostin-25 were added, then cells were aspirated and counted. Cell number
in the absence of etoposide for each condition was considered 100%. Data
represent the mean ± s.e.m. of three independent experiments done in qua¬
druplicate in duplicate plates, e, Effect of fibronectin on etoposide-induced
apoptosis and caspase-3 activation. H69 cells were seeded, and etoposide, pi
blocking antibody (pi-ve Ab), tyrphostin, z-VAD or sodium orthovanadate
(Na2V03) were added to each well. Upper, apoptosis, determined by acridine
orange staining; data represent mean (of three independent experiments




pro-caspase 3: blot is representative of a parallel sample. Left margin, molec¬
ular weight markers in kDa. d, Effect of fibronectin on topoisomerase Ilex
(Topo II) expression in the presence and absence of etoposide and tyrphostin.
Upper, western blot analysis with antibody against human topoisomerase Met.
Left margin, molecular weight markers in kDa. Lower, decantenation assay of
topoisomerase Hot activity; NW, high-molecular-weight interlocking kDNA
network; MC, decantenated individual DNA mini circles. Gels shown are rep¬
resentative of two independent experiments done in duplicate.
be important in ECM-mediated resistance to chemotherapy. Our
results indicate that the resistance to chemotherapy induced by
pi-mediated adhesion to ECM is due to an increase in the level
of PTK activity. However, increased intracellular tyrosine phos¬
phorylation had no effect on etoposide-induced topoisomerase
II inhibition. Thus, despite chemotherapy-induced DNA dam¬
age, ECM-mediated PTK activation blocks caspase activation,
which prevents apoptosis. It is not known how integrin-stimu-
lated PTK activation suppresses the early phase of apoptosis in
SCLC cells. R-Ras and insulin-like growth factor-1, which acti¬
vate phosphatidylinositol-3 kinase (PI3K), cooperatively inhibit
caspase-3 activation, preventing apoptosis of BaF3 cells37.
Activation of PI3K by integrins protects epithelial cells from de¬
tachment-induced apoptosis38. Integrin-stimulated PI3K activa¬
tion may impinge on the nuclear response to DNA-damaging
agents.
We made a retrospective analysis of available clinical case
notes to determine the translational research implications of
these findings. Sixteen patients 62.5 ± 2.3 years of age who had
received some standard form of chemotherapy were identified;
eight had no or focal Fn matrix and eight had extensive Fn ma¬
trix. They had a survival time of 11.5 ± 1.7 months (mean ±
s.e.m.). There was no substantial age or sex difference between
the two groups. Patients with extensive matrix around their tu¬
mors had a significantly shorter survival time from diagnosis
666
(8.4 ± 1.7 months) than did patients with focal or no matrix (15
± 2.6 months; mean ± s.e.m; P< 0.05, paired Student's r-test).
Our in vitro and in vivo data provide strong preliminary evi¬
dence that adhesion to ECM proteins is essential in SCLC cell re¬
sistance to chemotherapy. Cancer cells bound to ECM may
escape chemotherapy-induced cell death and then, with subse¬
quent genetic damage, drug-resistant clones are selected. This is
an excellent model to explain not only SCLC behavior in vivo but
also why partial responses and local recurrence of SCLC are often
seen after chemotherapy. With the development of increasingly
specific tyrphostins, identification of the PTKs mediating (31-in-
tegrin-dependent survival signals may provide new therapeutic
strategies to improve the response of SCLC to chemotherapy.
Methods
Cell Culture. H69, H510 and H345 cell lines from ATCC (Rockville,
Maryland) were grown in RPMI 1640 medium (Sigma) supplemented with
10% (volume/volume) heat-inactivated fetal calf serum and 5 mg/ml L-glut-
amine in an atmosphere of 5% C02. For experiments, cells were grown in
SITA (RPMI 1640 supplemented with 30 nM selenium, 5 |xg/ml insulin, 10
pg/ml transferrin and 0.25% (weight/volume) BSA). Cell viability was rou¬
tinely greater than 90%, asjudged by trypan blue exclusion.
Tissue immunohistochemistry. Formalin-fixed, paraffin-embedded SCLC
resection specimens from University of Edinburgh Department of Pathology
files (1989-1994) were de-waxed in xylene and rehydrated through graded
alcohols to water. Antigen unmasking was done by either pre-incubating
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sections in 0.1% trypsin, pH 7.6, at 37 °C for 15 min (for Fn, Ln and
tenascin) or boiling them in a microwave oven for 15 min in 0.1 M citrate,
pH 6.0 (for collagen IV). Primary antibodies against Fn (1:100 dilution: FN-
3E2), Ln (1:50 dilution; LAM-89), tenascin (1:400 dilution: BC-24) and colla¬
gen IV (1:100 dilution: Col-94) were all from Sigma. Sections were
processed using a Techmate 500 (Dako, Carpinteria, California). Antibody
detection was done using a multilink streptavidin-biotin complex method,
and visualization was achieved using a di-amino benzidine chromagen
method following the manufacturer's instructions (Dako, Carpinteria,
California). Slides were counterstained using Harris' hematoxylin. Negative
control samples were incubated in primary antibody diluent only. All slides
were reviewed independently by two people. Staining was graded on a
semi-quantitative scale as no staining, focal staining or extensive (> 50% of
section area) staining.
Flow cytometric analysis of integrin expression. Cells (1 x 105) were
washed in PBS containing 0.2% (weight/volume) BSA and 0.1% sodium
azide (EPICS buffer), plated onto 96-well flexible assay plates and incubated
at 4 °C for 30 min with integrin subunit antibodies (1:500 dilution) followed
by a 30-minute incubation with species-appropriate FITC-conjugated sec¬
ondary antibodies (1:40 dilution; Dako, Carpinteria, California). Cells were
resuspended in EPICS buffer and analyzed by flow cytometry using an EPICS
profile 2 (Coulter, Hialeah, Florida). All photomultiplier settings were stan¬
dardized throughout the study. Mean fluorescence intensity arbitrary units
on a log scale were recorded for each sample. The antibodies against inte¬
grin were all from Serotec unless otherwise stated: av (13C2; M. Horton,
Edinburgh, UK), a2 (AK7), a3 (11G5), a4 (HP2/1), a5 (SAM-1) and a6 (4F-
10 (lgG2b)). (36 (E7P6G10P0) and (35 (PiF6) were from D. Salter (Edinburgh,
UK); p4 (3E1) was from Life Technologies; P3 (PM6/13) and P2 (MHM23)
were from Dako (Carpinteria, California); and pi (mAb13) was from Becton
Dickinson (San Jose, California).
Adhesion assay. First, 96-well plates (CoStar, Cambridge, Massachusetts)
were coated with 100 pi of 20 pg/ml fibronectin, 10 pg/ml laminin (Life
Technologies) or 10 pg/ml collagen IV (Sigma) overnight at 4 °C and
blocked with 1 mg/ml BSA (1 h at 25 °C). Then, SCLC cells (5 x 10") that had
been washed twice in RPMI were added to the wells in the presence or ab¬
sence of the function-blocking pi antibodies P5D2 (10 pg/ml; P. Hughes,
Scripps Research Institute) or 4B4 (10 pg/ml; Coulter, Hialeah, Florida) or 1
mM Mn2'. After 45 min of incubation at 37 °C, non-adherent cells were re¬
moved by gentle washing and adherent cells were fixed with 3% formalde¬
hyde and stained with 1% methylene blue. After plates were washed with
distilled water, 100 pi of 0.1 M HCI was added to each well and the ab-
sorbance of the resulting solution was measured at 630 nm on a plate reader
(Dynatech Technologies, Chantilly, Virginia). Each condition was assayed in
quadruplicate in duplicate plates.
Chemosensitivity assay. Cells (0.5 x 10s-1.0 x 10s) cultured in SITA
medium were seeded into 96-well microtiter plates in the presence or ab¬
sence (where indicated) of 100 pi pre-coated fibronectin (20 pg/ml),
laminin (10 pg/ml) or collagen IV (10 pg/ml). The cytotoxic agents plat¬
inum (cis-platinum (II) diammine dichloride), etoposide, doxorubicin
(Sigma) and cyclophosphamide (CIS-4-sulfoethylthio-cyclophosphamide)
(Asta Pharmaceuticals, Franfurt, Germany) were added to each well 1 h
after seeding. Where indicated, function-blocking (31 antibodies (P5D2 or
4B4, both at 10 pg/ml) were added at the time of cell seeding, and etopo¬
side and/or 25 pM tyrphostin-25 (Calbiochem. La Jolla, California) were
added with the cytotoxic agent (1 h after cell seeding). Each condition was
assayed in quadriplicate in duplicate plates. After 72 h, cells were either de¬
tached from the plates and aspirated and cytospun onto glass slides.
Apoptotic cell populations were then assessed (described below). Live cells
were determined by trypan blue exclusion, using a hemocytometer. The
total cell number was determined using a Coulter counter (Coulter,
Hialeah, Florida).
Assessment of SCLC cell apoptosis. To assess apoptosis, 1 pi of an ethidium
bromide (100 pg/ml)/acridine orange (100 pg/ml) (1/1 volume/volume)
mixture was added to 200 pi SCLC cells, and the percentage of cells under¬
going apoptosis was determined using fluorescent microscopy as de¬
scribed39. Apoptosis was also assessed using a Cell Detection ELISA91"5 kit
following the manufacturer's instructions (Boehringer), or by staining cy-
tospin preparations using May-Grtinwald-Giemsa stain.
Clonogenic assay. Cells (1 x 10") were suspended in a 0.3% (weight/vol¬
ume) agarose/SITA mix containing neuropeptides (10 nM bradykinin or 50
nM galanin), ECM proteins (10 pg/ml laminin or 20 pg/ml fibronectin) and
0-25 pg/ml etoposide. The cells were layered over a solid base of 0.5%
(weight/volume) agarose in SITA containing the same additives, in 35-mm
plastic dishes. Cultures were incubated in a humidified atmosphere of 5%
COj/95% air at 37 °C for 21 d, and were then stained with nitroblue tetra-
zolium. Colonies greater than 120 pm in diameter (16 cells) were counted
using light microscopy.
Confocal microscopy. SCLC cells (1 x 105) in SITA medium were allowed to
attach for 45 min at 37 "C to glass cover slips pre-coated with 25 pg/ml poly-
L-lysine or 10 pg/ml collagen IV. Unattached cells were gently removed by
washing with SITA medium and attached cells were allowed to spread for 4
h. After fixation with 3% paraformaldehyde in PBS for 20 min, residual
paraformaldehyde was 'quenched' using 50 mM NH„CI/PBS. Cells were per-
meabilized with 0.1% Triton X-100 in PBS for 4 min and were blocked with
0.2% fish skin gelatin/PBS before being stained with rhodamine phalloidin
(1:400 dilution) for 20 min at room temperature. Immunofluorescence was
measured using a BioRad MRC 600 laser confocal microscope with a Zeiss
63x objective.
Immunoblotting. To determine the effect of fibronectin on tyrosine phos¬
phorylation, 1x10" H69 SCLC cells cultured in SITA medium were seeded in
6-well plates in the absence or presence of 20 pg/ml fibronectin with or
without function-blocking (31 antibody (10 pg/ml 4B4). Etoposide (25
pg/ml) or tyrphostin-25 (25 pM) were added to each well 1 h after cell seed¬
ing. After 72 h, cells were aspirated and pelleted, and lysates were assessed
by western blot analysis (see below) with anti-phosphotyrosine antibodies. A
50:50 mixture of PY20 (Santa Cruz Biotechnology, Santa Cruz, California)
and 4G10 (Upstate Biotechnology, Lake Placid, New York) was used.
To determine the effect of fibronectin on etoposide-induced apoptosis
and caspase-3 activation, H69 SCLC cells (1 x 106) cultured in SITA medium
were seeded in 6-well plates. Etoposide (25 pg/ml), function-blocking (31 an¬
tibody (10 mg/ml), tyrphostin-25 (25 pM), z-Val-Ala-DL-Asp-fluromethylke-
tone (100 pM) or sodium orthovanadate (200 pM) were added to each well
1 h after cell seeding. After 72 h of culture, apoptosis was determined by
acridine orange staining (described above) and the level of pro-caspase 3
was determined by western blot analysis (see below) using an anti pro-cas¬
pase 3 antibody (CPP-32; Transduction Laboratories, Lexington, Kentucky).
For western blot analysis, cell pellets were lysed at 4 °C using standard
RIPA buffer and 20 pg of protein were separated by 10% SDS-PAGE. Proteins
were transferred to Hybond C nitrocellulose membranes (Amersham), and
immunodetection was done using the enhanced chemiluminescence system
(ECL; Amersham). The antibody against human topoisomerase Ilex was from
TopoGEN (Columbus, Ohio). Species-appropriate HRP-conjugated sec¬
ondary antibodies were from Dako (Carpinteria, California).
Decatenation assay. Cells (5 x 106) were cultured in SITA medium in 6-well
plates in the presence or absence of 1 ml pre-coated fibronectin (20 pg/ml).
Cells were allowed to 'settle' before the addition of 25 pg/ml etoposide or
25 pM tyrphostin-25. Each condition was assayed in duplicate. After 72 h,
nuclear extracts were prepared as described30. Topoisomerase II activity was
measured by the ATP-dependent decatenation of kDNA, in which an inter¬
locking kDNA network is decatenated to individual DNA minicircles and
small catenanes. Reaction buffer (50 mM Tris-HCI, pH 7.5, 10 mM MgClj,
100 mM KCI, 0.5 mM EDTA, 30 pg/ml BSA, 1 mM ATP, 0.5 mM dithiothre-
itol and 100 pg/ml kDNA) was mixed with drug and enzymes (in that order)
in a total volume of 45 pi, and the reaction mixtures were incubated for 30
min at 37 °C. The reaction was then stopped and reaction products were
analyzed by agarose gel electrophoresis in 1 % gels using 89 mM Tris-borate
(pH 8.3) and 2 mM EDTA buffer.
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